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Variant GnRH ligand and receptor subtypes have been identified in a number 
of non-mammalian vertebrate species, however research into avian species 
GnRH systems is lacking.  Two isoforms of GnRH are present in the domestic 
chicken, the evolutionarily conserved GnRH-II and diverged cGnRH-I.  The 
expression of two GnRH ligands parallels the expression of two chicken GnRH 
receptor subtypes; cGnRH-R-I and the novel cGnRH-R-III.  The occurrence of 
two isoforms of the receptor in the chicken raises questions about their specific 
biological functions and interactions with the two ligands.  Differential roles for 
these molecules in regulating gonadotrophin secretion or other functions are 
currently unclear.  To investigate this, cGnRH-R-III cDNA was cloned from a 
broiler chicken anterior pituitary gland and its structure and expression was 
compared with cGnRH-R-I.  Expression profiling of cGnRH-R-III cDNA 
showed that it is predominantly expressed in the anterior pituitary, 
approximately 1400 times more abundantly than cGnRH-R-I suggesting that 
cGnRH-R-III is the predominant regulator of chicken gonadotrophin synthesis 
and secretion.  Additionally, pronounced sex and age differences existed, with 
higher pituitary cGnRH-R-III mRNA levels in sexually mature females versus 
juvenile females.  In contrast, higher mRNA expression levels occurred in 
juvenile males compared to sexually mature males.  Determination of ligand-
binding selectivity and the level of cGnRH-R-III activation in response to the 
endogenous ligands, cGnRH-I and GnRH-II, was anticipated as facilitating the 
elucidation of the physiological roles of the receptor subtypes.  Additionally, the 
development of analogs that differentially promote or inhibit activation of the 
receptor subtypes may be valuable tools for determining the role of receptor 
types in the regulation of gonadotrophin production.  To investigate this, 
pharmacological profiling of cGnRH-R-III in terms of ligand-binding selectivity 
and inositol phosphate production in response to GnRH analogs was 
determined in comparison with the pharmacological profile of cGnRH-R-I.   




binding affinity for GnRH-II than cGnRH-I (IC50: 0.57 v 19.8 nM) and more 
potent stimulation of inositol phosphate production (EC50: 0.8 v 4.38 nM).  
Similar results were found for cGnRH-R-I, (IC50: 0.51 v 10.8 nM) and (EC50: 0.7 
v 2.8 nM).  Mammalian receptor antagonist 27 distinguished between cGnRH-
R-I and cGnRH-R-III (IC50: 2.3 v 351 nM), and application of this synthetic 
peptide may facilitate delineation of receptor subtype function either in-vitro or 
in-vivo.  The length of the C-terminal tail of cGnRH-R-III is 8 residues longer 
than that of cGnRH-R-I and this observation stimulated investigation of 
differences in ligand-induced internalisation between the two receptor subtypes.  
The initial rate of receptor internalisation was faster for cGnRH-R-III than for 
cGnRH-R-I (26%.min-1 v 15.8%.min-1).  Although proteins encoded by cGnRH-
R-III splice variants do not bind GnRH ligands independently and mRNAs 
were not detectable by Northern blot analysis, cGnRH-R-III_SV2 significantly 
reduced maximum ligand-binding of cGnRH-R-III, suggesting that it may 
impair the function of the full-length type III cGnRH receptor.  It was 
anticipated that the two cGnRH-R subtypes may have differential roles in the 
regulation of luteinising hormone (LH) and follicle stimulating hormone (FSH) 
gene transcription through the activation of differential second messenger 
pathways.  Three putative Src homology domain 3 (SH3) binding motifs were 
identified in the type III cGnRH receptor cytoplasmic C-terminal tail domain 
which are not present in the type I cGnRH-R and suggested the potential for 
differential coupling to the Mitogen Activated Protein Kinase (MAPK) cascade.  
To investigate this possibility, activation of the MAPK cascade via cGnRH-R-III 
and cGnRH-R-I was determined by quantifying elevation of phosphorylated 
ERK (pERK 1/2) in response to GnRH.  Studies performed in COS-7 cells 
showed a 4-6 fold increase in ERK 1/2 phosphorylation via the type I and type 
III receptors within 10 minutes of GnRH-I or GnRH-II stimulation, indicating 
that both receptors signal through the ERK 1/2 pathway in response to cGnRH-
I or GnRH-II.  The responses were dose-dependent at cGnRH-R-I and cGnRH-
R-III.   Effects of pre-treatment with PLC and c-Src inhibitors showed that both 




c-Src.  However, it must be noted that 100% of the PLC activity was not 
inhibited by PLC inhibitor as measured by inositol phosphate production at 60 
minutes, and the PLC inhibitor has not been shown to inhibit PLC in the same 
time frame used for the pERK experiments.  Mutagenesis of the individual SH3 
binding motifs of cGnRH-R-III were performed and the effects on pERK 1/2 
levels quantified.  The results indicated that the SH3 binding motifs of cGnRH-
R-III do not contribute to additional MAPK activation when compared to the 
native cGnRH-R-III.  Both cGnRH-R-I and cGnRH-R-III were HA epitope-
tagged (HA-cGnRH-R-I and HA-cGnRH-R-III) and the methodology was 
optimised for HA-cGnRH-R-III immuno-precipitation.  Several size forms of 
HA-cGnRH-R-III were detectable by immuno-precipitation, facilitating 
characterisation of the composition of the receptor protein-protein complexes 
formed using a western blot approach.  In summary, the abundance of cGnRH-
R-III expression compared to cGnRH-R-I suggests it is probably the major 
mediator of pituitary gonadotroph function, and that tissue-specific recruitment 
of cGnRH-R-isoforms has occurred in the avian pituitary during evolution.  
Pharmacological profiling demonstrated that cGnRH-R-III, like cGnRH-R-I, 
has a higher ligand-binding selectivity and induction of inositol phosphate 
production in response to GnRH-II than with cGnRH-I, although cGnRH-I is 
established as the physiological regulator of gonadotroph function.  These 
results suggest that evolutionary recruitment of ligand-receptor pairing for 
particular physiological processes does not correlate with in-vitro properties 
such as highest ligand-binding affinity or efficacy of inositol phosphate 
production.  Therefore evolutionary plasticity has occurred in the tissue-specific 
adoption of GnRH ligand and receptor subtypes for regulation of particular 
physiological functions in birds. 
















The main scope of this literature review is to introduce the Gonadotrophin-Releasing 
Hormone (GnRH) isoforms and GnRH receptor (GnRH-R) subtypes across various 
orders of species.  It also includes a brief description of the second messenger 
cascades stimulated on activation of the GnRH receptor and motifs pertaining to 
pharmacological properties of GnRH receptors.  More detailed information (e.g. 
signal transduction pathways) is provided in the introduction sections of each 
specific chapter.  The GnRH system is fundamental to the understanding of 
reproductive biology and has been researched for several decades.  This review aims 
to highlight the plethora of GnRH system research in several classes of animals and 
the topical relevance of research in avian species.  Studies of GnRH systems in avian 
species promise to provide a unique perspective of the interplay between GnRH 
isoforms and their receptors in the control of reproduction at a particular branch in 
the vertebrate evolutionary tree.  These studies may facilitate comprehension of the 
function of the avian hypothalamic-pituitary-gonadal axis (HPG-axis) which 
impinges upon the success of the poultry industry and on captive breeding programs 
to preserve certain endangered species.  In this chapter the current understanding of 
the GnRH system is described in avian species and other animals, and the research 
objectives of this thesis using the domesticated chicken as a commercially important 
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1.2. Overview of reproductive biology in egg laying animals 
Many vertebrates are seasonal breeders which are driven by environmental cues e.g. 
availability of food, weather and changes in day-length.  With the exceptions of some 
rare viviparous species, most fish, amphibians and reptiles are oviparous.  All birds 
are oviparous.  However, the method of fertilisation in oviparous animals does not 
follow a universal process.  For example, although a few oviparous fish achieve 
internal fertilisation through an intromittent organ (e.g. horn shark or skates) most 
fish achieve fertilisation of their eggs externally.  In amphibians fertilisation can be 
achieved in a variety of ways; the order Anuran (e.g. frogs) mostly uses external 
fertilisation, whereas the Caudata (e.g. salamander) fertilisation is mainly internal 
(Beck, 1998).  In contrast, caecilians and tailed frogs use internal fertilisation.  Large 
amount of eggs are produced in fish and amphibians (e.g. 5 million in cod and 1000 
in common frogs) over the spawning periods, which vary over a number of days.  
The number of eggs produced is roughly proportional to the body size and length of 
time required for in-ovo development.  It is also possible that the number of eggs 
produced is a function of the probability of ensuring fertilisation and long-term 
survival due to the inefficiency of external fertilisation.  In fish and amphibians, 
multiple ovarian follicles develop simultaneously and in synchrony to enable mass 
spawning, therefore ovarian function and its regulation may be expected to reflect 
these required needs.  An integrated GnRH system has been postulated to be 
functional in teleost fish and amphibians with GnRH released from the hypothalamus 
stimulating the pituitary to synthesise and release gonadotrophins.  There is some 
speculation that an intra-gonadal GnRH system may be functional in teleosts (Foran 
and Bass, 1999).  In tunicates, there are several GnRH forms which directly activate 
the gonads (Adams et al., 2003; Powell et al., 1996), suggesting that GnRH 
regulation of the gonads was an early-evolved function prior to the neuroendocrine 
role facilitated by the development of the pituitary gland (Millar, 2005).  The 
spawning events of fish are probably controlled by luteinising hormone (LH) and 
follicle stimulating hormone (FSH), but research into the relevance of both 
gonadotrophins in fish is not completely understood (Swanson et al., 2003), although 
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it is established that the final maturation and ovulation of the oocyte is controlled by 
LH (Swanson, 1991).   Teleost fish lack a hypophyseal portal system and the GnRH 
in the preoptic area of the brain may directly supply and stimulate the pituitary gland 
(Oka and Ichikawa, 1990; Peter et al., 1990).  This differentiates teleost fish from 
other vertebrates and changes in fish GnRH neurons, may be more rapidly reflected 
in blood gonadotrophin levels (Foran and Bass, 1999). 
 
The divergence of fish and amphibians is generally thought to have occurred 400-
360 million years ago during the early Devonian Period and the divergence of 
amphibians and amniotes (reptiles, birds and mammals) is thought to have occurred 
approximately 350 million years ago, during the late Paleozoic Era, however, the 
common ancestor remains unidentified (Elinson and Beckham, 2002).  The defining 
attribute of amniotes is the cleidoic egg (Reisz, 1997), which, encased in a hard egg 
shell and comprising extraembryonic membranes, removed amniotes’ reliance on 
aquatic development (Elinson and Beckham, 2002).  Unlike most fish and 
amphibians, fertilisation occurs within the oviduct in amniotes.  In reptiles and birds, 
fewer eggs are produced per season (e.g. 12 in viper and 16 in chickens) and this is a 
reflection of body size and length of time required for in-ovo development and also 
reflects the efficiency of internal fertilisation.  Our understanding of how the GnRH 
system integrates with reproductive physiology in reptiles and avian species is 
deficient in both groups of animals (Morgan and Millar, 2004).   
 
Birds are a diverse group of species that evolved from an ancestral reptilian lineage 
during the Mesozoic Era about 150 million years ago, with the crocodilian lineage 
being the most closely related extant reptile lineage to that of birds.  The organisation 
of the avian GnRH system is distinct from that of reptiles (Ensembl database), 
(Morgan and Millar, 2004), suggesting the GnRH systems in these orders of animals 
may have evolved differently to accommodate the different reproductive systems.  
The reproductive physiology of reptiles and birds is similar in that they both possess 
a hierarchical order of pre-ovulatory ovarian follicles (Ikemoto and Park, 2007; 
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Johnson and Leone, 1985).  The domestic chicken (like most birds) is unusual in that 
it ovulates daily (Johnson and Leone, 1985) with one egg produced per ovulation due 
to the synchronised hierarchy of follicles.  Some differences in reproductive general 
endocrinology between fish, amphibians, reptiles and birds are outlined below 
(Table 1.1).   
 
Reproductive tissues develop partially during embryogenesis (George and Wilson, 
1994), and GnRH may play a role during this time period (Livne et al., 1993; 
Salisbury et al., 1982; Simonian and Herbison, 2001).  These tissues become 
quiescent in the sexually immature animal.  Later, GnRH plays a role at the onset of 
puberty when reproductive tissues develop further to become fully functional (Millar 
et al., 2004).  The onset of puberty is co-ordinated by the hypothalamus in response 
to metabolic cues, and various hormones are involved in this process.  Reproductive 
behaviour involves hypothalamic integration of visual, auditory, olfactory, tactile and 
nutritional inputs (see Table 1.1. for references).   
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Table 1. 1 
Reproductive peptide hormones and endocrine glands of the HPG-axis in various fish, amphibian, repltian, avain and 
mammalian species 
 





Ranid frogs, bullfrog, 
African clawed frog 
Leopard gecko, 
Green anole, garter 
snake 
Chicken, sparrow, 
pigeon, zebra finch, 
starling, ring dove 


































Kisspeptin  Kiss 1  
Kiss 2 
 
  Kiss 1a and b   
Kiss 2 Kiss 2 NONE (?) 
Kiss 1 





Table 1.1 Continued 
 





Ranid frogs, bullfrog, 
African clawed frog 
Leopard gecko, 
Green anole, garter 
snake 
Chicken, sparrow, 
pigeon, zebra finch, 
starling, ring dove 
Cow, sheep, rat, pig, 
primates, human 























(Foster et al., 1987) 
(Cheng et al., 1998) 
Seasonal, 
enviromental and 





Pituitary No hypophyseal 
portal vasculature 
-separate population 
of LH and FSH 
gonadotrophs 
 
-co-expression of LH 
and FSH in some 
gonadotrophs 
 
- co-expression of LH 
and FSH in some 
gonadotrophs 
 
- separate population 
of LH and FSH 
gonadotrophs 
 
- co-expression of LH 
and FSH in some 
gonadotrophs (except 
bovine) 
 -Hierarchical follicles 
-no studies into local 














   
   
   
   
   
   

















   
   
   
   
   
   
   
   
-Suggested local 
GnRH system  
1-6 syncronised 
follicles 
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1.2.1. Reproductive biology of birds 
Most birds are seasonal breeders and reproduce under the influence of day-length 
(photoperiods).  Daylight perceived by retinal and hypothalamic photoreceptors 
impinges upon the brain and influences internal circadian rhythms (Sharp, 2005).  
This information is integrated within the hypothalamic region of the brain, where 
multiple hormonal and metabolic signals are processed.   
 
When sexual maturity is attained at around 24 weeks after hatching in chickens, 
mating can proceed.  The male ejaculates semen onto the everted cloaca of a hen and 
fertilisation involves entry of several spermatozoa into the egg in the oviduct.  The 
large yolky egg of birds does not cleave after each successive cell division and this 
anatomical feature makes union of male and female pronuclei and the formation of 
the blastocyst unique among vertebrates.  The embryonic development commences 
in the oviduct of the hen, where the embryo grows up to 4mm in diameter.  Once the 
egg is laid (22 hours after ovulation) and cooled to ambient temperature the embryo 
then enters embryonic diapause.  The embryonic development is reactivated on 
incubation, and is dependent on environmental conditions.  Jungle fowl lay 12-20 
eggs over 17-25 days and once maternal behaviour is expressed, egg production is 
curtailed.  The hen incubates the eggs and rears the young for several weeks before 
returning to another phase of egg production.  A chicken can endure a series of 
reproductive cycles and live to approximately 4-6 years.  The roles of GnRH in the 
brain during these physiological events are poorly characterised.   
 
Chickens were first domesticated from the Red Junglefowl and Grey Junglefowl in 
south–east Asia before the 6th millennium BC (Eriksson et al., 2008).  Identification 
of the Leghorn strain during the Middle Ages in Livorno, Italy was a revolutionary 
milestone in poultry breeding (Etches, 1996).  This strain maintains egg production 
for long periods and displays maternal behaviour infrequently.  During the years of 
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domestication, the appearance and reproductive physiology of chickens has been 
transformed.  By the 1950s two distinct lines of commercial chicken emerged; 
Layers (egg production) and Broilers (meat production) (Etches, 1996).  Layer 
chickens have been genetically selected for high egg productivity whereas broiler 
chickens are selected for fast growth rate and increased body size.  Commercial 
laying hens are capable of producing up to 310 eggs per year 
(http://www.lohmanngb.co.uk/brown-char.html), whereas broilers selected for rapid 
growth rate have a poor reproductive efficiency, mainly due to disfunction in the 
orderly hierarchical ovarian follicular development (Robinson et al., 1993).  The 
domestic chicken is of great economic importance as it provides a nutritious source 
of protein in the form of meat and eggs.  The highest consumption rates are in 
industrialised western countries with the US ranking first (54kg/capita/year) and the 
European Union ranking  fifth (22kg/capita/year) in 2006 (Magdelaine et al., 2008).  
Poultry comprises one quarter of the worlds meat consumption and table egg 
production is around 280 billion per year (Sharp, 1998).  The success of the poultry 
industry and the power of genetic selection for desirable reproductive traits rely on 
birds with correct functioning of the HPG-axis to control ovulation rate, ovulation, 
semen production, incubation behaviour, the development of photorefractoriness and 
features associated with  sexual senescence (Dunn I. C. et al., 2009).  Further 
characterisation of the avian GnRH system may therefore provide unique 
information to enable better comprehension of the interplay between GnRH ligands 
and their receptors in the control of avian reproduction.  Additionally, studying the 
evolutionary biology of GnRH systems enables a further comprehension of how 
GnRH systems may have evolved to assume their function in modern taxa. (Okubo 
and Nagahama, 2008).   
The next sections 1.3 and 1.4 will outline the GnRH ligand and receptor subtypes found in 
vertebrates and non-vertebrates.  This will provide information on the complexity of GnRH 
systems.  In section 1.6, information available on GnRH systems in avian species is 
presented to lead into the experimental chapters in which the GnRH system in the domestic 
chicken was investigated.   
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1.3. Gonadotrophin-Releasing Hormone (GnRH) 
The co-ordinated functions of the HPG-axis regulate the reproductive system.  The 
‘HPG-axis’ refers to three endocrocine glands (hypothalamus, pituitary and gonad) 
as an entity, acting in a co-ordinated fashion.  The hypothalamus integrates signals 
from the environment (external cues/positive and negative), gonads and body 
(internal cues/positive and negative) to direct synthesis and release of GnRH.  This 
hormone synchronises the development and maturation of the reproductive system 
and modulates its function in mature animals through appropriate activation of 
gonadotrophin secretion from the pituitary gland.  Gonadotrophins stimulate growth 
and maintain the functions of the gonads.  The cellular and molecular complexity of 
the HPG-axis continues to be elucidated and is presented in outline in Fig. 1.1, using 
the mammalian (human) HPG-axis as an example where there is a well-developed 
pituitary gland and reproduction is dependent on oestrous cycles. 
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Figure 1. 1 
 
Fig. 1.1 A schematic diagram of the hypothalamo-pituitary-gondal axis (HPG-axis) 
from Sisk C and Foster D, Nature Neuroscience 2004; 7(10):1040-1047.  Internal and 
external cues and the developmental clock regulate the synthesis of GnRH in neurons which 
arise in the hypothalamus and project to the median eminence.  GnRH enters the 
hypophyseal portal vasculature where it binds to pituitary gonadotrophs to elicit the 
synthesis and release of LH and FSH.  These regulate development of the gonads and 
production of sex steroids (e.g. oestrogen and testosterone).  A neuroendocrine feedback 
loop exists, where the sex steroids influence the function of hypothalamic GnRH neurons.  
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1.3.1. GnRH isoforms 
It is well established that GnRH plays a pivotal role in the control of reproductive 
function and is a central initiator of the reproductive hormonal cascade in pubertal 
and  mature animals (Millar, 2005).  The first GnRH isoform to be characterised was 
isolated from extracts of porcine and ovine hypothalami in 1971 as a decapeptide 
(pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly.NH2) (Amoss et al., 1971; Baba et al., 
1971; Matsuo et al., 1971; Schally et al., 1971).  This finding pioneered the 
identification of GnRH peptides and/or the genes which encode them in a wide range 
of species.  Multiple forms of GnRH have been identified and their features have 
been extensively reviewed (Millar, 2005) (Tsai and Zhang, 2008).  To date, the 
GnRH family consists of 28 members found within two animal superphyla: 
Deuterostoma (vertebrates, echinoderms, tunicates, etc.) and Protostome (nematodes, 
molluscs, arthropods, etc.).  These superphyla differ in embryonic development.  In 
Deuterostoma the blastopore becomes the anus, whereas in Protostomes it develops 
into the mouth, however, together with other smaller phyla they make up the 
Bilateria in having bilateral symmetry.  Four longer peptide hormones consisting of 
twelve amino acids have recently been placed within the GnRH family.  These 
GnRH-like dodecapeptides are found within the Protostome superphyla, three within 
the phylum Mollusca (octopus, aplysia and the owl limpet) and one in the phylum 
Annelida (annelid) (Iwakoshi et al., 2002; Tsai, 2006; Tsai et al., 2003; Tsai and 
Zhang, 2008; Zhang et al., 2008).  The remaining twenty-four GnRH decapeptide 
forms have been identified within the Deuterostome superphlya, and are restricted to 
the phylum Chordata, with nine unique forms found in the protochordate tunicates 
and fifteen forms of GnRH found in vertebrates (Adams et al., 2003; Millar et al., 
2004; Tello and Sherwood, 2009; Tsai, 2006). The Deuterostome GnRH peptides 
possess a common molecular architecture, with conservation of the NH2-terminal 
amino acids (pGlu-His-Trp-Ser) and COOH-terminal domain (Pro-Gly.NH2), with 
the exception of the two conservative Tyr substitutions in the NH2-terminal in the 
guinea-pig (pGlu-Tyr-Trp-Ser) and lamprey I (pGlu-His-Tyr-Ser) (Adams et al., 
2003; Millar et al., 2004) (Fig. 1.2).  The most basal chordates (or protochordates) in 
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which GnRH peptides have been identified are tunicate and amphioxus (common 
lancelet) (Adams et al., 2003; Chambery et al., 2009).  The amphioxus GnRH 
peptide amino acid sequence is identical to that of mammalian GnRH (Chambery et 
al., 2009) whereas, the nine tunicate GnRH isoforms all vary from mammalian 
GnRH (Adams et al., 2003; Tello et al., 2005) (Fig. 1.2).  GnRH sequence variants 
have also been identified in lamprey, fish, frog, chicken and guinea pig (Fig. 1.2).  
The GnRHs found within Deuterostoma phylum Chordata include representatives 
from cartilaginous fish (e.g. dogfish and shark), teleost fish, amphibians, reptiles, 
aves and mammals (Kah et al., 2007).  Significantly, the identification of two GnRH 
peptides in the chicken between 1979 and 1984 (King and Millar, 1979; King and 
Millar, 1982a; King and Millar, 1982b; Miyamoto et al., 1983; Miyamoto et al., 
1982; Miyamoto et al., 1984) precipitated investigations into the identification of 
multiple forms of GnRH in vertebrates (Okubo and Nagahama, 2008).  In most 
vertebrate species there are usually two to three forms of GnRH (Millar, 2005), with 
fewer GnRH genes in mammals compared to protochordates, fish and amphibians 
(Morgan and Millar, 2004).  The most ubiquitous and highly conserved form of 
GnRH is chicken GnRH-II (Millar, 2005), which was first isolated from a chicken 
brain (Miyamoto et al., 1984). 
 
There is a lack of consensus regarding the nomenclature and forms of GnRH.  In 
vertebrate species GnRH forms have been generally designated names according to 
the order in which they were identified, sometimes making for complications in 
terminology where more than one GnRH form is present in the species (Morgan and 
Millar, 2004; Okubo and Nagahama, 2008).  A universal nomenclature based on 
phylogenetic analysis was suggested for molecular forms of prepro-GnRH in which 
three GnRH forms are classified (Fernald and White, 1999; White et al., 1998).  The 
classification of three forms of GnRH was further characterised based on genes and 
cDNA encoding GnRH (White et al., 1994; White et al., 1995) and comparative 
genomic analysis (Okubo et al., 2002).  Phylogenetic analysis confirmed the 
clustering of three forms of GnRH (Millar et al., 2004).  Thus, in the vertebrate 
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lineage there are three distinct paralogous forms of GnRH but all three forms to date 
are known to co-exist only in species of the teleost lineage (Okubo and Nagahama, 
2008).  It is unclear which phylogenetic group lamprey GnRH-I and GnRH-III and 
dogfish GnRH belong to (Okubo and Nagahama, 2008).  It has been suggested that 
lamprey and tunicate GnRH are unique to their species (Chambery et al., 2009).  A 
recent phylogenetic study comparing GnRH genes from representatives of both the 
Protostome and Deterostome superphyla classified the GnRHs into five major 
clusters (Fig. 1.3), GnRH-I, GnRH-II, GnRH-III, GnRH-IV (the lamprey forms) and 
GnRH-V (the Protostome forms) (Tsai and Zhang, 2008).  Additionally, the tunicate 
GnRH isoforms are shown to be distantly related to GnRH-III and GnRH-I (Tsai and 
Zhang, 2008) (Fig. 1.3).    
Figure 1. 2 
 
Fig 1.2 Primary amino acid sequence of naturally occurring GnRHs.  This figure was 
adapted form the original kindly donated by Dr. J. Tello.  The GnRH amino acids in the 
Protostome superphyla are dodecapeptides whereas those in the Deuterostoma superphyla 
are decapeptides.  The boxed regions show the conserved NH2 and COOH terminal residues 
in the decapeptides with the exception of the two Tyr residues in the Guinea pig and 
Lamprey I.  Note that the GnRH isoforms are named according to the species in which they 
were discovered and identical GnRHs may be present in more than one species.   
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Figure 1. 3 
 
Fig. 1.3. Phylogenetic tree of prepro-GnRHs in chordates and protostomes generated 
by the minimum evolution method adapted from Tsai P and Zhang L Biol. Reprod. 
2008;79:798-805.  The bootstrap values (in %) over 50% are given at each branch point. Prepro-
GnRHs are clustered into five groups (GnRH I to GnRH V). Each sequence is denoted by the name of 
its GnRH peptide form, the species from which it was isolated (in italics), and a GenBank accession 
number. Arabic numbers at the end of vertebrate sequences are used to indicate different precursors 
that encode the same GnRH peptide. Arabic numbers at the end of ciGnRH (tunicate) indicate 
different molecular forms of GnRH. The following abbreviations are used to denote the GnRH peptide 
forms: cGnRH-I, chicken GnRH-I; cGnRH-II, chicken GnRH-II; cfGnRH, catfish GnRH; ciGnRH, 
Ciona GnRH; gpGnRH, guinea pig GnRH; hrGnRH, herring GnRH; lGnRH-I, lamprey GnRH-I; 
lGnRH-III, lamprey GnRH-III; mGnRH, mammalian GnRH; pjGnRH, pejerry GnRH; sGnRH, 
salmon GnRH; sbGnRH, sea bream GnRH; wfGnRH, whitefish GnRH; octGnRH, octopus GnRH; 
apGnRH, Aplysia GNRH; anGnRH, annelid GnRH; olGnRH, owl limpet GnRH (Tsai and Zhang, 
2008). 
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A seminal study on African cichlid fish showed that three distinct GnRH genes are 
expressed in three separate cell populations and differential selective pressure on 
different parts of each gene suggested different functions for the three GnRH genes 
(White et al., 1995).  Studies investigating the anatomical localisation of GnRH-
producing neurons show that there is a heterogeneous distribution of the GnRH 
forms in the brain, which is likely to reflect different physiological roles (Fernald and 
White, 1999; Okubo and Nagahama, 2008).   
 
The structure of the mature chicken GnRH-II decapeptide hormone is conserved in 
species from bony fish to humans, and was suggested as the most primitive evolved 
form (Millar and King, 1987) and has subsequently been designated GnRH-II (Millar 
et al., 2004).  GnRH-II is produced in the midbrain tegmentum (Fernald and White, 
1999; Okubo and Nagahama, 2008).  In contrast, GnRH-I was designated due to its 
hypothalamic localisation (Sealfon et al., 1997; Troskie et al., 1998) and is released 
exclusively into the pituitary through projections to the median eminence (Fernald 
and White, 1999; Okubo and Nagahama, 2008).  In non-mammalian vertebrate 
members within the GnRH-I cluster, GnRH-I vary diversely in peptide sequence, 
although mammalian GnRH has been suggested to represent the ancestral form 
(Okubo and Nagahama, 2008), as it has been found in ancient fish (King et al., 1995; 
Lepretre et al., 1993; Sherwood et al., 1991) and more recently the peptide has been 
purified from amphioxus (Chambery et al., 2009).  Interestingly, in several mammals 
the GnRH-II gene has been inactivated or deleted and therefore they only possess the 
mammalian GnRH form (Morgan and Millar, 2004; Stewart et al., 2009).  A recent 
review on the GnRH-II genes in mammals shows that the GnRH-II is functionally 
compromised in 12 out of 22 mammalian GnRH-II genes studied, although large 
sections of the GnRH-II gene are retained in most mammalian species, suggesting 
that mammalian ancestors had a functional GnRH-II system (Stewart et al., 2009).   
 
The third form of GnRH is localised to the terminal nerve ganglion in the forebrain 
in teleost fish and is designated GnRH-III (Fernald and White, 1999; Okubo and 
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Nagahama, 2008; White et al., 1998).  Like GnRH-II, the peptide sequence for 
GnRH-III is completely conserved but is known to be present only in the teleost 
lineage (Millar et al., 2004; Okubo and Nagahama, 2008).  It was suggested that the 
gene encoding this peptide was generated after the divergence of the teleosts from 
the vertebrate (tetrapod) lineage (Millar et al., 2004).  However, more recent analysis 
of GnRH gene loci suggests that the third form of GnRH did not arise from a teleost-
specific genome duplication, and the gene may have been deleted during the early 
evolution of tetrapods (Okubo and Nagahama, 2008).  The GnRH forms may have 
either been adopted for specialised physiological function, or their roles may have 
become redundant, resulting in conversion to a pseudogene or may have been 
completely lost in certain species during the evolution of vertebrates.  It is also 
possible that the GnRH gene which retains function may have been able to 
compensate for the role of the non-functional or deleted genes (Okubo and 
Nagahama, 2008). 
 
1.3.2. GnRH functions 
The anatomical localisation of the neurons producing GnRH-I in the hypothalamus 
and their projections to the median eminence allows for its release into the pituitary 
vasculature (Millar, 2005; Sealfon et al., 1997; Troskie et al., 1998).  Therefore, it is 
the GnRH isoform primarily responsible for regulating production and secretion of 
pituitary gonadotrophins.  In mammals it is well established that GnRH-I plays a 
fundamental role in the control of reproduction by regulating gonadotrophins and 
promoting steroidogenesis and gametogenesis (Millar et al., 2004).  Pulsatile release 
of GnRH-I into the hypophyseal portal system stimulates the biosynthesis and 
secretion of LH and FSH (Fink, 1988).  Interestingly, studies have shown GnRH to 
induce production of other endocrine hormones, including growth hormone 
(Marchant et al., 1989), prolactin (Weber et al., 1997) and somatolactin (Kakizawa et 
al., 1997) in primary pituitary cell cultures from teleost species.  It is therefore 
feasible that GnRH may have a role in the control of various pituitary hormones in 
teleosts (Okubo and Nagahama, 2008). 
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The conservation of GnRH-II decapeptide sequence over 500 million years of 
evolution suggests it has an important physiological role although its precise 
functions remain unclear (Millar et al., 2004; Okubo and Nagahama, 2008).  
Localisation of GnRH-II the midbrain tegmentum (Okubo and Nagahama, 2008), 
and in the central and peripheral nervous systems (Millar et al., 2004) suggests that it 
acts as a neuromodulator (Millar et al., 2004; Okubo and Nagahama, 2008).  In 
support of this neuromodulatory role, GnRH-II expression occurs in amphibian 
sympathetic ganglia (Troskie et al., 1997) and GnRH-II treatment results in 
regulation of ion channels in bullfrog sympathetic ganglion cells (Bosma et al., 1990; 
Jones, 1987).  Functions for GnRH-II in modulation of reproductive behaviour and 
as a sensor of metabolic states have been proposed and intensively reviewed by 
Millar et al, 2004 and Obuku and Nagahama, 2008 and include functions in sexual 
arousal, reproductive behaviour, sexual behaviour, food intake and energy balance 
(Millar et al., 2004; Okubo and Nagahama, 2008). 
 
GnRH-III has been localised to the terminal nerve ganglion in the forebrain in teleost 
fish (Okubo and Nagahama, 2008; White et al., 1995).  Terminal nerve GnRH 
neurons project to the olfactory placode, optic nerves and are transported to a wide 
range of regions in the brain (Gonzalez-Martinez et al., 2001; Gonzalez-Martinez et 
al., 2002; Okubo and Nagahama, 2008).  The putative functions of GnRH-III have 
been reviewed by Obuku and Nagahama, 2008 and include functions in reproductive 
behaviour (e.g. nest-building), olfactory and visual sensory effects and possible 
hypophysiotropic functions through their overlap with GnRH-I neurons in the 
forebrain (Mohamed and Khan, 2006; Mohamed et al., 2005; Okubo and Nagahama, 
2008; Pandolfi et al., 2005; Vickers et al., 2004; Wong et al., 2004). 
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1.4. Gonadotrophin-releasing hormone receptor (GnRH-R) 
It has been assumed that GnRH isoforms elicit physiological effects by binding to 
cognate receptors, termed the Gonadotrophin-Releasing Hormone Receptors (GnRH-
R).  As outlined above (section 1.3) GnRH isoforms are heterogeneously distributed 
in the nervous system and the peripheral nervous system and this may reflect their 
physiological roles (Okubo and Nagahama, 2008).  However, the principle 
established function of GnRH is the control of reproduction through activity within 
the HPG-axis, and this is reflected in the expression of vertebrate GnRH receptors in 
pituitary gonadotrophs which constitute 8-15% of the anterior pituitary cells (Ruf et 
al., 2003; Stojilkovic et al., 1994).  The activation of the GnRH receptor through 
binding GnRH maintains the homeostatic activity within the reproductive hormonal 
cascade, by stimulating transcription of gonadotrophin genes and hormone secretion 
which in turn result in the functional maturation of the gonads (Fig. 1.4).   
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Figure 1. 4 
 
Fig. 1.4.  Schematic two-dimensional representation of the human GnRH receptor from 
Millar R et. al. Frontiers in Neuroendocrinology. 2008; 29(1):17-35.  GnRH receptors are 
typical of rhodopsin family GPCRs and share a common molecular architecture consisting of 
7 trans-membrane domains (boxed) connected by three extracellular loops, and three 
intracellular loops, an amino terminal extracellular domain and an intracellular carboxyl 
terminus.  Ligand binding residues (red) and residues thought to be important in receptor 
structure or binding pocket configuration (green) are shown. These include disulfide bond 
formation and glycosylation sites. Residues involved in receptor activation are shown in 
blue. Residues in squares are ones highly conserved throughout the rhodopsin-like family of 
GPCRs and designated as N.50 using the nomenclature of Ballesteros and Weinstein*. 
Residues involved in coupling to G proteins are shown in orange. Putative protein kinase C 
(PKC) and protein kinase A (PKA) phosphorylation sites are indicated. The intermolecular 
interactions between GnRH-I residues and the receptor are indicated with red lines.  The 
activation of the GnRH receptor through binding GnRH maintains the reproductive 
hormonal cascade by stimulating transcription and secretion of gonadotrophin hormones 
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1.4.1. GnRH receptor isoforms 
The earliest report of cloning a GnRH receptor cDNA occurred 21 years after the 
first GnRH peptide hormone was identified.  The first GnRH receptor cDNA was 
cloned from the mouse pituitary αT3 gonadotrope cell line and the amino acid 
sequence deduced and shown to be characteristic of GPCRs (Tsutsumi et al., 1992).  
The functionality of the receptor was confirmed by injecting sense RNA transcripts 
into Xenopus oocytes and determining receptor ligand-binding affinity (Tsutsumi et 
al., 1992).  GnRH-Rs are guanine nucleotide binding protein (G Protein) coupled 
receptors (GPCRs) (Limor et al., 1989; Perrin et al., 1989) specific for GnRH.  
GnRH receptors possess a common molecular architecture typical of rhodopsin 
family GPCRs, consisting of 7 trans-membrane domains connected by three 
extracellular loops (ECL), and three intracellular loops (ICL), an amino terminal 
extracellular domain and an intracellular carboxyl terminus, although mammalian 
GnRH receptors lack the intracellular cytoplasmic tail domain (Millar et al., 2004; 
Tsutsumi et al., 1992) (Fig.1.4).  Like GnRH isoforms, GnRH receptors have been 
identified within two animal superphyla, Deuterostomes and Protostomes.  The 
GnRH receptors found within the Protostomes lie within the phylum Mollusca 
(octopus) (Kanda et al., 2006).  The GnRH receptors found within the Deuterostomes 
are restricted to the phylum Chordata and include representatives from the  
protochordates (e.g. tunicates and amphioxus) (Tello and Sherwood, 2009) and 
vertebrates, inclusive of cartilaginous fish (e.g. dogfish), teleost fish, amphibians, 
reptiles, aves and mammals (Kah et al., 2007; Millar et al., 2004).   
 
Retention of several functional forms of GnRH in teleost species and two in most 
non-mammalian vertebrates suggested that two or three types of functionally 
different cognate GnRH receptors may exist, with each GnRH isoform functioning 
through its cognate GnRH receptor (Millar et al., 2004; Morgan and Millar, 2004).  
The high conservation of ECL 3 facilitated the PCR amplification of this region from 
genomic DNA from various vertebrates (Troskie et al., 1998).  Subsequently, 
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numerous full-length GnRH receptor sequences have been identified, with more than 
one receptor isoform identified within a single species.  In most vertebrates there are 
usually two to three forms of GnRH receptor present (Millar, 2005), although there 
are fewer GnRH ligand genes in mammals compared to protochordates, fish and 
amphibians (Morgan and Millar, 2004).   
 
Several distinct GnRH receptor genes have been identified in certain species of fish, 
with five identified in the masu salmon (Jodo et al., 2003; Jodo et al., 2005),  four 
identified in zebrafish (Tello et al., 2008), and three in medaka (Okubo et al., 2003).  
This may reflect whole-genome duplication in ancestral fish followed by slow 
sequence divergence resulting in retention of functionally identical genes (Hordvik, 
1998; Morgan and Millar, 2004).  In amphibians, up to three separate GnRH receptor 
genes have been identified in the bullfrog (Wang et al., 2001a) and two genes have 
been identified in African clawed frog (Troskie et al., 2000).  In reptiles and avian 
species, studies of GnRH systems have lagged behind and warrant further attention 
(Morgan and Millar, 2004).  Only one GnRH receptor was identified in the leopard 
gecko prior to 2005 (Ikemoto et al., 2004), although a recent report shows that there 
are now three separate genes (Ikemoto and Park, 2007).   In avian species, one GnRH 
receptor was identified prior to 2006 (Sun et al., 2001a; Sun et al., 2001b) and in this 
thesis the cloning and characterisation of a novel GnRH receptor from an avian 
species (chicken) is described (See Chapter 3).  In most mammalian species there is 
only one functional GnRH receptor gene, although in some primates (e.g. macaque 
and green monkey) a second functional GnRH receptor gene exists (Millar, 2003; 
Morgan and Millar, 2004; Neill et al., 2001).  In a recent study, 22 sequences of the 
mammalian GnRH receptor gene encoding the type II GnRH receptor were analysed 
and eight were found to be genetically intact (orangutan, African green monkey, 
macaque, marmoset, tree shrew, kangaroo, rat, pig and elephant), whereas the 
remaining 14 exhibited gene disruption or deletion (Stewart et al., 2009).    
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There is a lot of confusion regarding the nomenclature of GnRH receptor subtypes, 
with no standard nomenclature being adopted.  GnRH receptor genes have been 
designated names on an ‘ad hoc’ basis according to the chronology of their sequence 
derivation, or their pharmacological characteristics or tissue-specific expression, 
which makes interspecies comparisons particularly confusing (Millar et al., 2004).  
The re-naming of GnRH receptors according to phylogenetic classification is being 
adopted, in which three distinct classes of GnRH receptors from the vertebrate 
lineage can be grouped into separate clusters (Millar et al., 2004).   
 
A recent phylogenetic study examining GnRH receptor genes, with representatives 
from both the Protostome (octopus) and Deterostome superphyla inclusive of 
protochordates (amphioxus and tunicates) and chordates (fish, amphibian, avian and 
mammals), classify the GnRH receptors into 6 major clusters (Tello and Sherwood, 
2009) (Fig. 1.5).  There are three vertebrate clusters (as described above); type I 
GnRH receptors (mammalian and non-mammalian), type II GnRH receptors, type III 
GnRH receptors plus protochordate-specific GnRH receptors (urochordate and 
amphioxus) and a more distantly related cluster present in invertebrates (octopus and 
adipokinetic hormone receptor (AKHR) -like) (Fig. 1.5).  Interestingly, unlike the 
lamprey-specific GnRH genes (Tsai and Zhang, 2008) (Fig. 1.3), the lamprey GnRH 
receptor is classified with the type II GnRH receptors (Fig. 1.5).  Similarly, the 
tunicate GnRH genes are distantly related to GnRH-III and GnRH-I (Tsai and Zhang, 
2008) (Fig. 1.3) and the receptors lie in a separate protochordate lineage which does 
not coincide with the protochordate amphioxus receptors (Fig. 1.5).  This suggests 
that there was a rapid lineage-specific divergence in urochordate GnRH receptor 
sequences after the split from an amphioxus-like ancestor (Tello and Sherwood, 
2009).  This relationship appears to confirm the classification of GnRH variants (Fig. 
1.2) found in tunicates (Fig. 1.3).  The Prostosomian GnRHs were shown to 
represent a monophyletic lineage and were designated the name GnRH-V (Tsai and 
Zhang, 2008), this coincides with the separate cluster in which octopus GnRH 
receptor resides along with AKHR-like receptors (Fig. 1.5).   
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Surprisingly however, two of the four GnRH receptors identified in amphioxus 
(protochordate) coincide with the cluster in which the Protostome octopus GnRH 
receptor resides, along with AKHR receptors.  Adipokinetic hormone (AKH) (an 
invertebrate neuropeptide metabolic hormone found in insects) which is similar to 
the gene encoding vertebrate GnRH and also possesses a NH2-terminal pGlu and a 
COOH-terminal amide, is the cognate ligand for a GnRH receptor ortholog identified 
in the common fruit fly (Drosophila melanogaster) (Hauser et al., 1998; Staubli et 
al., 2002).  The nematode roundworm (C. elegans) AKH-GnRH-like peptide was 
also identified, and its precursor was similar to AKH found in insects and the GnRH 
precursor genes from protochordates and vertebrates (Lindemans et al., 2009).  The 
identification of a GnRH receptor homolog in the nematode roundworm enabled 
studies that showed both the nematode AKH-GnRH-like peptide and fruit fly AKH 
activate the nematode ‘GnRH receptor’ (Lindemans et al., 2009; Vadakkadath 
Meethal et al., 2006).  Additionally, gene silencing of the nematode roundworm 
AKH-GnRH-like peptide or the ‘GnRH receptor’ resulted in a delay in the egg laying 
process (Lindemans et al., 2009).  Therefore a functional role for AKH-‘GnRH 
receptor’ in reproduction probably arose prior to the divergence of the Protosomian 
and Deuterostomian superphyla (Lindemans et al., 2009).  The presence of fruit fly 
GnRH receptor ortholog and nematode roundworm, amphioxus and octopus GnRH 
receptor homologs coinciding in a separate cluster and/or the response to AKH-
GnRH like peptides suggest that this hormonal system evolved early during life on 
earth but was lost during vertebrate evolution. 
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Figure 1. 5 
 
Fig. 1.5. Consensus maximum likelihood phylogenetic tree of vertebrate GnRH-Rs and 
invertebrate GnRHR-like sequences (1000 bootstrap replicates) from Tello, J. A. et al. 
Endocrinology 2009;150:2847-2856.  Consensus maximum likelihood phylogenetic tree of 
vertebrate GnRHRs and invertebrate GnRHR-like sequences (1000 bootstrap replicates). Bootstrap 
proportions (shown as a percentage) for each hypothesized receptor group are indicated next to the 
branch leading to the group. The receptors sequences used to create the phylogram are: human (Homo 
sapiens) GnRHR1 (NP_000397); green monkey (Cercopithecus aethiops) GnRHR2 (AAK52746); 
rhesus monkey (Macaca mulatta) GnRHR2 (NP_001028014); house mouse (Mus musculus) GnRHR1 
(AAA37716); two chicken (Gallus gallus) GnRHRs (GnRHR1: NP_989984, GnRHR2: 
NP_001012627); three bullfrog (Rana catesbeiana) GnRHRs (GnRHR1: AAG42575, GnRHR2: 
AAG42949, GnRHR3: AAG42574); two pipid frog (Xenopus tropicalis) GnRHRs [GnRHR1, 
compiled from the Ensembl X. tropicalis genome project (version JGI 4.1) using peptide ID 
ENSXETP00000038462 and scaffold 22, GnRHR2: compiled from Ensembl peptide ID 
ENSXETP00000036235 and scaffold 3972]; two Nile tilapia (Oreochromis niloticus) GnRHRs (type 
1: BAC77240, type 2: BAC77241); three Japanese medaka (Oryzias latipes) GnRHRs (GnRHR1: 
BAB70506, GnRHR2: BAB70505, GnRHR3: BAC97833; two goldfish (Carassius auratus) GnRHRs 
(type A: AAD20001, type B: AAD20002); two African cichlid (Astatotilapia burtoni) GnRHRs 
(GnRHR1: AAU89433, GnRHR2: AAK29745); lamprey (Petromyzon marinus) GnRHR 
(AAQ04564), four tunicate (Ciona intestinalis) GnRHRs (GnRHR1: NP_001028997, GnRHR2: 
NP_001028996, GnRHR3: NP_001028995, GnRHR4: NP_001028994); octopus (Octopus vulgaris) 
GnRHR (BAE66647); fruitfly (Drosophila melanogaster) AKH receptor (AKHR; AAC61523); and 
the cockroach (Periplaneta Americana) AKHR (AAQ17230). The human arginine vasopressin type 
1A (AVPR1A; NP_000697) and oxytocin (OXTR; NP_000907) receptors were added as outgroups to 
root the tree. 
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1.4.2. GnRH receptor isoform functions 
According to phylogenetic classification, the vertebrate type I GnRH receptors are 
represented in teleost fish (numerous), amphibians (bullfrog), reptiles (leopard 
gecko) and avian (chicken) species and in mammals (human, mouse, rat).  The type 
II receptors include receptors from primitive fish (lamprey), amphibians (bullfrog, 
Western clawed frog), reptiles (leopard gecko) and mammals (rhesus monkey, 
African green monkey).  The type II GnRH receptors are more closely related to type 
III GnRH receptors than to type I receptors and it has been suggested that these two 
GnRH receptor subtypes may have arisen from genome duplication in an ancestral 
gene in lower vertebrates (Millar et al., 2004).  Unlike the type II GnRH receptors, 
the type III GnRH receptors include sequences from teleost fish (numerous), 
amphibians (bullfrog, pipid frog) and reptiles (leopard gecko) but do not occur in 
mammals (Fig.1.5).  
 
Comparisons of the expression with the three distinct classes of GnRH receptors 
from the vertebrate lineage [type I (mammalian and non-mammalian), type II and 
type III GnRH receptors] (Millar et al., 2004), will further aid attribution of function 
to specific receptor types.  Sometimes however, more than one GnRH receptor 
identified in a single species resides in the same phylogenetic clade as another GnRH 
receptor identified in the same species.  For example, the three medaka GnRH 
receptors classify into two distinct lineages (Okubo et al., 2003).  Two of the medaka 
GnRH receptors are type III and the other one is a type I (Tello et al., 2008) 
(Fig.1.5).  In the zebrafish, where four GnRH receptors have been identified, two 
distinct GnRH receptor types reside in the type III clade and two in the type I clade 
(Tello et al., 2008).  In the bullfrog and the leopard gecko, the three GnRH receptors 
that were identified (Ikemoto and Park, 2007; Wang et al., 2001a) segregate into 
three separate GnRH receptor groups (type I, type II and type III).  The first chicken 
GnRH receptor that was identified is designated a type I non-mammalian GnRH 
receptor type (Millar et al., 2004; Sun et al., 2001b) and the novel chicken GnRH 
receptor described in this thesis is a type III receptor (Chapter 3).  In most 
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mammalian species there is only one functional GnRH receptor gene which is 
classified as a mammalian type I GnRH receptor.  Eight GnRH receptor genes 
encoding a second form of GnRH receptor were found to be functionally intact are 
classified as type II GnRH receptors (Millar, 2003; Morgan and Millar, 2004; 
Stewart et al., 2009) 
 
The attribution of physiological significance to each GnRH receptor type by 
investigating the spatial expression of GnRH receptors is further complicated as 
studies have shown that more than one receptor type can be expressed in the same 
tissue.  For example, in the zebrafish, the anatomical distribution of the four GnRH 
receptors (type III and type I) is widespread in the brain, eye and gonads and 
additionally, all four of the GnRH receptors are expressed in the pituitary (Tello et 
al., 2008).  The sea bass possesses five isoforms of GnRH receptor (type III and type 
I) and all but one are expressed in the pituitary (Moncaut et al., 2005).  In goldfish, 
two subtypes of the GnRH receptor have been identified (both type I) (Illing et al., 
1999) and they are both expressed in the pituitary.  Therefore, GnRH systems exhibit 
species-specific recruitment of receptor subtypes and ligands within different tissues 
and there is also plasticity in the spatiotemporal expression patterns of GnRH 
receptor subtypes (Ikemoto and Park, 2007; Illing et al., 1999; Moncaut et al., 2005; 
Troskie et al., 2000; Wang et al., 2001a).  Additionally, in the catfish, both identified 
GnRH receptors (both type I) are expressed in a number of tissues (testes, brain and 
pituitary), there is a clear difference in levels of expression between the two in the 
brain and pituitary, and one receptor subtype is exclusively expressed in the ovary 
and heart (Bogerd et al., 2002).  In the bullfrog, three subtypes of GnRH receptor are 
expressed but only one (type III) predominates in the pituitary (Wang et al., 2001a).  
Two subtypes of GnRH receptor occur in the African clawed frog (Xenopus laevis) 
(Troskie et al., 2000) and one (type I) predominates in the pituitary.  The leopard 
gecko expresses three receptor subtypes in the pituitary, with one receptor subtype 
(type III) predominating in the anterior pituitary (Ikemoto and Park, 2007).  
Therefore, these observations also suggest that there is plasticity in evolutionary 
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recruitment of GnRH receptor subtypes for regulation of pituitary gonadotrophin 
production.  The type I GnRH receptor identified in the chicken is widely expressed 
in a range of tissues at low transcript levels.  Comparisons of this receptor and the 
novel chicken GnRH receptor expression levels were investigated in this thesis 
(Chapter 3).   
 
Studies of GnRH receptor activation by the naturally occurring endogenous ligands 
relevant to each species should help in the attribution of physiological function.  
Understanding ligand-binding interactions is important for understanding receptor 
function, as it is indicative of receptor activation (Millar et al., 2004). Most non-
mammalian GnRH peptides are at least an order of magnitude less active than 
mammalian GnRH at mammalian type I GnRH receptors as they lack a charged 
residue in position eight of the decapeptide (Fig. 1.2) (see section 1.3.1) (Millar et 
al., 1989).  Non-mammalian GnRH receptors are less selective for mammalian 
GnRH compared to non-mammalian GnRHs (Barran et al., 2005; Bogerd et al., 
2002; Illing et al., 1999).  It is now firmly established that GnRH-II  (relative to 
GnRH-I) has a higher binding affinity for all non-mammalian vertebrate receptors 
irrespective of their classification based on structural similarities (Pfleger et al., 
2002).  The promiscuity of receptor subtype activation in-vitro by different 
endogenous GnRH ligand isoforms as seen in teleost fish (Illing et al., 1999; 
Moncaut et al., 2005), amphibians (Troskie et al., 2000; Wang et al., 2001a) and 
reptilian (Ikemoto and Park, 2007) species,  suggests that a complex interplay 
between ligands and receptors may be possible in-vivo.  For example, in the goldfish, 
the two GnRH receptors (both type I) have a higher ligand selectivity for GnRH-II 
although they exhibited an 84 fold difference between them in affinity for GnRH-III 
(Illing et al., 1999).  In the catfish, one of the two identified GnRH receptors (both 
type I) had a higher ligand-binding selectivity for the endogenous GnRH-II than for 
GnRH-I (Bogerd et al., 2002).  Both receptors also had higher ligand-binding 
selectivity for GnRH-II compared to other analogs (Bogerd et al., 2002).  In the 
leopard gecko two of the three identified GnRH receptors (type I and III), were more 
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potently activated by GnRH-II than GnRH-I, although there was a marked difference 
in the potency of GnRH-II at these two GnRH receptors (Ikemoto and Park, 2007).  
Interestingly, however, there were no statistically significant differences in GnRH-II 
and GnRH-I stimulation at the third GnRH receptor (type II) (Ikemoto and Park, 
2007).  In the bullfrog, the three GnRH receptors (type I, II and III) were more 
potently stimulated with GnRH-II and GnRH-III compared to GnRH-I (Wang et al., 
2001a).  The greatest potency was observed with GnRH-II (Wang et al., 2001a).  
However, the receptor activation results in the leopard gecko and the bullfrog are not 
solely indicative of ligand-binding since receptor coupling efficiency may contribute 
to the observed differences.  The type I chicken GnRH receptor was shown to exhibit 
a higher ligand-binding selectivity with GnRH-II and GnRH-II exhibits greater 
potency at the receptor compared to the endogenous cGnRH-I and mammalian 
GnRH-I (Sun et al., 2001b).  In this thesis the comparison of the ligand-binding 
affinities and potency of endogenous ligands and GnRH analogs at the type I and the 
novel type III chicken GnRH receptor is compared (Chapter 4).  Interestingly, one 
of the protochordate GnRH receptors identified in amphioxus, has a higher ligand 
selectivity for GnRH-I than GnRH-II, and this preferential selectivity has never been 
observed in any other non-mammalian GnRH receptor (Tello and Sherwood, 2009).   
 
1.4.3. GnRH receptor isoform structure 
As mentioned previously, non-mammalian GnRH receptors are typical GPCRs 
which consist of seven alpha-helical transmembrane domains (TMD), connected by 
three extracellular loops (ECL) and three intracellular loops (ICL) plus a cytoplasmic 
C-terminal domain (Millar et al., 2004; Sealfon et al., 1997).  However, unlike all 
most GPCRs, mammalian GnRH receptors lack the intracellular cytoplasmic tail 
domain (Millar and Pawson, 2004; Tsutsumi et al., 1992)  The ECLs and the 
extracellular ends of the TMDs are mostly involved in binding GnRH analogs 
(Millar et al., 2004).  Conformational changes in the TMDs elicited by ligand-
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binding are involved in receptor activation and the ICLs participate in interactions 
with G Proteins and signal transduction apparatus (Millar et al., 2004). 
 
The arginine residue in position 8 of mammalian GnRH-I is a crucial determinant for 
high-affinity binding and ligand-binding selectivity for mammalian GnRH receptors 
(Flanagan et al., 1994; Illing et al., 1999; Millar et al., 1989; Millar and King, 1983).  
It is believed to interact with an acidic residue of the GnRH receptor (Fig. 1.4) to 
induce a βII conformation of the ligand (Fromme et al., 2001; Millar et al., 2004).  
The glutamate residue in ECL3 at position 301 in the mouse receptor was shown to 
have a role in receptor recognition of Arg8 of mammalian GnRH (Flanagan et al., 
1994) possibly through an ionic interaction with the positively charged arginine side 
chain (Flanagan et al., 1994; Millar et al., 2004).  Interestingly, ECL3 of each 
receptor type possesses a distinctive sequence motif and this has a key influence on 
ligand-receptor selectivity (Millar et al., 2004).  Mammalian type I receptors possess 
a S-E/D-P motif whereas non-mammalian type I receptors have a P-X-S/Y motif 
(Millar et al., 2004; Wang et al., 2004).  A site-directed mutation study has shown 
that the residues surrounding the glutamic acid residue (E) are important for 
differential ligand-binding selectivity (mGnRH-I vs GnRH-II) between mammalian 
and non-mammalian GnRH receptors (Wang et al., 2004).  Ligand contact sites have 
been identified in type I GnRH receptors and have been shown to be conserved in all 
vertebrate type I GnRH receptors (Millar et al., 2004).  These include: (1) A highly 
conserved lysine residue in TMD3 of GnRH receptors which preserves agonist 
binding to GnRH receptors (Zhou et al., 1995) and interacts with His2 or pGlu of 
GnRH ligands.  These residues are conserved in all ligands except in the guinea pig 
and where His2 is substituted with a Tyr residue (Fig. 1.2).  This interaction is 
facilitated by a hydrogen bond formation (Hoffmann et al., 2000; Millar et al., 2004; 
Sealfon et al., 1997).  (2) An asparagine residue located near the extracellular surface 
of TMD2 is a critical determinant of ligand potency, particularly for ligands with 
glycinamide(10) (Davidson et al., 1996), which is conserved in all native GnRH 
ligands (Fig 1.1).  This Asn residue serves as a docking site for the C-terminal 
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Gly10NH2  of the ligands through hydrogen-bond formation (Millar et al., 2004).  (3) 
The aspartic acid (Flanagan et al., 2000) located at the extracellular boundary of 
TMD2 may form an inter-helical interaction with a lysine residue in TMD3 of GnRH 
receptors (Zhou et al., 1995) to contribute to the formation of the agonist binding 
pocket (Flanagan et al., 2000).  This residue may also interact with His2 of GnRH 
ligands (Flanagan et al., 2000).   
 
The C-terminal tail of GnRH receptors influences receptor ligand-specificity, 
receptor expression at the cell surface, receptor phosphorylation, internalisation and 
desensitisation (Blomenrohr et al., 1999; Heding et al., 1998; Willars et al., 1999).  
Desensitisation of receptors is caused by sustained stimulation of the receptor 
(McArdle et al., 2002) and is a consequence of receptor phosphorylation.  
Phosphoryation stabilises ß-arrestin association with the receptor, resulting in the 
inhibition of G protein binding, dissociation from signalling complexes and 
subsequent inactivation of effector proteins (McArdle et al., 1999; McArdle et al., 
2002).  The C-terminal cytoplasmic domain is important in receptor desensitisation 
as phosphorylation of amino acids located in this region facilitates ß-arrestin 
association with the receptor (McArdle et al., 2002),  although residues in the 
intracellular loops may also facilitate ß-arrestin binding  (Ferguson, 2001).   
 
Aspartic acid residues in both loci of the functional helix2/helix7 micro-domain are 
conserved in non-mammalian GnRH receptors and serve to regulate G protein 
coupling and expression (Flanagan et al., 1999; Zhou et al., 1994).  Functionally 
verified residues in mammalian GnRH receptors known to be important for receptor 
G protein coupling and signal transduction include alanine in ICL3 (Myburgh et al., 
1998), and the Arginine cage motif (DRXXX(I/V)) which resides at the cystolic end 
of TMD3 (Ballesteros et al., 1998).  
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1.5. GnRH Receptor Signalling 
GnRH receptors are GPCRs (Limor et al., 1989; Perrin et al., 1989) specific for 
GnRH.  The heterotrimeric G proteins consist of an α subunit which binds guanine 
nucleotides and a complex consisting of tightly bound ß and γ subunits (Spiegel et 
al., 1992).  This structure has been determined at the atomic level by X-ray 
crystallography (Fig. 1.6).  Stimulation of the receptor by the ligand (GnRH) results 
in a conformational change in Gα resulting in the release of GDP and the association 
of GTP with the α subunit (Spiegel et al., 1992).  This causes a further 
conformational change of the α subunit leading to G protein activation and a 
dissociation of the ßγ-complex (Bourne et al., 1991; Spiegel et al., 1992) (Fig. 1.6).  
Thus GPCRs act as guanine nucleotide exchange factors for the associated G 
proteins, which on ligand-receptor stimulation result in the Gα and Gβγ subunits 
activating effector systems (Naor, 2009).  The activation of the effector proteins 
initiates diverse downstream second messenger signalling pathways that characterise 
the nature of the response to receptor activation (Kraus et al., 2001; McArdle et al., 
1999).  Activation of GnRH receptors by GnRH initiates a cascade of intracellular 
signal transduction pathways that results in the synthesis and release of 
gonadotrophins from the pituitary gonadotrophs into the systemic circulation (Conn 
and Crowley, 1994; McArdle et al., 2002; Sealfon et al., 1997; Stojilkovic and Catt, 
1995).   
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Figure 1. 6 
 
 
Fig. 1.6. Schematic diagram of a three-dimensional crystal structure of a GPCR 
embedded in a cell membrane adapted from: 
http://www.vanderbilt.edu/vicb/Articles/LensSummer2005/WhereAreTheNewDrugs.htm 
The GPCR is loosely attached to a heterotrimeric G protein, consisting of alpha, beta and 
gamma subunits, inside the cell. On ligand activation, the receptor changes shape eliciting 
the release of guanosine diphosphate (GDP) from the alpha subunit. GDP is replaced by the 
higher-energy guanosine triphosphate (GTP). Hydrolysis of GTP causes the alpha subunit to 
dissociate from the beta and gamma subunits. The subunits then interact with other 
intracellular proteins to transmit signals via two independent pathways. Within a few 
seconds, GTP is hydrolysed to GDP by Gα-GTPase, the G protein subunits reassociate, and 
the signalling is “turned off”. 
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1.5.1. G protein dependent signalling 
G proteins consist of a family of alpha, beta and gamma subunits.  Different alpha 
subunit isoforms include Gαq/11*, Gαs, Gαi, and Gα12/13 (Kraus et al., 2001).  GnRH 
receptors primarily couple to Gαq in pituitary gonadotrophs (Grosse et al., 2000; 
Hsieh and Martin, 1992; Naor et al., 1986; Naor et al., 2000), but evidence shows 
that GnRH receptors may also couple to Gαi and Gαs (Hawes et al., 1993; Liu et al., 
2002; Stanislaus et al., 1998).  GnRH receptors interact with multiple G proteins in a 
‘cell-context’ dependent manner and may affect different signal transduction 
mechanisms according to cell type (Dobkin-Bekman et al., 2006).  GnRH receptors 
couple to Gαq proteins (Anderson et al., 1992; Hsieh and Martin, 1992) which exert 
signal transduction principally by activating membrane associated phospholipase C 
(PLC) (Hsieh and Martin, 1992).  GnRH receptors additionally couple to Gαi and 
Gαs proteins (Ruf et al., 2003), which results in the inhibition or stimulation of 
adenylyl cyclase respectively (Birnbaumer, 1992; Stojilkovic et al., 1994).  Gαi can 
also transmit signals via transactivation of receptor tyrosine kinases (RTKs) (Luttrell 
et al., 1999).  Gα12/13 signals through protein tyrosine kinases (PTKs) (Jiang et al., 
1998).  In this review, only Gαq will be described in great detail as this is most 
relevant to the results. 
 
1.5.2. Gαq coupling 
GnRH-Rs couple to Gαq proteins which on GnRH stimulation cause an increase of 
PLC beta (PLCβ) activity (Naor et al., 1986; Naor et al., 2000).  There are six distinct 
isoforms of PLC (Stewart et al., 2007), although the full details remain unclear 
regarding which isoforms couple to Gαq proteins on GnRH receptor activation.  
GnRH induced activation of GnRH receptor and subsequent activation of Gαq results 
in a rapid Ca2+ independent stimulation of PLCβ (Naor et al., 1986).  This increases 
intracellular levels of Ca2+ which acts by positively stimulating more activation of 
PLCβ (Kunkel et al., 2007).   
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Phospholipase A2 (PLA2) and phospholipase D (PLD) are both activated by GnRH 
after a time delay of about 5-15 minutes after PLC activation (Naor, 2009; Poulin et 
al., 1996; Zheng et al., 1994).  Activation of PLD results in the formation of 
phosphatidic acid (PA) by acting on a membrane phospholipid (phosphatidylcholine) 
which is then converted to diacyl-glygerol (DAG) by a PA-phosphohydrolase, which 
facilitates a prolonged activation of protein kinase C (PKC) (Naor, 2009).  The PLA2 
generates long chain unsaturated fatty acids, for example arachidonic (AA), linoleic 
and linolenic acids which have been implicated in the activation of PKC (Naor, 
1991; Naor, 2009).  Activation of PLCβ results in the hydrolysis of 
phosphatidylinositol 4,5-biphosphate (PIP2) and formation of inositol(1,4,5)-
triphosphate (IP3) and DAG.  IP3 and DAG second messengers result in Ca2+ 
mobilisation from the endoplasmic reticulum by activating calcium channels present 
and PKC activation respectively (Naor, 2009; Naor et al., 2000; Naor et al., 1998; 
Ruf et al., 2003; Stojilkovic et al., 1994).  Ca2+ is a ubiquitous second messenger with 
a wide range of actions (Berridge et al., 2000). 
 
1.5.3. Mitogen-Activated Protein Kinase 
The organisation of the mitogen-activate protein kinase (MAPK) cascade is complex.  
Activation of the MAPK cascade is initiated through a GTP-binding protein (smGP 
or RAS family of proteins) or alternatively, by certain adaptor proteins.  These then 
transduce their signal directly or through a mediator kinase to the MAPK kinase 
kinase (MAP3K) point of the MAPK cascade.  A series of phosphorylation events 
facilitated by the enzymes e.g. MAPK kinase (MAPKK), MAPK and MAPK-
activated protein kinase (MAP-KAPKs) can occur (Naor et al., 2000) (Fig. 1.7.).  
There are four separate modules of the MAPK cascade that are named according to 
their MAPK component and include extracellular signal-related kinase (ERK), Jun 
N-terminal kinase (JNK), p38MAPK (p38) and big MAPK (BMK) (Naor et al., 
2000) (Fig. 1.7.).   
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Figure 1. 7 
 
Fig. 1.7. Schematic representation of the mitogen-activated protein kinase (MAPK) 
cascades from Naor Z et. al., Trends in Endocrinology and Metabolism 2000; 1(3):91-
99.  Abbreviations: Extracellular signal-related kinase (ERK), Jun N-terminal kinase (JNK), 
p38MAPK and big MAPK (BMK) (Naor et al., 2000). 
 
1.5.4.  GPCR signalling to the MAPK cascade via G proteins 
As mentioned, following ligand stimulation, activated GPCRs affect Gα and Gβγ 
subunit functions (Naor, 2009).  Activated Gαq primarily PLCβ which produces IP3 
(which induces Ca2+) and DAG (Naor et al., 2000).  Ca2+ is a ubiquitous second 
messenger signalling molecule with a wide range of actions (Berridge et al., 2000).  
The signal transduction continues with the free Ca2+ activating CaM kinase II which 
phosphorylates and inhibits RAS-GTPase-activating protein (RAS-GAP), inducing 
RAS and subsequently MAPK activation (Chen et al., 1998).  Alternatively Ca2+ and 
DAG activate PKC or through Ca2+/RAS-guanine nucleotide exchange factors 
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(GEFs) and RAS activation lead to MAPK activation (Farnsworth et al., 1995; Naor 
et al., 2000; Nishizuka, 1992).  Activated PKC activates c-RAF which is partially 
dependent on RAS, resulting in stimulation of the ERK cascade (Kolch et al., 1993).  
Additionally, Ca2+ and PKC may induce activation of receptor PTKs (Zhang et al., 
1996) which, influenced by interaction with cell adhesion integrin complexes, lead to 
MAPK activation (Naor et al., 2000).  Thus a variety of signalling pathways (which 
have not been fully elucidated) result in PTK transactivation via the adaptor protein 
Shc and activate the Grb-SOS-RAS protein complex, resulting in MAPK activation 
(Naor et al., 2000).  Gαs interacts with adenylyl cyclase to stimulate production of 
cAMP (Birnbaumer, 1992), which activates protein kinase A (PKA) (Beebe, 1994), 
or RAS-GEF (de Rooij et al., 1998).  Both induce activation of RAP1 and through 
RAF activation result in activation of the MAPK cascade (Naor et al., 2000).  Gαi 
transduces signal transduction through interaction with RAP-GAP (Jordan et al., 
1999; Mochizuki et al., 1999) which in turn inactivates RAP1 activity, resulting in 
ERK activation (Naor et al., 2000).  Gα12 and Gβγ may also signal thought the MAPK 
cascade, although the signalling mechanisms have not been elucidated in detail (Naor 
et al., 2000).  Gα12 primarily signals through Bruton’s tyrosine kinase (BTK) 
stimulation (Jiang et al., 1998), whereas Gβγ complexes can signal through 
phosphoinositide 3-kinase (PI3K) to activate the MAPK cascade (Naor et al., 2000).  
The pathways from Gαq and Gβγ to RAS-RAF-MEK-ERK is complex, and may 
involve some cell type specific components (Dobkin-Bekman et al., 2006; Karnoub 
and Weinberg, 2008).  Signalling to the MAPK cascade by Gαq, Gαs, Gαi, Gα12 and 
Gβγ as outlined above is summarised below (Fig. 1.8).  There is evidence for 
feedback regulation involving particular protein phosphatases resulting in transient 
effects on the MAPK pathway (Karnoub and Weinberg, 2008; Omerovic et al., 
2007).  The feedback regulation may also involve some cell-type specific 
components (Karnoub and Weinberg, 2008; Omerovic et al., 2007).  The complexity 
of RAS-MAPK signalling complexes continues to be elucidated such that cell 
context-specific signalling may be better understood in the future (Karnoub and 
Weinberg, 2008). 
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Figure 1. 8 
 
Fig. 1.8.  Schematic representation of G protein-coupled receptor (GPCR) and G 
protein signalling towards mitogen-activated protein kinase (MAPK) cascades from 
Naor Z et. al., Trends in Endocrinology and Metabolism 2000; 1(3):91-99. Dashed 
arrows represent indirect activation/inactivation of the MAPK cascades. Abbreviations: 
BTK, Bruton tyrosine kinase; Dyn, dynamin; FAK, focal adhesion kinase; GAP, GTPase-
activating protein; GEF, guanine nucleotide exchange factor; GRF, guanine-specific 
nucleotide-releasing factor; GRK, GPCR kinase; PI3K, phosphoinositide 3-kinase; PKA, 
protein kinase A; PKC, protein kinase C; PLC, phospholipase C (Naor et al., 2000). 
 
1.5.5. Signalling cascades and their involvement in GnRH regulation of 
gonadotrophin gene expression 
MAPK regulate gene transcription by activating nuclear transcription factors or 
through phosphorylation of protein kinases (Kraus et al., 2001).  A role for PKC, 
ERK and JNK but not p38 were implicated in GnRH regulation of the common alpha 
gonadotrophin subunit (Fowkes et al., 2002; Roberson et al., 1999; Weck et al., 
1998; Xie et al., 2005).  LH beta subunit gene transcription was shown to be 
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mediated by Ca2+ (Weck et al., 1998), although the role of Ca2+, ERK, and c-Src, but 
not JNK have been implicated in the transcriptional regulation of the common alpha 
gonadotrophin subunit in  αT3-1 cells (Harris et al., 2003).   In contrast studies have 
shown that Ca2+ is involved in common alpha gonadotrophin subunit activation, 
although the effect of GnRH on LH beta is mediated by PKA and ERK (Call and 
Wolfe, 1999; Saunders et al., 1998).  JNK but not PKC and ERK has been implicated 
in LH beta regulation (Yokoi et al., 2000), although in Lβ-T2 cells PKC, ERK and 
JNK but not Ca 2+ have been implicated in LH beta gene expression (Harris et al., 
2003).  FSH beta subunit gene regulation appears to be mediated by PKC, ERK, 
JNK, p38 and c-Src but not Ca 2+ (Bonfil et al., 2004).  These conflicting results may 
reflect the different cell types, gene promoters from different species and cell culture 
conditions used experimentally (Naor, 2009).  
 
Activation of the MAPK cascade results in transcriptional regulation, as certain 
components are able to translocate to the nucleus (Dobkin-Bekman et al., 2006; Naor 
et al., 2000).  A number of studies have shown that ERK can translocate to the 
nucleus (Bonfil et al., 2004; Caunt et al., 2006; Harris et al., 2003; Liu et al., 2002).  
ERK is able to phosphorylate the ternary complex factor Elk 1, and Elk 1 can bind to 
GnRH-response element located within the common alpha subunit gene promoter 
region (Marais et al., 1993; Roberson et al., 1995).  c-Jun and c-Fos may be activated 
by JNK and ERK respectively, which then act on AP-1 sites present on the FSH beta 
promoter (Bonfil et al., 2004; Coss et al., 2004; Huang et al., 2001).  C-Jun substrate, 
has been implicated in GnRH activation of the LH beta subunit promoter (Yokoi et 
al., 2000).  Additionally, c-Jun and ATF-2 (both substrates of JNK) can bind to the 
CRE domain of the human common gonadotrophin alpha subunit promoter (Heckert 
et al., 1996) 
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1.6. Avian GnRH system 
1.6.1. Endogenous chicken GnRH ligands 
Two GnRH isoforms are present in the chicken (cGnRH-I and GnRH-II) (Sharp and 
Ciccone, 2005).  Chicken GnRH-I (cGnRH-I) was the first non-mammalian GnRH 
identified (King and Millar, 1982a; King and Millar, 1982b; Miyamoto et al., 1982).  
cGnRH-I differs from mammalian GnRH (mGnRH) by the substitution of a 
glutamine in place of an arginine residue in position 8 of the mammalian decapeptide 
(Miyamoto et al., 1983).  The second form of GnRH, GnRH-II was first identified in 
the chicken, and later found to be present in all vertebrate classes (Miyamoto et al., 
1984).  Recently a third variant of an avian GnRH has been suggested in the 
hypothalamus of songbirds, and has been deduced to be structurally similar to 
lamprey GnRH-III (l-GnRH-III) (Bentley et al., 2004).  Contrary to this however, 
there is no genomic DNA evidence for a third GnRH ligand in the chicken to date 
(Morgan and Millar, 2004), suggesting that if it does exist in songbirds, it is not 
present in the chicken.  Despite their early identification the function of the two 
GnRH ligands in the chicken still presents a conundrum.  Pulsatile release of GnRH 
controls differential LH and FSH secretion in mammals, with higher GnRH pulse 
frequencies leading to increased LH release, whereas lower frequencies result in 
increased FSH secretion (Wildt et al., 1981).  Although there have been no direct 
evidence of GnRH pulsitility in birds, GnRH release is probably pulsatile in birds.  In 
support of this view, chicken plasma LH is episodically released which is likely to be 
a reflection of GnRH pulsatility (Senthilkumaran et al., 2006; Vizcarra et al., 2004).  
In quail there is evidence from experiments performed on hypothalamic slices to 
show that GnRH release is pulsatile (Li et al., 1994), further supporting the probably 
pulsatile release of GnRH in chickens. 
 
Conflicting studies have been reported on the ability of the cGnRH ligands to 
stimulate gonadotrophin production, but age, sex and reproductive status of the 
experimental birds needs to be considered (Bédécarrats et al., 2006).  Both cGnRH-I 
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and GnRH-II stimulate LH release from chicken pituitary in-vitro (Hattori et al., 
1986a; Millar et al., 1986) and in-vivo (Chou et al., 1985b; Hattori et al., 1986b; 
Proudman et al., 2006; Sharp et al., 1986).  More recent studies have shown 
exogenous lGnRH-III is capable of inducing release of LH in song sparrows (Bentley 
et al., 2004).  Pituitary responsiveness to cGnRH-I and GnRH-II is sexually 
differentiated in the domestic hen, with LH release being greater in the cockerel than 
in the hen. The relative potencies of cGnRH-I and II ligands are identical in mature 
male chickens (cockerel) and juvenile chicken of either sex, while GnRH-II is more 
potent in releasing LH  in the mature laying hen (Sharp et al., 1987).  The study 
performed by Sharp et al. in 1987 confirmed previous in-vivo observations in 
cockerels (Chou et al., 1985a) and hens (Sharp et al., 1986), and studies in-vitro 
(Hattori et al., 1986a; Millar et al., 1986) showing that GnRH-II is more potent in 
releasing LH when compared with cGnRH-I in the hen, but not in the cockerel.  
cGnRH-I and GnRH-II have been reported to stimulate FSH release in-vitro, (Hattori 
et al., 1986a; Millar et al., 1986).  Using a newer specific antibody, there is no 
evidence in-vivo of cGnRH-I, GnRH-II and lGnRH-III having a significant effect on 
FSH release from chicken pituitary gonadotrophs (Bruggeman et al., 1998; Dunn et 
al., 2003; Krishnan et al., 1993; Proudman et al., 2006).  Probably, cGnRH-I does not 
directly stimulate FSH release, but may stimulate FSH biosynthesis, while a role for 
GnRH-II in FSH production has not been established (Dunn et al., 2003; Sharp and 
Ciccone, 2005).  It must be noted that evidence on release of LH and FSH in the 
experiments outlined above does not necessarily implicate a physiological role of 
cGnRH-I and GnRH-II as hypothalamic portal delivery of the cGnRH ligands to the 
pituitary needs to be considered.     
 
Immunisation of laying hens against cGnRH-I, but not against GnRH-II, results in a 
complete regression of the reproductive system and a decrease in plasma LH (Sharp 
et al., 1990), suggesting that gonadotrophin secretion is controlled by cGnRH-I 
rather than GnRH-II.  This is consistent with the presence of cGnRH-I in the median 
eminence (Mikami et al., 1988a; Sharp et al., 1990) (Fig. 1.9.) and the correlation 
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between hypothalamic cGnRH-I peptide content and reproductive status (Sharp et 
al., 1990).  In contrast, immuno-histochemical studies have not found GnRH-II in the 
chicken median eminence using antibodies specific for GnRH-II (Fig. 1.9.)  (Mikami 
et al., 1988a; Sharp et al., 1990), and no change in hypothalamic GnRH-II peptide 
content is seen in cockerels around the onset of puberty (Sharp et al., 1990).  
Moreover, in the purification and structural identification of GnRH from 249,000 
chicken median eminence samples, only one form of GnRH (cGnRH-I) was found 
(King and Millar, 1982a; King and Millar, 1982b).  Controversially however, three 
different studies suggest GnRH-II is present in the median eminence of the chicken 
(Vangils et al., 1993) and quail (Clerens et al., 2003; D'Hondt et al., 2001; Vangils et 
al., 1993).  These studies used the same antibody and its specificity remains 
questionable; given that these claims are so controversial no attempt to negate the 
staining with cGnRH-I was made.  Another study has suggested the presence of a 
lGnRH-III-like peptide in the chicken hypothalamus (Berghman et al., 2000), 
although appropriate controls for antibody specificity were not included in the 
experiment, leaving the finding open to criticism.  
 
Therefore, cGnRH-I is thought to be the hypothalamic peptide responsible for 
regulating the pituitary gonadotroph (Mikami et al., 1988a; Sharp et al., 1990).  
However hypothalamic GnRH-II levels do decrease when the pre-ovulatory release 
of LH is maximal or declining in the hen. Thus GnRH-II may be involved in 
neuroendocrine events preceding ovulation (Wilson et al., 1990) or serve other 
reproduction related functions, such as behaviour.  In other avian species GnRH-II 
affects reproductive behaviour in ring doves and soliciting behaviour in female song 
sparrows  (King and Millar, 1995; Maney et al., 1997).  The cGnRH peptides achieve 
their physiological roles through chicken GnRH receptors (cGnRH-R); however the 
effects of pharmacological doses of the peptides may be misleading because they 
may activate either or both of the cGnRH receptor isoforms.  Therefore 
investigations in to the pharmacological responses of endogenous ligands at the 
cGnRH receptor isoforms will provide better understanding. 
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Figure 1. 9 
 
PARASAGITTAL SECTION 
Fig. 1.9.  Schematic representation of a parasagittal section of an adult chicken brain 
indicating the location of GnRH immunoreactive perikarya, adapted from Dunn, I. and 
Millam, J. Poultry and Avian Biology Reviews 9(2):61-85.  The blue regions represent the 
sites of GnRH-II and the red regions represent the sites of cGnRH-I immunostaining.  
Majority are in regions marked with an X.  Other regions of the brain are indicated on the 
diagram.  The anterior pituitary gland is anatomically positioned relative to the brain.  Note 
the size of the pituitary gland is not to scale.  Arrows represent axon projections to the 
median eminence.  (Dunn and Millam, 1998) 
 
1.6.2. The HPG-axis in the chicken 
cGnRH-I neurons integrate the signals from the external and internal environment to 
produce pulsatile output of cGnRH-I which subsequently plays a pivitol role in the 
control of reproduction through the HPG-axis (Dunn I. C. et al., 2009).  cGnRH-I 
neurons emerge from the  olfactory placode or the presumptive ectoderm of the nasal 
cavity (Elamraoui and Dubois, 1993) and migrate to the olfactory epithelium along 
the olfactory nerve to the hypothalamus (Norgren, 1996) (Fig. 1.9.).  In adult 
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chickens, 12% of cGnRH-I cell bodies are located in the pre-optic hypothalamus and 
the majority of cGnRH-I neurons are extra-hypothalamic in the septal region of the 
subpallium, which distinguishes the  axis from several mammalian species (Kuenzel 
and Golden, 2006).  The hypothalamic control of reproduction is accomplished at 
two levels.  (1) cGnRH-I synthesis in the cell bodies in the pre-optic hypothalamus 
(2) cGnRH-I release from nerve terminals at the median eminence (Dunn I. C. et al., 
2009).   
 
Sexual maturation in cockerels coincides with increases in hypothalamic cGnRH-I 
peptide content  and there is also an increased capacity to release cGnRH-I in the 
median eminence in sexually maturing cockerels (Knight, 1983; Knight et al., 1985).  
The changes in day-length (photoperiod) are perceived in the hypothalamus, which 
results in increased hypothalamic cGnRH-I mRNA content (Dunn and Sharp, 1999).  
However, there is an inhibitory effect of sex steroid hormones on hypothalamic 
neurons, which reduces cGnRH-I peptide content and expression of cGnRH-I mRNA 
(Dunn I. C. et al., 2009) (Fig. 1.10).  This has been demonstrated by an increase in 
hypothalamic peptide content after castration (Knight et al., 1983; Sharp et al., 1990; 
Sun et al., 2001a) and release of cGnRH-I from the median eminence (Lal et al., 
1990).  The effects of surgical castration on cGnRH-I peptide content and mRNA 
were reversible on administration of oestrogen (Dunn et al., 2003; Sharp et al., 1994; 
Sun et al., 2001a).  There is a pre-ovulatory release of cGnRH-I which is induced by 
circulating progesterone derived from the dominant pre-ovulatory ovarian follicle 
(Wilson and Sharp, 1973).  The onset of incubation behaviour coincides with a 
dramatic decrease in cGnRH-I mRNA (Dunn et al., 1996). Interestingly in ageing 
reproductively active hens, there is no decrease in hypothalamic cGnRH-I content 
(Sharp et al., 1992) although cGnRH-I levels in the hypothalamus are more 
susceptible to negative-stimuli (Contijoch et al., 1992).  Studies on ageing hens show 
there is a decrease in cGnRH-I in the median eminence (Contijoch et al., 1992).  
There is a lower cGnRH-I mRNA in food-restricted birds versus those fed ad-libitum 
and food-restriction reduces the release of cGnRH-I from the median eminence 
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(Ciccone et al., 2007; Lal et al., 1990).  Studies performed by immunoneutralisation 
of inhibin in cockrels showed that there was accelerated puberty and hindered age-
related sexual senescence in these birds (Satterlee et al., 2006).  Therefore, it is 
feasible that inhibin has a inhibitory effect on gonadotrophin biosynthesis (Dunn I. 
C. et al., 2009).   
  
However, in 2000, the discovery of a novel inhibitory hypothalamic peptide from the 
Japanese quail hypothalamus that belongs to the RF-amide neuropeptide family 
characterised by a C-terminal Arg-Phe-NH2 motif that inhibits gonadotrophin 
secretion from the pituitary gland was identified, and termed Gonadotrophin 
Inhibitory Hormone (GnIH) (Tsutsui et al., 2000).  GnIH nerve terminals are present 
in the external layer of the median eminence, and are therefore appropriately located 
to be released into the hypophyseal portal vasculature (Tsutsui et al., 2000).  There is 
also a direct contact between GnIH fibres and GnRH neurons in the hypothalamus, 
which suggests that GnIH may directly influence the synthesis and release of GnRH-
I  (Bentley et al., 2003).  In primary chicken pituitary cultures, GnIH treatment 
reduced LH and FSH release as well as  mRNAs  encoding the common alpha 
subunit and the FSH beta subunit, but not the LH beta subunit (Ciccone et al., 2004).  
Chronic treatment with GnIH may affect LH beta subunit expression in quail (Ubuka 
et al., 2006).  GnIH mRNA is increased in incubating hens although it is not 
increased in out-of-lay hens (Ciccone et al., 2005).  GnIH therefore may play a role 
in regulation of gonadotrophin secretion although more research is required to 
establish it’s role in the HPG-axis (Dunn I. C. et al., 2009). 
 
Therefore, there is both a stimulatory and inhibitory arm in the hypothalamic control 
of reproduction (Fig. 1.10).  This inhibitory component would be controlled by the 
activity of GnIH, whereas the stimulatory control is accomplished by both the 
synthesis and release of cGnRH-I.  cGnRH-I synthesis and release which is 
dependent on external (e.g. day-length, food availability) and internal (sexual 
maturation, steroids, proteins, incubation, aging, GnIH) cues.  However, the release 
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of cGnRH-I elicits its effects through cGnRH receptor isoforms.  It is the activation 
of the cGnRH receptor isoforms that results in the relay of information from the 
release of cGnRH-I into the pituitary.  Therefore studies of the cGnRH receptor 
isoforms will be beneficial in understanding the hypothalamic control of 
reproduction.   
Figure 1. 10 
 
Fig. 1.10.  Schematic representation of the hypothalamic-pituitary-gonadal axis (HPG 
axis) in the chicken showing the key components discussed in this thesis.  Factors with 
stimulatory effects are indicated in green text and green arrows, whereas factors with 
inhibitory effects are indicated in red text and red arrows. There is both stimulatory (GnRH) 
and inhibitory (GnIH) hypothalamic control of reproduction influencing the synthesis and 
release of luteinising hormone (LH) and follicle stimulating hormone (FSH).  The release of 
cGnRH-I elicits its effects through cGnRH-R isoforms which are expressed in the pituitary.  
It is the activation of the cGnRH receptor isoforms that results in the relay of information 
from the release of cGnRH-I into the pituitary and the subsequent synthesis and release of 
LH and FSH.  Components of this figure were taken from the following website: 
http://www.exchange3d.com/cubecart/animals-and-plants/chicken-brain-3d-
model/prod_5740.html 
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1.6.3. Chicken GnRH Receptor Isoforms 
cGnRH-I is released from the median eminence into the hypophyseal portal 
vasculature to the pituitary.  Pituitary gonadotrophs are the target cells for GnRH-I 
released from the median eminence as they express the cognate GnRH receptors 
(Stojilkovic et al., 1994). Although the expression of cGnRH receptors in 
gonadotrophs has not been confirmed by in-situ hybridisation, chicken pituitary 
glands are capable of releasing LH in response to GnRH in-vitro suggesting the 
gonadotrophs express cGnRH receptors.  Interestingly, in avian species, the two 
gonadotrophins, FSH and LH, are not expressed in the same cell type (Proudman et 
al., 1999; Puebla-Osorio et al., 2002).  The specific receptor types through which the 
cGnRH ligands elicit biological responses in the chicken are not known.  Identifying 
the expression of cGnRH-R subtypes on LH and FSH cells would inform of their 
potential differential function on gonadotrophin biosynthesis.  The type I chicken 
GnRH receptor (cGnRH-R-I) was previously identified in 2001 and found to be 
expressed in the chicken in a wide range of central nervous and peripheral nervous 
system tissues at the transcriptional level (Sun et al., 2001a; Sun et al., 2001b).  The 
cloned cGnRH-R-I receptor encodes a 375 amino acid peptide with a signature 
molecular architecture characteristic of GPCRs (Sun et al., 2001b).  Pharmacological 
studies proved cGnRH-R-I had a higher binding affinity and is more potent at 
stimulating inositol phosphate accumulation with GnRH-II than cGnRH-I (Sun et al., 
2001b), although cGnRH-I is thought to be the hypothalamic peptide responsible for 
regulating the pituitary gonadotroph (Mikami et al., 1988a; Sharp et al., 1990).  This 
suggested the existence of an alternate receptor which would have a higher binding 
affinity and inositol phosphate accumulation with cGnRH-I, the ligand primarily 
responsible for gonadotrophin synthesis.  The advent of the chicken genome 
sequence (Ensembl 2004) made it feasible to perform sequence homology searches 
to identify novel cGnRH receptor isoforms.  A novel cGnRH-R cDNA sequence was 
identified using this approach, and is the focus of this thesis. 
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1.7. Aims of this Thesis 
The overall aim of this thesis is to gain further understanding of the control of 
reproduction in the chicken with particular reference to the physiological roles of the 
two cGnRH receptor subtypes.  The studies presented in this thesis focus on 
comparisons of the expression, pharmacology and signalling cascades activated by 
the two cGnRH receptor subtypes.  Specific hypotheses and aims are presented in 
subsequent chapters as follows: 
CHAPTER 3 
Hypothesis: It is hypothesised that the chicken GnRH system utilises receptor 
subtypes and ligands in a tissue-specific fashion. 
Aims: To clone the cDNA encoding the novel isoform of the cGnRH-R from a 
broiler chicken (commercial meat-type chicken) and to compare it with the type I 
cGnRH receptor.  Comparisons of functionally important amino acid residues and 
sequence micro-domains can be made using amino acid sequence alignment of the 
two cGnRH receptors and phylogenetic classification can be performed.  The use of 
real-time RT-PCR will enable the quantification of cGnRH receptor mRNA 
expression in various tissues; in addition to the changes in expression of the two 
receptors in birds of varying reproductive stages can be determined.  This will be 
supported by determining the number of different transcripts arising from the novel 
cGnRH receptor isoform by Northern blot analysis and determining the cellular 
localisation of the cGnRH receptor isoform expression in the pituitary gland by in-
situ hybridisation 
CHAPTER 4 
Hypothesis:   It is hypothesised that since cGnRH-R-III mRNA is predominantly 
expressed in the pituitary (Chapter 3) it may be more functionally “selective” for the 
GnRH ligand that primarily regulates the pituitary gonadotroph function. 
Aims: The aims of this study were to compare and further characterise the 
pharmacological properties of the novel isoform of cGnRH receptor with the type I 
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cGnRH receptor.  This includes analysis of ligand-binding and inositol phosphate 
production in response the endogenous ligands, cGnRH-I and GnRH-II, which may 
elucidate the physiological roles of the receptor subtypes.  To identify a GnRH 
analog that differentially binds and activates one of the chicken GnRH receptor 
homologs which would facilitate in-vivo and in-vitro studies to allow delineation of 
the role of each cGnRH-R subtype in terms of gonadotrophin synthesis and release.  
To evaluate the ability of the splice variants of the novel cGnRH receptor to bind to 
cGnRH ligands and determine their effects on full-length receptor function.  
Additionally, to perform a comparison the ligand-induced internalisation of both 
cGnRH receptors 
Chapter 5 
Hypothesis:  It is hypothesised that since three Src homology 3 (SH3) binding 
motifs were identified in the novel cGnRH receptor (and not the type I cGnRH-R) 
(Chapter 3) it may differentially target signalling pathways through subtype-specific 
interactions with SH3 domain-containing proteins to differentially activate the 
MAPK cascade when compared to the type I cGnRH-R subtype.  
Aims:  In an attempt to elucidate the physiological roles of the receptor subtypes and 
attribute a differential functional capacity to the two receptor subtypes, the ability of 
the two receptors to differentially activate the MAPK signalling cascade was 
investigated.  This included comparative dose and time-dependent analysis of pERK 
1/2 activation via the two chicken GnRH receptor subtypes.  To identify whether the 
SH3 binding motifs identified exclusively in the novel type III cGnRH receptor 
attribute a differential capacity in terms of pERK 1/2 activation.  To examine the 
protein complexes directly interacting with the two chicken GnRH receptor subtypes 
using immuno-precipitation and western blotting. 
























This chapter details the methods and laboratory techniques used throughout this 
thesis, and the procedures used in the experiments.  In addition explanations are 
given of the technicalities of procedures where necessary.  All materials used and 
suppliers information is provided.  All work not performed by myself has been 
acknowledged.  Where RNAse free H20 is used, it applies to H20 treated with 0.1% 
Diethylpyrocarbonate (DEPC) overnight then autoclaved. 
 
2.2. Animal husbandry and welfare 
Birds were sacrificed by cervical dislocation or barbiturate overdose in accordance 
with the UK Home Office guidelines for animal welfare.  Tissue samples were 
collected according to the experimental purpose.  
 
2.3. Phylogenetic Tree Construction 
Phylogenetic tree construction of avian, reptilian and amphibian GnRH receptors  
amino acid sequences was performed using the MEGA4 program using the default 
settings (Tamura et al., 2007).  The evolutionary history was inferred using the 
neighbour-joining method (Saitou and Nei, 1987).  The neighbour-joining method of 
phylogenetic tree construction uses distance measures to correct for multiple hits at 
the same sites, and chooses a topology showing the smallest value of the sum of all 
branches as an estimate of the correct tree (Saitou and Nei, 1987).  Simplitically, it 
uses an iterative algorithm, which is based on a topology that gives the least total 
branch length at each step of the algorithm (Gascuel and Steel, 2006).  The reliability 
of the inferred tree was estimated by applying a bootstrap test, which is evaluated 
using a bootstrap resampling technique (Felsenstein, 1985).  Bootstrapping analysis 
gives a way to judge the strength of support for nodes on phylogenetic trees 
(Felsenstein, 1985). A number is presented by each node, which reflects the 
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percentage of bootstrap trees which also resolve that clade.  If a bootstrap value for a 
give interior branch is 95% or higher, then the topology at that branch is considered 
reliably correct (Efron et al., 1996).   
 
2.4. Ribonucleic Acid (RNA) extraction from neuroendocrine tissues 
and non-neuroendocrine tissues 
2.4.1. Collection of neuroendocrine and non-neuroendocrine samples 
for RNA extraction 
The tissues were rapidly dissected with sterile dissection instruments, weighed and 
placed in RNAase-free eppendorfs which were snap frozen in liquid nitrogen and 
stored at -80°C.  
2.4.2. Trizol Extraction method 
The tissue was placed in matrix D tubes (Q-biogene-Alexis, Nottingham, UK) 
containing 600µl of Trizol (Invitrogen, Paisley, UK) which is a mono-phasic solution 
of phenol and guanidine isothiocyanate.  Homogenisation was performed to disrupt 
the tissue architecture and release the RNA with a FastPrep FP120 homogeniser (Q-
biogene-Alexis, Nottingham, UK) using two 20-second pulses at speed 4.5.  100µl of 
chloroform was added, the solution was then vortexed, incubated on ice for 15 
minutes and then vortexed again to ensure lysis of cells.  The solution was 
centrifuged at 18630xg (g centrifugal force) for 15 minutes to separate the RNA from 
tissue debris, DNA and proteins.  The upper aqueous layer which contains the RNA 
was transferred into an eppendorf containing 2µl (40µg) of molecular biology grade 
glycogen (Sigma-Aldrich, Dorset, UK).  An equal volume of isopropanol was added 
to the retrieved supernatant to precipitate the RNA.  The solution was vortexed 
vigorously, incubated on ice for 15 minutes and vortexed once more to ensure 
mixing and precipitation of all RNA molecules.  Precipitated RNA was isolated by 
centrifugation of the tube at 18630xg for 15 minutes and the supernatant was 
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removed immediately and the RNA pellet was washed twice with 1000µl of 70% 
EtOH.  After each wash the solution was centrifuged at 9505xg for 8 minutes.  All 
residual EtOH was removed from the tube, and the RNA pellet was air dried in a 
desiccator for approximately 45 minutes.  The transparent pellet was dissolved in 
100µl of RNAse free H20 and stored at –80°C. 
2.4.3. Ultraspec II extraction method on small and large tissue samples 
The tissue was placed in matrix D tubes containing 1000µl of Ultraspec II (Biotecx, 
Abington, UK).  Homogenisation was performed to disrupt the tissue architecture 
and release the RNA with a FastPrep FP120 homogeniser using two 20-second 
pulses at speed 4.5.  After a 5 minute incubation on ice to allow the complete 
dissociation of nucleoprotein complexes, 200µl of chloroform was added to separate 
the aqueous and organic phases.  The solution was then vortexed, incubated on ice 
for 15 minutes and then vortexed again to ensure isolation of RNA molecules.  The 
solution was centrifuged at 18630xg for 15 minutes to separate the RNA from tissue 
debris, DNA and proteins.  400µl (small tissue/neuroendocrine) or 500 µl (large 
tissue/non-neuroendocrine) of the clear upper aqueous layer supernatant which 
contains the RNA was transferred into an eppendorf prepared with 200µl (small 
tissue) or 250µl (large tissue) of isopropanol and 20µl (small tissue) or 25µl (large 
tissue) of RNA TackTM Resin (Biotecx, Abington, UK) and vortexed thoroughly.  
The precipitated total RNA attached to the RNA Tack Resin was then separated from 
the solution by centrifugation of the tube at 18630xg for 5 minutes.  The supernatant 
was removed immediately and the RNA pellet was washed twice with 1000µl of 
70% EtOH.  After each wash the solution was centrifuged at 16060xg for 8 minutes.  
All residual EtOH was removed from the tube, and the total RNA attached to the 
RNA TackTM Resin was air dried in a desiccator for approximately 45 minutes.  The 
RNA TackTM Resin was re-suspended in 30µl of RNAse free H20 and stored at –
80°C. 
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2.4.4. RNA quantification and analysis of integrity 
The quality and the quantity of the RNA extracted can be analysed by measuring the 
optical density (OD) at 260nm and 280nm of a 1:50 dilution of the sample.  The ratio 
of the OD260/OD280 is an indication of the purity of the RNA and can be compared 
with pure RNA (ratio =2.1). 
Ratio = (OD260 / OD280) 
Quantity = (OD260 x 40 x 50) / 1000 = total RNA µg.µl-1 
An aliquot of the dissolved RNA from each sample was analysed by agarose gel 
electrophoresis (non-denaturing agarose gel) on an agarose gel to check the RNA 
integrity.  Two bands corresponding to the two ribosomal subunits (28s and 18s) 
within each total RNA sample should be visible.  Prior to running the gel, all 
equipment was cleaned with RNAse-Zap® (Ambion, Warrington, UK) and 
thoroughly rinsed with RNAase free H20.  The samples were prepared by heating the 
samples to 65°C for ten minutes to alleviate the RNA secondary structure and run 
immediately. 
 
2.5. Reverse transcription of total RNA to single stranded cDNA 
Reverse transcription of total RNA was done using a First Strand synthesis kit (GE 
Healthcare, Buckinghamshire, UK) to synthesise single stranded complementary 
deoxyribonucleic acid (cDNA).  5µg of total RNA made up to 8µl by adding the 
appropriate amount of RNAse free H20.  The total RNA was then heated to 65°C for 
10 minutes to alleviate RNA secondary structure allowing more efficient priming and 
cDNA synthesis.  The RNA was chilled on ice, as rapid cooling prevents the 
formation of secondary structure.  The remaining components listed below were 
added for first strand cDNA synthesis to give a 15µl total volume reaction mix. 
Bulk reaction mix......................................................................................................5µl 
200mM Dithiothreitol (DTT)....................................................................................1µl 
0.2 µg/µl Not I-d(T)18 bifunctional primer ................................................................1µl 
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The reaction mix was then incubated at 37°C for 1hour.   A final incubation at 90°C 
for 5 minutes was performed to denature the reverse transcriptase enzyme.   Samples 
of cDNA were stored at -20°C for long term storage. 
 
2.6. Chicken GnRH-R-III cDNA amplification using PCR in samples 
from male and female, juvenile and sexually mature birds 
2.6.1. Tissue distribution of cGnRH-R-III mRNA expression 
Forward (f) and reverse (r) primers which are complimentary to the 3’ ends of each 
of the sense and anti-sense strand of the target DNA were designed to span exon 
boundaries.  cGnRH-R-III-713-735f (exon 2-3) (GCT CGC TGT GCC GCA GCT 
GT) and cGnRH-R-III-933-952r (exon 3-4) (ACG TCC CTG GAG GAG AAG AG)  
were used to amplify cGnRH-R-III cDNA from anterior pituitary, hind brain, 
cerebrum, cerebellum, median eminence, anterior hypothalamus, posterior 
hypothalamus, olfactory bulb, optic lobe, adrenal gland, kidney, small intestine, 
spleen, testes, ovary and liver cDNA samples of the pre-pubertal males and females 
(initial denaturation step, 95°C for 4minutes; 40cycles of 95°C/30s, 62°C/30s, 
72°C/45s and a final extension 72°C/7minutes).  The PCR products were visualised 
using agarose gel electrophoresis.   
 
2.7. mRNA Quantification using Real-time PCR 
2.7.1. cGnRH-R-I and cGnRH-R-III mRNA Expression using Real-time 
PCR 
Total RNA was prepared as described in methods section (2.4).  cDNA synthesis was 
performed using a standardised quantity of total RNA (5µg), using a First Strand 
synthesis kit as described in methods section (2.5).  Real-time PCR was used to 
quantify the mRNA expression of cGnRH-R-I and cGnRH-R-III in the pituitary 
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gland, median eminence, small intestine and gonads using the method based on the 
fluorescence of SYBR ® Green I dye (Invitrogen, Paisley, UK) with the 
recommended amplification conditions.  Primers that spanned the exon boundaries; 
cGnRH-R-III-713-735f (GCT CGC TGT GCC GCA GCT GT) and cGnRH-R-III-
933-952r (ACG TCC CTG GAG GAG AAG AG) for cGnRH-R-III mRNA 
amplification and primers cGnRH-R-I-701-722f (AGC TAA AGA TCA ACA AAA 
GTC T) and cGnRH-R-I-1100-1082r (TTG GAG CCA CCT GAT GTC A) for 
cGnRH-R-I amplification were used.  Standard curves for amplification of each 
GnRH receptor homolog cDNA were made with the cGnRH-R-III cDNA in 
Bluescript II SK(+) vector (described in 2.10.2), and a cGnRH-R-I cDNA in 
Bluescript II SK(+) vector (Agilent Technologies, Cheshire, UK ) (containing 488 bp 
inserted into the EcoRV/NotI site  of the vector, that corresponds to bases 1-421 of 
AJ304414 and 1-68 of AJ506779).  A linear regression analysis of serially diluted 
quantities of cDNA template versus cycle threshold values was plotted, allowing the 
calculation of the quantity of target nucleic acid from the test-sample cycle threshold 
values.  PCR reaction with either template reached plateau phase following the same 
number of amplification cycles, indicating similar amplification efficiencies. 
 
2.8. Northern Blot Probe Synthesis 
2.8.1. Oligonucleotide Probes 
5’ end labelling using [γ-32P]-dATP and T4 polynucleotide kinase (PNK) was 
performed with 20pmol 73-120-cGnRH-R-III_sense (TGG TGC CGA TGT GGG 
AGC GCT GGG AGC AGT GAG TGG GCG GTG TTT GA) and 73-120-cGnRH-
R-III_anti-sense (TCA AAC ACC GCC CAC TCA CTG CTC CCA GCG CTC CCA 
CAT CGG CAC CA) oligonucleotides using the mirVana Probe and Marker Kit 
(Ambion, Warrington, UK).  The probes were subsequently purified with the 
components included in the kit.  These oligonucleotides, designed in the 5’ region 
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upstream of the translation start site in exon 1 are specific for cGnRH-R-III and are 
not homologous to cGnRH-R-I. 
2.8.2. DNA Probes 
A chicken actin alpha 1 skeletal muscle (ACTA1) (Accession Number 001031063) 
DNA probe was synthesised from 0.25µg of purified insert DNA by random primer 
labelling with 32P-dCTP using the Rediprime Kit (Random primer labelling) (GE 
Heathcare, Buckinghamshire, UK) and purified using Sephadex G50 Nick columns 
(GE Heathcare, Buckinghamshire, UK) according to the manufacturer’s 
recommendations.  The probe was to check for equal loading of sample RNAs in 
Northern blotting. 
2.8.3. RNA probes 
A RNA probe was synthesized by in-vitro transcription of 1µg of cGnRH-R-
III_1210f-3217r-pBSK(+) using the T7 promoter linearized with EcoRI. The fragment 
was gel purified as above. Transcription was performed using a T7 transcription kit 
(Promega, Hampshire, UK) according to the manufacturer’s instructions using [32P] 
UTP (800 Ci/mmol), (GE Healthcare, Buckinghamshire, UK)  Free nucleotides were 
removed using Sephadex G50 Nick columns according to the manufacturer’s 
recommendations.  
 
2.9. Northern blotting 
2.9.1. Northern blotting using [γ-32P] labelled oligonucleotide probes to 
detect cGnRH-R-III expression 
Total RNA was isolated using Ultraspec II according to the manufacturer’s 
instructions as described above (2.4).  Poly (A)+ RNA was purified from anterior 
pituitary gland, small intestine and testes total RNA pools using Oligotex mRNA 
Spin-Columns (Qiagen, Crawley, UK).  3µg of Poly (A)+ RNA was loaded on a 
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denaturing 1% agarose-formaldehyde gel and electrophoresed for 2.5 hours at 100 
volts.  Transfer of the RNA to a Hybond-N nylon membrane, (GE Healthcare, 
Buckinghamshire, UK) was performed by capillary action overnight in 10 x saline-
sodium citrate (SSC) buffer.  The RNA was fixed by baking the membrane for 2 
hours at 80°C.  Pre-hybridisation and hybridisation of the membrane was carried out 
using ULTRAHyb-Oligo hybridisation buffer (Ambion, Warrington, UK) according 
to manufacturer’s instructions overnight at 42°C using radiolabelled oligonucleotide 
probes (1x106cpm probe/ml hybridisation buffer).  Post-hybridisation stringency 
washes were 2x15 minute in 0.1% SSC, 0.1% sodium docecyl sulphate (SDS) at 
70°C.  The membrane was exposed to Kodak BioMax MA autoradiographic film 
(Sigma-Aldrich, Dorset, UK) for 2 days at -80°C prior to development. 
2.9.2. Northern analysis using [α-32P] labelled RNA probe to detect 
cGnRH-R-III expression 
Alternatively, total RNA was prepared from muscle, brain cortex and pituitary gland 
tissues and 15µg was subsequently prepared for Northern blotting according to the 
method of Pelle and Murphy (1993).  The gel was washed in 50mM NaOH, 10mM 
NaCl for 45 minutes and the RNA was transferred to Hybond-XL membrane, (GE 
Healthcare, Bukinghamshire, UK) using capillary transfer overnight with 20 x SSC.  
After washing in 2 x SSC the RNA was cross-linked to the filter using Ultraviolet 
light in a Stratalinker™ (Agilent Technologies, Cheshire, UK) set at 120 millijoules.  
Hybridization and pre-hybridisation was carried out using ULTRAHyb solution 
(Ambion, Warrington, UK) according to the manufacturer’s instructions at 68°C.  
The cGnRH-R-III_1210f-3217r-pBSK(+) anti-sense RNA probe was added at a 
concentration of 1x106 cpm/ml and hybridization was performed overnight at 68 °C. 
The membrane was then rinsed in 2 x SSC, 0.1% SDS twice, each for 5 minutes, 
followed by a series of more stringent washes to a final wash of  0.01 x SSC, 0.1% 
SDS (2 x 30 min) at 90°C. The membrane was exposed overnight to a phosphor-
imaging screen and digital images were captured using a Molecular Imager FX (Bio-
Rad, Hertfordshire, UK). 
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2.10. Cloning of chicken GnRH receptor isoform cDNA sequences 
2.10.1. Cloning the cGnRH-R-I cDNA into pcDNA I/Amp vector 
The expression construct containing cGnRH-R-I gene cloned into pcDNA1/Amp 
(Invitrogen, Paisley, UK) mammalian expression vector was used as previously 
reported (Sun et al., 2001b).  The construct was recovered from a glycerol stock (Bob 
Millar Lab / MRC, HRSU Edinburgh), by growing the colony for plasmid DNA 
purification using the QIAprep Miniprep Kit (Qiagen, Crawley, UK) according to the 
manufacturer’s protocols.  Once the integrity of the insert DNA was verified, the 
selected clone was grown for plasmid DNA purification using the HiSpeed Plasmid 
Maxi Kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. 
2.10.2. Cloning the cGnRH-R-III cDNA into pBluescript II SK(+) 
vector 
Trizol RNA extraction method as described in methods (2.4.2) was applied to isolate 
total RNA from pooled mature male and female pituitary glands.  cDNA synthesis 
was performed on 5µg of total RNA using the First Strand synthesis kit as described 
in methods section (2.5).  NCBI Genbank sequence AY895154 was used as a 
reference sequence for design of cGnRH-R-III cDNA primers. Primers cGnRH-R-
III-1210f (TGA GTG GGC GGT GTT TGA) and cGnRH-R-III-3217r (TAG AGG 
CAT TGT GGA GCA GA) flanking the entire coding region of the receptor were 
used to amplify pituitary cDNA using standard PCR conditions (initial denaturation 
step of 95°C/5minutes, 35 cycles of denaturation 95°C/30s, annealing 61.9°C/30s 
and elongation 72°C/90s and a final extension 72°C/7minutes).  Once amplification 
of the desired 1386bp PCR product was achieved, blunt ending (filling in recessed 
3’ends of DNA fragments) of the PCR product was performed with the addition of 
10% by volume of DNA polymerase I (Klenow fragment) (Promega, Hampshire, 
UK) and subsequent incubation at 37°C for 15 minutes prior to deactivating the 
enzyme at 75°C for 5 minutes.  The residual dNTPs from the PCR provided the 
necessary nucleotides for the blunt ending.  The blunt-ended PCR product band was 
then electrophoresed on a 2% agarose gel and excised.  The DNA was extracted from 
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the gel using the GeneClean® Spin Kit (Q-Biogene, Nottingham, UK), according to 
the manufacturer’s recommendations.  200ng of a pBluescript II SK(+) vector 
(PBSK+) was linearised at the EcoRV site of the multiple cloning site (MCS) in a 
final volume of 10µl.  A final dilution of the reaction mix by the addition of 30µl 
H2O was performed to give a final plasmid concentration of 5ng.µl-1.  An additional 
dephosphorylation step on the linearised plasmid prior to ligation was performed, 
which reduces the chances of the plasmid re-circularising, by removal of the 5’-
terminal phosphates.  The procedure makes use of shrimp alkaline phosphatase 
(Roche Applied Science, West Sussex, UK) which is easily denatured after use by 
heat treatment at 65°C.  A rapid DNA ligation kit (Roche Applied Science, West 
Sussex, UK) was used to insert the DNA into the vector.  The components listed 
below were added to give a 20µl total volume reaction mix. 
~0.4 μg.μl-1 purified PCR product............................................................................ 7 μl 
Linearised 5ng.μl-1 pBSK+ vector ............................................................................ 1 μl 
5x DNA dilution buffer............................................................................................ 1 μl 
T4 DNA ligase ......................................................................................................... 1 μl 
2x T4 DNA ligation buffer..................................................................................... 10 μl 
The reaction mix was allowed to incubate at room temperature for 5 minutes.  An 
additional EcoRV digest was performed after ligation to eliminate any plasmid that 
had re-circularised without insert.  The tubes were then chilled on ice prior to 
transformation.  The ligation reaction was transformed into XL1 Blue E. coli 
competent cells (Agilent Technologies, Cheshire, UK).  The ligation reaction was 
added to a 50μl aliquot of the competent cells and incubated on ice for 30 minutes.  
The cells were heat shocked for 45 seconds at 45°C and immediately cooled on ice 
for 60 seconds.   700μl of room temperature SOC was added to each sample and the 
cells were shaken at 250 rpm at 37°C for 45 minutes.  The cells were then plated 
onto pre-warmed agar plates and incubated at 37°C for 16 hours.  Colonies were 
picked after 16 hours and grown for plasmid DNA purification using the QIAprep 
Miniprep Kit according to the manufacturer’s instructions.  Once the integrity of the 
insert DNA was verified, the selected clone was grown for plasmid DNA purification 
using the HiSpeed Plasmid Maxi Kit according to the manufacturer’s instructions. 
Chapter 2                                                                                    Materials and Methods
 
 61
2.10.3. Cloning the cGnRH-R-III cDNA into pcDNA 3.1/myc-His-A 
vector 
The cGnRH-R-III fragment between the BamHI and HincII restriction sites of 
pBSK(+) vector cloned above was removed by restriction digest and subcloned into a 
mammalian expression vector pCDNA3.1/myc-His-A (Invitrogen, Paisley, UK) 
between the BamHI and EcoRV sites of the MCS.  The rapid DNA ligation kit was 
used as described in 2.10.2, to clone the DNA sequence.  The ligation reaction was 
transformed into XL1 Blue E. coli competent cells as in 2.10.2.  Colonies were 
picked after 16 hours and grown for plasmid DNA purification using the QIAprep 
Miniprep Kit according to the manufacturer’s instructions.  Once the integrity of the 
insert DNA was verified, the selected clone was grown for plasmid DNA purification 
using the HiSpeed Plasmid Maxi Kit according to the manufacturer’s instructions. 
 
2.11. Verification of the sequence of cloned chicken GnRH Receptor 
cDNAs 
2.11.1. cGnRH-R-I cDNA in pcDNA I/Amp vector 
The sequence of the cGnRH-R-I cDNA inserted into pcDNA I/Amp vector was 
verified by HincII digest. 
2.11.2. cGnRH-R-III cDNA in pBluescript II SK(+) vector 
The insert was amplified with primers BSKPF (CGA TTA AGT TGG GTA ACG C) 
and BSKPR (CAA TTT CAC ACA GGA AAC AG) using the plasmid DNA from a 
single bacterial colony as a template, with the following conditions (inactivation step, 
95°C for 5minutes; 30cycles of 95°C/15s, 56°C/20s, 72°C/45s and a final extension 
72°C/2minutes).  The entire amplicon containing the insert was analysed by 
sequencing with M13-forward and M13-reverse infrared dye (IRD)-labelled primers.  
Additionally, the sequence of the cGnRH-R-III cDNA inserted into pBSK(+) vector 
was verified by BamHI, HindIII, HincII, AvaI and PstI  restriction digest. 
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2.11.3. cGnRH-R-III cDNA in pcDNA 3.1/myc-His-A vector 
The clone was amplified with primers pcDNA3.1/myc-His_826f (TAA CTA GAG 
AAC CCA CTG CTT ACT), and pcDNA3.1/myc-His_1060r (AAT GGT GAT GGT 
GAT GAT GA), and subsequently sequenced with IRD-labelled primer T7-prom-
IRD-700 (TAA TAC GAC TCA CTA TAG GG), to further validate the GnRH 
receptor expression construct.  Additionally, the sequence of the cGnRH-R inserted 
into pCDNA3.1/myc-His was verified by BamHI, BsmI, PstI and HincII restriction 
digest. 
 
2.12. In-situ Hybridisation Probe synthesis 
2.12.1. Synthesis of Dioxygenin (DIG)-labelled RNA probes using 
T7 and T3 RNA polymerase 
The cGnRH-R-III cDNA in pBSK(+) vector was linearised with either BamHI 
(antisense / T7 promoter) or HindIII (sense / T3 promoter) restriction endonucleases.  
1µg of the plasmid was used to synthesis RNA run-off transcripts from the T3 or T7 
promoter using RNAse polymerase, by adding the following solutions and adjusting 
the total reaction volume to 20µl with RNAse free H20, prior to incubating the 
reaction for four hours at 37°C. 
5 x Transcription buffer ............................................................................................4 µl 
DTT...........................................................................................................................2 µl 
RNA labelling mix –DIG..........................................................................................2 µl 
RNAse inhibitor .....................................................................................................0.5 µl 
RNA polymerase.......................................................................................................1 µl 
A probe derived from pro-opio-melanocortin (POMC) cDNA was used as a positive 
control for experimentation.  The POMC plasmid was designed to reference 
sequence NM001031098.  Hypothalamic cDNA was amplified with POM3-f (ATG 
CTG GGA GAA CAG CAA GTG CC) and POM5–r (GTT CCA ACC CTT CTC 
CAT CTT C) and cloned into pBSK(+) vector.  The POMC cDNA in pBSK(+) vector 
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was individually linearised with either EcoRI (antisense / T7 promoter) or HindIII 
(sense / T3 promoter).  1µg of the plasmid was used to synthesis RNA run-off 
transcripts from the T3 or T7 promoter using RNAse polymerase as above.  The 
probes were then purified using Probe Quant G-50 Micro Columns (GE Healthcare, 
Buckinghamshire, UK) according to the manufacturer’s instructions. The quality and 
the quantity of the RNA synthesised was analysed by measuring the optical density 
(OD) at 260nm and 280nm and by electrophoresis on a 2% agarose gel. 
 
2.12.2. Synthesis of [35S] dATP(alphaS) labelled oligonucleotide 
probes using 3’ End labelling with Terminal Transferase 
3’ end labelling using [35S]dATP(alphaS) (GE Healthcare, Buckinhamshire, UK) and 
Terminal Transferase, was performed with 10pmol cGnRH-R-III_sense-cocktail (73-
120-cGnRH-R-III_sense (TGG TGC CGA TGT GGG AGC GCT GGG AGC AGT 
GAG TGG GCG GTG TTT GA) and 1261-1290-cGnRH-R-III_sense (CGG GTT 
CCT TCC ACT GTT CGG CCT CAT CCC)) and, cGnRH-R-III_antisense-cocktail 
(73-120-cGnRH-R-III_anti-sense (TCA AAC ACC GCC CAC TCA CTG CTC CCA 
GCG CTC CCA CAT CGG CAC CA) and 1261-1290-cGnRH-R-III_anti-sense 
(GGG ATG AGG CCG AAC AGT GGA AGG AAC CCG)) oligonuclotides using 
the Terminal Transferase recombinant DNA labelling kit (Roche-Applied Sciences, 
West Sussex, UK) according to the manufacturers instructions, with the exception of 
the incubation time being prolonged by 30 minutes.  These oligonucleotides, 
designed in the 5’ region upstream of the translation start site in exon 1 are specific 
for cGnRH-R-III and are not homologous to cGnRH-R-I.  The labelled oligoprobes 
were then purified using the QIAquick nucleotide removal kit (Qiagen, Crawley, 
UK) according to the manufacturer’s instructions.  The POMC probes were used as 
positive controls for each experiment and were labelled according to the method 
described for cGnRH-R-III oligoprobes.  The quantification of the incorporation of 
the radioactivity in 2µl of the oligoprobe was measured in 4ml of scintillation fluid 
on a beta-counter.  A count greater than 50000dpm per 2µl of labelled oligopobe was 
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acceptable for subsequent hybridisations.  Additionally, polyacrlyamide gel 
electrophoresis was performed to check the incorporation of the radioactivity by 
running the oligonucleotides on a 50cm 6% acrylamide gel at a constant current of 
80W.   The gel was then dried and exposed to a phosphoscreen and analysed with a 
phosphoimager (Biorad, Hertfordshire, UK).  The sample was stored at -20°C or 
used immediately. 
 
2.13. In-situ Hybridisation to detect cGnRH-R-III mRNA expression 
2.13.1. Whole-mount in-situ hybridisation using Digoxigenin-
labelled RNA probes  
Collection of neuroendocrine tissue samples for in-situ hybridisation 
The tissues were rapidly dissected, with sterile RNAse free instruments.  The tissues 
were immediately immersed in sterile 1x phosphate buffered saline (PBS) (pH 7.4) 
and either used immediately or frozen on dry ice or alternatively in -20°C 100% 
hexane placed on dry ice and chilled to -65°C.  The tissue samples were stored 
wrapped in a container with hexane solution and stored at -80°C till required.   
Fixation and dehydration of neuroendocrine tissue samples 
The tissue samples were placed in a 4% paraformaldehyde (PFA)/PBS (pH 7.4) and 
maintained at 4°C overnight.  The samples were then subjected to the following 
dehydration stages at room temperature, series of 10 minute dehydration washes 
twice in 1 x PBT buffer (PBS and 0.1% Tween 20), 25% MeOH/PBT, 50% 
MeOH/PBT, 75% MeOH/PBT and finally twice in 100% MeOH.  The samples were 
then stored at -20°C or immediately subjected to tissue permeabilisation. 
Tissue Permeabilisation 
The tissues were transferred to 4°C MeOH and DMSO (dimethyl sulphoxide) (1:1) 
solution, and closely monitored.  Once the tissue drops, immediately add 25% by 
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volume of 10 x Triton-X-100 (Sigma-Aldrich, Dorset, UK) for the appropriate times 
(10 minutes for pituitary samples, 30 minutes for whole brain samples).  The samples 
were then subjected to 3 x 10 minute washes in PBT. 
Pre-hybridisation and Hybridisation 
The samples were placed in pre-hybridisation solution (50% formamide, 5 x SSC, 
2% Blocking Reagent (<2% maelic acid) (Roche Applied Science, West Sussex, 
UK), 0.1% Trition-X-100, 0.1% CHAPS (VWR, Leicestershire, UK), 20µg/ml tRNA 
(Boehringer, Berkshire, UK), 5mM EDTA, 50µg/ml Heparin (Sigma-Aldrich, 
Dorset, UK) overnight at 65°C, and then hybridised for 2-3 days in hybridisation 
solution (50% formamide, 5 x SSC, 2% Blocking Reagent (Roche Applied Science, 
West Sussex, UK), 0.1% Trition X, 0.1% CHAPS, 20µg/ml tRNA, 5mM EDTA, 
50µg/ml Heparin with a minimum of 25% of RNA in 2ml of  hybridisation buffer.   
Immuno-detection with Anti-DIG antibody 
The samples were washed following hybridisation.  The following series of washes 
were performed, two washes in 2 x SSC each for 10 minutes at 70°C, three washes in 
2 x SSC/0.1% CHAPS each for 20 minutes at 70°C, three washes in 0.2 x SSC/0.1% 
CHAPS each for 20 minutes at 70°C and two final 10 minute washes in KTBT 
(50mM Tris-HCL pH7.5, 150mM NaCl, 10mM KCl, 1% TritonX-100) at room 
temperature.  The sample was blocked in 20% heat inactivated FCS/KTBT for 3 
hours at 4°C and then incubated in a 1:1000 dilution of mouse anti-DIG-AP Fab 
fragment (Boehringer, Berkshire, UK) in 20% heat inactivated FCS/KTBT overnight 
at 4°C.  The sample was then subjected to five or more 1 hour washes in KTBT at 
room temperature and left at 4°C overnight in KTBT.   
Colour detection  
The sample was washed twice each for 15 minutes in freshly made NTMT (100mM 
Tris-HCl pH9.5, 50mM MgCl, 100mM NaCl, 0.1% TritonX-100) at room 
temperature.  In the dark, add 3.5µl/ml nitro-blue tetrazolium chloride (NBT) 
(Sigma-Aldrich, Dorset, UK) and 3.5µl/ml 5-bromo-4cholor-3-indolyl-posphate 
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(BCIP) (Sigma-Aldrich, Dorset, UK) in NTMT.  The colour development was 
terminated in 4% formal saline (10% formalin neutral buffered in PBS) once 
sufficient staining was observed.  If a deeper blue staining was required, the sample 
was incubated NTET (1ml, 5M NaCl, 1ml, 0.5 EDTA pH8, 5ml 1M Tris-HCl pH8, 
0.5ml Tween20, 42.5ml dH20) at 4°C for several days if necessary. Once the desired 
staining was achieved, the sample was fixed in 4% formaldehyde/PBS. 
Gelatin Embedding and Cutting Sections 
The sample was transferred to 5% sucrose, PBS until the specimen sank.  The 
specimen was then transferred to 20% sucrose, PBS at 4°C and stored overnight.  
The tissue samples were pre-warmed to 38°C in 20% sucrose, PBS and then 
delicately placed in 38°C molten gelatine sucrose mixture (7.5% gelatin in 15% 
sucrose, PBS) and maintained at 38°C to infiltrate, until they sunk.  The sample was 
then mounted in the correct orientation for sectioning and allowed to cool at room 
temperature in a mould.  The blocks were either stored for up to 5 days at 4°C or 
used immediately.  The trimmed gelatin block was then mounted on a chuck and 
frozen in a small volume of -20°C isopentane which was placed on solid CO2 (dry 
ice) and chilled to -80°C.  The tissue was sectioned with a cryostat at 30μm thickness 
and mounted onto Superfrost plus slides (Menzel-Glaser, Braunschweig, Germany).  
 
2.13.2. In-situ hybridisation using DIG-labelled RNA probes on 
tissue sections 
Collection and sectioning of neuroendocrine samples for in-situ 
hybridisation 
The tissues were rapidly dissected, with RNAse free instruments.  The tissues were 
immediately immersed in sterile PBS and either used immediately or frozen on dry 
ice or alternatively in -20°C hexane placed on dry ice and chilled to -65°C.  The 
tissue samples were stored wrapped in paper tissue in a container with hexane and 
stored at -80°C till required.  The tissue was sectioned with a cryostat at 25μm 
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thickness and mounted onto Superfrost slides (Menzel-Glaser, Braunschweig, 
Germany) and stored at -80°C. 
Fixation and Hybridisation 
The sections mounted on the slides were fixed with 4% PFA/PBS for 10 minutes 
prior to hybridisation.  The slides were then subjected to 2 x 5 minute washes in 
sterile PBS.  The probe was diluted in hybridisation buffer to 1µg/ml.  100µl of the 
probe mix was added to each slide, and then covered with a coverslip and hybridised 
overnight at 65°C in a sealed perspex box humidified with Whatman paper (VWR, 
Leichestershire, UK) saturated with 1x NaCl/50% formamide. 
Post-hybridisation washes 
The slides were transferred into slide racks and subjected to 1 x 15 minute and 2 x 30 
minute washes in washing solution (1 x SSC, 50% formamide, 0.1% Tween-20) pre-
warmed to 65°C.  The slides were then subjected to 2 x 30 minute washes in MABT 
(100mM Malic acid, 150mM NaCl, 0.1% Tween 20) at room temperature. 
Blocking and antibody staining 
The sections were blocked with blocking buffer (MABT + 2% blocking reagent + 
20% heat inactivated sheep serum) for 60 minutes at room temperature.  100µl per 
slide of a 1/2000 dilution of the anti-DIG antibody (Boehringer, Berkshire, UK) in 
blocking buffer was added to the slides and incubated at room temperature overnight 
in a humidified chamber. 
Post antibody washes and staining reaction 
The excess antibody was washed off at room temperature by subjecting the slides to 
5 washes in MABT, each for 20 minutes.  The sections were then washed twice in 
staining buffer (without NBT and BCIP) each for 10 minutes.  The sections were 
then stained in staining buffer in the dark until adequately stained.  Once the required 
staining was achieved, the reaction was stopped by subjecting the sections to 2 x 
PTw (PBS, 0.1% Tween-20) + EDTA washes.  The samples were then subjected to 
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dehydration washes; (twice in 1 x PBT buffer (PBS and 0.1% Tween 20), 25% 
EtOH/PBT, 50% EtOH/PBT, 75% EtOH/PBT and finally twice in 100% EtOH.  The 
slides were immersed briefly into HistoClear (VWR, Leicestershire, UK) twice and 
mounted using DPX (VWR, Leicestershire, UK) for visualisation. 
 
2.13.3. In-situ hybridisation protocol using [35S] dATP(alphaS) 
labelled oligonucletide probes on tissue sections 
Collection and sectioning of neuroendocrine samples for in-situ 
hybridisation 
The tissues were rapidly dissected, with RNAase-free instruments. The tissues were 
immediately frozen on dry ice or alternatively frozen in -20°C hexane placed on dry 
ice and chilled to -65°C.  The tissue samples were stored wrapped in paper tissue in a 
container with hexane and stored at -80°C till sectioning.  The tissue was sectioned 
with a cryostat at 15μm thickness and mounted on superfrost slides which were 
immediately placed on dry ice and transferred to -80°C for storage or used 
immediately.  The slides were removed from the freezer and dried in a stream of air 
from a fan to remove the frost and H20 prior to fixation. 
Fixation and dehydration of neuroendocrine samples 
The slides were then subjected to the following fixation and dehydration stages at 
room temperature; 4% PFA for 5 minutes,  twice in 1 x PBS buffer for 5min, RNAse 
free H20 for 10 seconds, 0.1M triethanolamine (TEA) + Acetic anhydride (AA) 
(25mls AA to 100mls TEA) for 10 minutes,  2 x SSC for 3 minutes, 70% EtOH for 3 
minutes, 95% EtOH for 3 minutes, 100% EtOH for 3 minutes, chloroform for 3 
minutes, 100% EtOH for 3 minutes and 95% EtOH for 3 minutes.  The slides were 
then blown dry in a stream of air from a fan or air dried.  The slides were either 
stored in appropriate slide storage boxes at room temperature at this stage, as they 
remain stable for a number of months or used immediately for hybridisation with the 
oligoprobes. 
Chapter 2                                                                                    Materials and Methods
 
 69
Hybridisation of radiolabelled oligonucleotide probes 
The following hybridisation reaction mix per slide was made immediately prior to 
hybridisation. 
Hybridisation cocktail ............................................................................................90 µl 
Yeast tRNA10mg/ml  ...........................................................................................1.0 µl 
Denhardt’s x100 (Sigma-Aldrich) ......................................................................1.25 µl 
Oligonucleotide Probe..........................................................................................3.75µl 
5M DTT ................................................................................................................4.0 µl 
The hybridisation reaction mix was then placed onto the sections, and covered with 
parafilm.  The hybridisation was performed at 42°C and 52°C overnight, in a 
humidified chamber (50% formamide + 50% 1 x SSC).  The control hybridisation 
was performed using a 10 x higher concentration of unlabelled probe in hybridisation 
buffer.  After the overnight hybridisation, the slides were washed with 1 x SSC at 
56°C four times, each for 45 minutes.  The slides were air dried or step alcohol 
dehydrated (dip in RNAse free H20, 70%, 95% and 100% EtOH, 3min/each).  The 
slides were then subjected to emulsion autoradiography. 
Emulsion autoradiography 
Emulsion autoradiography was performed in the dark with a safe light.  K2 emulsion 
(Ilford, Stafforshire, UK) (diluted to 50% with RNAse-free H20) was heated to 42-
45°C for 20 minutes prior to use in a slide dipping chamber placed within a water-
bath to maintain the temperature.  The slides were dipped and placed vertically in a 
light-proof box to dry for a minimum of two hours.  The slides were then stored in a 
light-proof slide box and stored at 4°C for the appropriate time prior to development.  
All development of slides was performed in the dark room.  The slides were 
transferred into slide racks and exposed to Phenisol Developer (Ilford, Stafforshire, 
UK) for 2.5 minutes, RNAse-free H20 for 30 seconds and Hypam Rapid Fixer 
(Ilford, Stafforshire, UK) (diluted to 25% with RNAse free H20) for 3 minutes.  At 
this stage, the samples can be exposed to light.  The slides were run under tap H20 for 
approximately 20 minutes.  The slides were then subjected to a haemotoxylin and 
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eosin counterstaining, by immersing the slide in haematoxylin (Sigma-aldrich, 
Dorset, UK) for 1 minute, followed by washing the slides for 1 hour in H20.  The 
slides were then dipped in eosin (Sigma-aldrich, Dorset, UK) 3 times,  60% EtOH  
five times, 95% EtOH eight times, 100% EtOH twice each for 2 minutes, and 
Histoclear twice, each for two minutes, and immediately mounted with DPX 
mountant. 
 
2.14. Immuno-histochemistry (IHC) to detect LH in Gonadotrophs 
2.14.1. Rapid IHC to detect LH specific gonadotrophs on 
sectioned pituitary glands 
Collection and sectioning of neuroendocrine samples for IHC 
One method that was applied prior to collection of the sample tissue was to perfuse 
the birds through the jugular vein.  Prior to perfusion, the birds were terminally 
anaesthetised with 0.8ml 60mg.µl of Expiral anaesthetic (Sanofi Animal Healthcare, 
Watford, UK).  The birds were perfused through the jugular vein with 400ml of 
heparinised saline (1L 0.9% saline + 10 mls heparin @1000U/ml) at a rate of 
20ml/minute.  Fixation of the tissue is performed with Zamboni fixative (IL-350ml 
H2O, 40g PFA, 150ml saturated picric acid and 500ml of 0.2M Buffer PB).  The 
birds are then perfused with 500ml of 5% sucrose solution through the jugular vein.  
The pituitary glands were dissected, and placed in a 30% sucrose solution overnight, 
alternatively, until the tissue sunk to the bottom of the solution. The tissue was 
frozen in -20°C isopentane closely monitored to -65°C.  The tissue was sectioned 
with a cryostat at 15μm thickness and mounted on Superfrost plus slides which were 
immediately placed on dry ice and transferred to -80°C for storage or used 
immediately.   
Alternatively, fresh tissues were rapidly dissected, with RNAse-free instruments 
cleaned with RNAse-Zap® and thoroughly rinsed with RNAase free H20 
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(alternatively sterile autoclaved instruments).  The tissues were immediately 
immersed in sterile PBS and frozen on dry ice immediately.  The tissue was 
sectioned with a cryostat at 8μm thickness and mounted onto Superfrost plus slides 
and stored at -80°C. 
Fixing the tissue 
The non-perfused frozen sections were thawed at room temperature for 30–60 
seconds taking care not to dry the tissue section as this would have resulted in 
increased tissue adhesion to the slide.  The slides were immersed in cold acetone for 
5 minutes and then rinsed in 1 x PBS (pH 7.4) for 1 minute. 
Immunohistochemistry 
Non-specific binding to tissue sections using 10% goat serum for 3 minutes, and then 
immediately incubated with the primary anti-turkey LH-ß antibody (produced in a 
rabbit immunized with turkey LH beta prepared by Prof. W.H. Burke and provide as 
a gift to Prof. P. Sharp, Roslin Institute, Edinburgh, UK), of varying concentration to 
optimise the staining technique, for 5-10 minutes.  The antibody has previously been 
shown to cross reacted with chicken LH, but not with chicken FSH, GH nor prolactin 
(Burke et al., 1979).   The slides were then subjected to 3 x 15 second washes in PBS 
prior to incubating with the secondary antibody (donkey anti-rabbit immunoglobulin) 
for 5-10 minutes.  The slides were then washed 3 times in PBS, each for 15 seconds 
and incubated in Vectastain ABC (Vector labs, Peterborough, UK) reagent for two 
minutes prior to incubating in 200-400u/ml 3,3’-Diaminobenzidine (DAB) for 5 
minutes.  The sections were then subjected to dehydration by immersing in 75% 
EtOH, and 80% EtOH each for 45 seconds and finally in 100% EtOH for 1 minute.  
The sections were then immersed twice in 100% Xylene solution each for 5 minutes 
and left to dry at room temperature for 10 minutes, and then stored overnight in an 
air-tight container with dry silica crystals. 
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Laser Capture Micro-dissection 
Laser capture micro-dissection using the Acturus PIX Cell III Laser Capture 
Instrument (Genetic Research Instumuntation, Essex, UK) was performed according 
to manufacturer’s instructions.  Once the cells of interest were located, a thermostatic 
film coated CapSure macro LCM cap (Arcturus, California, USA) was mounted over 
the target area.  The laser was then pulsed (set at various combinations of pulse 
power, laser pulse duration, and laser spot diameter)  through the cap resulting in the 
thermostatic film to form a thin protrusion that bridges the gap between the cap and 
tissue and adheres to the target cell by the activated laser over the target cell.  Lifting 
the cap, results in the removal of the target cell(s) which have adhered to the cap.  
The cap containing the cell was then placed onto an eppendorf tube containing RNA 
extraction buffer PicoPure RNA extraction kit, (Arcturus, California, USA).   
 
2.15. Transient gene expression following transfection by 
electroporation in COS-7 cells 
COS-7 cells were cultured in Dulbecco’s modified Eagles medium (DMEM) (Sigma-
Aldrich, dorset, UK) containing a final concentration of 10% FCS, 4mM L-
glutamine and 1 x penicillin/streptomycin for at least 48 hours prior to transfection.   
COS-7 cells were transiently transfected by electroporation with 10µg of expression 
construct per 4mm cuvette (Biorad, Hertfordshire, UK).  A single 150cm2 dish of 
80% confluent COS-7 cells (approximately 1x107 cells) was sufficient for a single 
electroporation (960µF capitance and 0.23kV) in a cuvette diluted in 700µL Opti-
Mem reduced serum buffer (Invitrogen, Paisley, UK).    The transfected cells from a 
single cuvette were seeded into two 12-well culture plates (Corning, Avon, France) 
in DMEM containing a final concentration of 10% FCS, 4mM L-glutamine and 1 x 
penicillin/streptomycin.  The cells were incubated in a humidified atmosphere of air 
and 5% CO2 at 37°C for two days prior to performing required assays. 
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2.16. Transient gene expression following co-transfection by 
electroporation in COS-7 cells 
COS-7 cells were transiently transfected by electroporation with cGnRH-R-III 
expression construct variants. The ability of the cGnRH-R-III splice variants (SVs) 
to bind endogenous chicken GnRH ligands was assessed in cells transfected with 
10µg of cGnRH-R-III_SV1 and cGnRH-R-III_SV2 expression constructs. In 
addition, cells co-transfected with 3.3µg of full-length construct and 6.6µg of empty 
pcDNA3.1 (10µg of vector in total) were used for comparative purposes. Effects of 
the splice variants on full-length receptor binding were determined by co-transfecting 
3.3µg of the full length cGnRH-R-III construct and 6.6µg of each cGnRH-R-III 
splice variant.  All assays were performed in triplicate, and each experiment repeated 
three times.  The transfected cells from a single cuvette were seeded into two 12-well 
culture plates in DMEM containing a final concentration of 10% FCS, 4mM L-
glutamine and 1 x penicillin/streptomycin.  The cells were incubated in a humidified 
atmosphere of air and 5% CO2 at 37°C for two days prior to performing required 
assays. 
 
2.17. Iodination of [His5-D-Tyr6] GnRH-I  
[His5-D-Tyr6]-GnRH-I peptide was radioactively labelled with Iodine125 using 
Chloramine-T method (Sigma-Aldrich, Dorset, UK) and purified using Sephadex 
G25 chromatography (Sigma-Aldrich, Dorset, UK), kindly provided by Robin Sellar, 
MRC, HRSU, Edinburgh.  The specific activity of the various batches produced were 
between 100-125Ci/mmol.   
 
2.18. 125I-[His5-D-Tyr6]-GnRH-I whole cell binding assays 
Radioligand binding assays were performed with 125I-[His5-D-Tyr6]-GnRH-I on 
intact cells 48 hours after transfection.  Cells were placed on ice and washed twice 
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with 4°C Dulbecco’s phosphate buffered saline with calcium chloride and 
magnesium chloride (PBS+Ca2++Mg2+), (Sigma-Aldrich, Dorset, UK).  The cells 
were then incubated for 4 hours at 4°C with 105cpm/500ul 125I-[His5-D-Tyr6]-GnRH 
and various concentrations of unlabelled cGnRH-I and GnRH-II in HEPES, DMEM, 
0.1%BSA in triplicate.  The cells were then washed twice with PBS+Ca2++Mg2+ and 
subsequently lysed with 0.5ml of 0.1M NaOH.  Radioactivity was measured and 
non-specific binding was determined in the presence of 1µM unlabelled cGnRH-I or 
GnRH-II using a gamma counter.  Each assay was repeated at least three times on 
separate occasions.  Competition curves were fitted using GraphPad Prism 
(GraphPad) by applying a ‘One Site Competition’ non-linear regression and were 
fitted to a sigmoidal dose-response curve with a assumed HILLSLOPE equal to -1 
with no constraints applied to the curve fitting.  This analysis describes the 
competition of the ligand for the receptor binding.  The IC50 value derived is the 
concentration of the competing ligand required to compete half of the specific 
binding.  The IC50 values were calculated for individual experiment performed in 
triplicate, followed by calculating the mean IC50 value for the number of times the 
experiment was performed.  In all cases, the IC50 is used as a measure of the relative 
affinity.  As the affinity of the radiolabelled ligand to cGnRH-R-I and cGnRH-R-III 
was not determined, the Cheng-Prusoff equation was not used to determine the 
“affinity” (Ki) or “dissociation constant” of each ligand.   
 
2.19. Determining agonistic and antagonistic effects of GnRH analogs 
on Inositol Phosphate (IP) accumulation 
24 hours after transfection cells were labelled with 1µCi/ml [3H]-myo-inositol, 
(Amersham Pharmacia Biotech) in 1ml of inositol-free “special DMEM” (Invitrogen, 
Paisley, UK) and incubated for a further 24 hours in a humidified atmosphere of air 
and  5% CO2 at 37°C. Media was removed and cells were incubated at 37°C with 
0.5ml HEPES, DMEM (Sigma-Aldrich, Dorset, UK) containing 10mM LiCl for 5 
minutes and repeated for further 30 minute incubation.  LiCl inhibits inositol 
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phosphotases resulting in the accumulation of inositol phosphate metabolites 
(Berridge et al., 1982).  The cells were then incubated for 60 minutes with a 
concentration gradient of GnRH analogs in 0.5ml HEPES, DMEM, 10mM LiCl to 
determine agonistic effects.  The antagonistic effects were determined by incubating 
for 60 minutes with a concentration gradient of GnRH analogs in the presence of 
1nM GnRH-II in 0.5ml HEPES, DMEM, 10mM LiCl.  In both cases, the incubation 
was promptly terminated by the removal of the media and the subsequent addition of 
1ml of 10mM formic acid for 60 minutes at 4°C.  The solution was then applied to 
tubes containing 500µl AG 1-X8 resin (Dowex) (Bio-rad Hertfordshire, UK).  The 
resin was allowed to settle and the the supernatant aspirated off.  The resin was 
washed with 1ml of H20, 1ml of 60mM ammonium formate and 1ml of 5mM sodium 
tetraborate.  Each wash was followed by aspirating off the supernatant prior to the 
addition of the next wash solution.  Finally, inositol phosphate product was eluted in 
1ml of 1M ammonium formate, 0.1M formic acid.  800µL of the supernated was 
removed from the resin and the ß-emission was measured by the radioactivity 
counted in 2.5mls of scintillation fluid (Optiphase HiSafe 3).  Inositol phosphate 
experiments were performed in triplicate and repeated at least three times.  
Functional data were analysed using GraphPad Prism (GraphPad) by applying non-
linear regression and were fitted to a sigmoidal dose-response curves with an 
assumed slope of 1.  No further constraints were applied to the curve fitting.  Curves 
generated were used to calculate EC50 (excitatory concentration) or IC50 (inhibitory 
concentration) values for receptor stimulation or inhibition respectively.  The EC50 or 
IC50 values were calculated for each individual experiment performed in triplicate, 
followed by calculating the mean Ec50 or IC50 value for the number of times the 
experiment was performed.    
 
2.20. Receptor mediated internalisation of 125I-[His5-D-Tyr6]-GnRH-I 
Internalisation of the radioligand 125I-[His5-D-Tyr6]-GnRH-I was measured across 
time points and expressed as a percent of total radioligand interacting with the cell.  
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Receptor transfected COS-7 cells were seeded into 12-well culture plates and 
incubated at 37°C/5% CO2 for 48 hours prior to performing the internalisation 
assays. The plates were placed on ice and the media removed and replaced with ice 
cold 0.5ml HEPES, DMEM, 0.1%BSA containing 105cpm/500ul 125I-[His5-D-Tyr6]-
GnRH-I.  The plates were incubated at 4°C for 5 hours.  Initiation of internalisation 
of the radioligand in the transfected cells was performed at 37°C at 5, 15, 45 and 90 
minutes with the control remaining at 4°C.   The internalisation was halted at each 
time point by removing the cells from 37°C and placing them immediately on ice and 
then removing the medium containing the radioligand.  The plates were then 
immediately washed with 0.5 ml ice cold PBS+Ca2++Mg2+ twice.  The cells were 
subsequently incubated on ice for 10 minutes in the presence of 0.5 ml ice cold acid 
wash solution (150mM NaCl, 50mM acetic acid, pH2.8) to determine all surface 
bound radioligand i.e. ligand that is bound to the receptor but not internalised.  The 
acid wash solution was removed and the cells were solubilised with 0.5ml 1M NaOH 
to quantify the content of internalised radioligand.  The internalisation percent 
calculated from time point 0 was subtracted from all other time point per replicate, as 
a means of removing the background radiolabelled ligand associated with the cell.  
Curves were fitted using GraphPad Prism (GraphPad) by applying the “One phase 
exponential association” which describes the pseudo-first association kinetics of the 
interaction between a ligand and its receptor. 
 
% internalisation =                                                      X 100. NaOH    
Total (acid and NaOH) 
 
 
2.21. Generation of cGnRH-R-III SH3 Binding Motif Mutants in pcDNA 
3.1/myc-His-A vector 
Mutagenesis of three identified putative SH3 binding motifs located at amino acid 
positions 369-373, 370-375 and 398-402 of cGnRH-R-III was carried out using the 
QuikChange site-directed mutagenesis kit (Agilent technologies, Chesire, UK) 
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according to the manufacturers instructions.  The proline codon was mutated to an 
alanine codon.  In brief, the insert of the cGnRH-R-III cDNA cloned into the 
pCDNA3.1/myc-His-A expression vector was PCR amplified with each individual 
SH3 motif mutant primer pair, each complementary to each opposite strands of the 
vector; SH3P317A-F (TGT GGG CAC AGC TCT GAG GCT GAG CCA CCC TCC 
CCA GCC ACG) and SH3P317A-R (CGT GGC TGG GGA GGG TGG CTC AGC 
CTC AGA GCT GTG CCC ACA); SH3P319A-F (TGT GGG CAC AGC TCT GAG 
CCT GAG GCA CCC TCC CCA GCC ACG) and SH3P319A-R (CGT GGC TGG 
GGA GGG TGC CTC AGG CTC AGA GCT GTG CCC ACA); and SH3P346A-F 
(GTA TGG GGG GCA CAG AGG GGG CAC ACC CAC CTA TCG AGC TGG) 
and SH3P346A-R (CCA GCT CGA TAG GTG GGT GTG CCC CCT CTG TGC 
CCC CCA TAC).  A Pfu Turbo DNA Polymerase (Agilent technologies, Chesire, 
UK) was used to amplify cDNA according to manufacturers instructions using the 
following amplification conditions (initial denaturation step of 95°C/30s, 16 cycles 
of denaturation 95°C/30s, annealing 55°C/60s and elongation 68°C/90s) to 
incorporate the oligonucleotide primers generating a mutated plasmid containing 
staggered nicks.  The reaction mixes are then cooled on ice for 2 minutes to ~37°C 
prior to the addition of 1µl of DpnI restriction enzyme (target sequence: 5´-
Gm6ATC-3´) (10U/µl).  The non-mutated supercoil dsDNA was then digested for 
one hour at 37°C.  The DpnI treated DNA (i.e. the nicked vector DNA) was then 
used to transform XL1 Blue E. coli super competent cells provided with the 
QuikChange site-directed mutagenesis kit according to manufacturers provided 
instructions.  The cells were then plated onto pre-warmed agar plates and incubated 
at 37°C for 16 hours.  Colonies were picked after 16 hours and grown for plasmid 
DNA purification using the QIAprep Miniprep Kit according to the manufacturer’s 
instructions.  Once the integrity of the insert DNA was verified, the selected clone 
was grown for plasmid DNA purification using the HiSpeed Plasmid Maxi Kit 
according to the manufacturer’s instructions. 
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2.22. Cloning of HA epitope-tagged cGnRH-R-I and cGnRH-R-III into 
pcDNA 3.3 vector 
The insert of the cGnRH-R-I cDNA cloned into the pcDNA/Amp expression vector 
was PCR amplified with primers Type I-cGnRH-R-HA-tag-F (GTT ATG TAT CCT 
TAT GATGTTCCCAACTATGCTATG TGC GTA CCA GCT GCT TTA ATC) and 
Type I-cGnRH-R-HA-tag-R (TCA GCA CAC CGT GTT AAC GGT T).  The insert 
of the cGnRH-R-III cDNA cloned into the pcDNA 3.1/myc-His-A expression vector 
was PCR amplified with primers Type III-cGnRH-R-HA-tag-F (GTT ATG TAT 
CCT TAT GAT GTT CCC AAC TAT GCT ATG GCC CGG CTC GGC) and Type 
III-cGnRH-R-HA-tag-R (TCA CAG CGC ACT GCT CTG G).  The forward primers 
for both receptors were designed to encode an HA epitope-tag to the N-terminal of 
either cGnRH receptor included the Kozak translation initiation consensus sequence 
(GTT ATG) and an HA epitope-tag (TAT CCT TAT GAT GTT CCC AAC TAT 
GCT).  A PfuUltra® Hotstart Polymerase (Agilent technologies, Chesire, UK) was 
used to amplify cDNA according manufacturers instructions using the following 
amplification conditions (initial inactivation step of 95°C/1minute, 30cycles of 
denaturation 95°C/60s, annealing 55°C/60s and elongation 72°C/90s and a final 
extension 72°C/10minutes).  The PCR products were run on a 2% agarose gel to 
ensure the PCR product amplified was of the desired length (1161bp for cGnRH-R-I 
and 1293bp for cGnRH-R-III).    The PCR products were excised and purified with 
Ultrafree-MC Filter Units (Millipore, Watford, UK) according to the manufacturer’s 
instructions.  3’ A-overhangs necessary for TOPO® cloning were then added post 
amplification by adding the following solutions to give a total reaction volume of 50 
µl with RNase free H20: 
Purified PCR product ................................................................................................*µl 
Taq Polymerase.........................................................................................................1µl 
dNTPs.......................................................................................................................1 µl 
10X Buffer ..............................................................................................................5 µl. 
The reaction mix was incubated at 72°C for 10 minutes.  The DNA was extracted 
from the reaction mixture by applying a phenol-chloroform extraction to remove the 
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polymerase.  The DNA was then ethanol-precipitated and re-suspended in an 
appropriate amount of TE buffer.  The HA epitope-tagged cGnRH-R-I and cGnRH-
R-III inserts were then ligated into the pcDNA 3.3-vector using the pcDNA 3.3-
TOPO® TA Cloning Kit (Agilent technologies, Chesire, UK) according to the 
manufacturers instructions.  The constructs were then used to transform competent E. 
coli. One Shot® TOP10 Chemically Competent E.Coli provided with the pcDNA 
3.3-TOPO® TA Cloning Kit were used according to the manufacturers instructions.  
The cells were then plated onto pre-warmed agar plates and incubated at 37°C for 16 
hours.  Colonies were picked after 16 hours and grown for plasmid DNA purification 
using the QIAprep Miniprep Kit according to the manufacturer’s instructions.  Once 
the integrity of the insert DNA was verified, the selected clone was grown for 
plasmid DNA purification using the HiSpeed Plasmid Maxi Kit according to the 
manufacturer’s instructions. 
 
2.23. Verification of the DNA sequence of the cloned chicken GnRH 
Receptor cDNAs 
2.23.1. cGnRH-R-III SH3 binding motif mutants in pcDNA 3.1/myc-
His-A vector 
The insert of both the cGnRH-R-III SH3 binding motif mutants insert was sequenced 
with a CMV-F primer (CGC AAA TGG GCG GTA GGC GTG) whose 
complimentary sequence is present in the MCS of the pcDNA 3.1/myc-His-A vector.   
2.23.2. HA Epitope-Tagged cGnRH-R-I and cGnRH-R-III in pcDNA 
3.3 vector 
The insert of both the HA epitope-tagged cGnRH-R-I and cGnRH-R-III insert was 
sequenced with a CMV-F primer (CGC AAA TGG GCG GTA GGC GTG) whose 
complimentary sequence is present in the MCS of the pcDNA 3.3 vector.  The 
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sequence of the HA epitope-tagged cGnRH-R-I and cGnRH-R-III inserted into 
pCDNA3.3 vector was also verified by PvuII restriction enzyme digest. 
 
2.24. GnRH ligand stimulations and inhibition of second messenger 
signalling cascades and preparation of NP40 cell lysates for immuno-
blotting 
cGnRH Receptor subtype transiently transfected COS-7 cells were seeded in 6-well 
culture plates (1 cuvette = 2x6-well culture plates).  After 24 hour incubation period, 
the media was removed and replaced with a serum-free media (Hepes, DMEM) for 
16 hours prior to stimulations. The cells were then stimulated with varying 
concentrations of GnRH analogs and/or inhibitors, for specific time points.  The 
stimulations were terminated by placing the cells on ice, aspirating off the media and 
washing the cells once with 4°C PBS+Ca2++Mg2+.  Cell lysis was performed with 
150μl per well of 4°C NP40-based solubilisation buffer (250mM NaCl, 5mM 
HEPES, 10% glygerol, 0.5% Nonidet P-40, 2mM EDTA (pH8) supplemented with 
1mM sodium orthovanadate, 1mM phenylmethysulphonyl fluoride (PMSF) and 
lmg/ml Leupeptin).  Cell lysates were scraped with a cell scraper and placed in 
chilled eppendorf tubes for centrifugation at 14000rpm for 10 minutes at 4°C.  100μl 
of the supernatant was recovered to a fresh eppendorf.  An equal volume of 2 x 
Laemmli Sample Buffer (LSB) was added to the clarified lysate.  Samples were 
stored at -20°C until required. 
 
2.25. GnRH ligand stimulations, preparation of NP40 cell lysates and 
immuno-precipitation   
cGnRH Receptor subtype transiently transfected COS-7 cells were seeded in 10cm 
culture dishes. (1 cuvette = 1x10cm culture dish).  After 24 hour incubation period, 
the media was removed and replaced with a serum-free media for 16 hours prior to 
stimulations. The cells were then stimulated with varying concentrations of GnRH 
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analogs and/or inhibitors, for specific time periods.  The stimulations were 
terminated by placing the cells on ice, aspirating off the media and washing the cells 
once with 4°C PBS+Ca2++Mg2+.  Cell lysis was performed with 1000μl per well of 
4°C NP40-based solubilisation buffer (as above).  Cell lysates were scraped with a 
cell scraper and placed in chilled eppendorf tubes for centrifugation at 14000rpm for 
10 minutes at 4°C.  The cells lysates were then sonicated and subjected to another 
centrifugation at 14000rpm for 10 minutes at 4°C.  500μl of the supernatants was 
removed and added to a fresh eppendorf.  50µl of Anti-HA Affinity Matrix (Roche 
Applied Science, West Sussex, UK) was added to 500μl (or a fixed amount of 
protein) of the cell lysate supernatant, and incubated while shaking overnight at 4°C.  
The column was centrifuged at 14000rpm for 5 minutes, and then washed with 
1000ul of 4°C NP40-based solubilisation buffer twice, followed by centrifugation.  
50μl of 2x LSB was added to the beads and vortex thoroughly.  Samples were stored 
at -20°C indefinitely until required for immuno-blotting.  
 
2.26. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
4-20% Tris-Glycine gels (Invitrogen, Paisley, UK) were loaded with protein samples 
denatured by heating to 100°C for 3 minutes.  15-20µl of sample per well was 
separated under electrophoresis at 90mA for 60 minutes in 1x SDS-PAGE Buffer 
(29g Tris Base, 144g Glycine, 10g SDS).  Pre-stained broad range SDS-PAGE 
standards (Biorad, Hertfordshire, UK) were electrophoresised alongside the samples 
to determine the protein sizes.  Polyvinylidene difluoride (PVDF) membranes 
(Perkin Elmer, Waltham, USA) were prepared by washing in 100% EtOH for 5 
minutes and then 3 x 10 minute washes with distilled H20.  A wash in Semi-Dry 
Transfer Buffer (20mM Tris, 192mM glycine, 20% MeOH, 0.1% SDS) was 
performed before protein transfer.  The gel was placed above the prepared PVDF 
membrane, and sandwiched with blotting pads (VWR, Leichester, UK) pre-soaked in 
Semi-Dry Transfer Buffer.  Proteins were transferred from the gel to the membrane 
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in a Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell (Biorad, Hertfordshire, 
UK) at 200mA, 25V, 300W for 60 minutes. 
 
2.27. Immuno-blotting 
The protein samples transferred onto the membrane was blocked with 10ml Blocking 
Buffer (4% BSA in 1 x TBS-T (100mM Tris-HCl (pH7) 150mM NaCl, 0.05% 
Tween 20, 0.05% NP40)) with shaking for 60 minutes.  The appropriate primary 
antibody (1:1000 dilutions in Blocking Buffer, 0.1% Sodium Azide) was added onto 
the membrane and incubated for 60 minutes while shaking.  After removal of the 
primary antibody, the membrane was subjected to 3x 10 minute washes in 1 x TBS-T 
(100mM Tris-HCl, 150mM sodium chloride, 0.05% Tween 20, 0.05% NP40).  10ml 
of the appropriate alkaline phosphatase-conjugated polyclonal IgG secondary 
antibody (Sigma-Aldrich, Dorset, UK) diluted at 1:10000 in Blocking Buffer was 
added onto the membrane and incubated for 60 minutes while shaking.  Prior to 
protein visualisation, the membrane was subjected to 3 x 10 minute washes in 1 x 
TBS-T.  Enhanced chemifluorescence (ECF) substrate (Amersham Pharmacia 
Biotech, Buckinghamshire, UK) was added according to the manufactures 
instructions  and  scanned using the Typhoon 9400 Phospho-Imager and 
subsequently quantified using Image-Quant TL software (Molecular Dynamics, 
Amersham Biosciences, Buckinghamshire, UK).  The membrane was prepared for 
subsequent probes by removing the ECF substrate from the membrane by incubation 
in 40% MeOH for 30 minutes.  Antibodies were then removed from the membrane 
by incubation at 80°C for 30 minutes in 10ml of Stripping Buffer (25mM Tris-HCl 
(pH7) 8% SDS, 0.72M ß-mercaptoethanol).  The membrane was then washed 3x 10 
minute washes in 1 x TBS-T.  The membranes were either stored dry or used 
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Table 2. 1 
Primers used in experiments 
Primer ID 5’ to 3’ sequences 
cGnRH-R-III-713-735f (exon 2-3) GCT CGC TGT GCC GCA GCT GT 
cGnRH-R-III-933-952r (exon 3-4) ACG TCC CTG GAG GAG AAG AG 
cGnRH-R-I-701-722f AGC TAA AGA TCA ACA AAA GTC T 
cGnRH-R-I-1100-1082r TTG GAG CCA CCT GAT GTC A 
73-120-cGnRH-R-III_sense TGG TGC CGA TGT GGG AGC GCT GGG AGC AGT GAG TGG GCG 
GTG TTT GA 
73-120-cGnRH-R-II_anti-sense TCA AAC ACC GCC CAC TCA CTG CTC CCA GCG CTC CCA CAT 
CGG CAC CA 
cGnRH-R-III-1210f TGA GTG GGC GGT GTT TGA 
cGnRH-R-III-3217r TAG AGG CAT TGT GGA GCA GA 
M13 F GTT GTA AAA CGA CGG CCA GT 
M13 R CAG GAA ACA GCT ATG ACC 
pcDNA3.1/myc-His_826f TAA CTA GAG AAC CCA CTG CTT ACT 
pcDNA3.1/myc-His_1060r AAT GGT GAT GGT GAT GAT GA 
T7-prom-IRD-700 TAA TAC GAC TCA CTA TAG GG 
CMV-F primer CGC AAA TGG GCG GTA GGC GTG 
SH3P317A-F TGT GGG CAC AGC TCT GAG GCT GAG CCA CCC TCC CCA GCC 
ACG 
SH3P317A-R CGT GGC TGG GGA GGG TGG CTC AGC CTC AGA GCT GTG CCC 
ACA 
SH3P319A-F TGT GGG CAC AGC TCT GAG CCT GAG GCA CCC TCC CCA GCC 
ACG  
SH3P319A-R CGT GGC TGG GGA GGG TGC CTC AGG CTC AGA GCT GTG CCC 
ACA  
SH3P346A-F GTA TGG GGG GCA CAG AGG GGG CAC ACC CAC CTA TCG AGC 
TGG  
SH3P346A-R CCA GCT CGA TAG GTG GGT GTG CCC CCT CTG TGC CCC CCA 
TAC 
Type I-cGnRH-R-HA-tag-F GTT ATG TAT CCT TAT GAT GTT CCC AAC TAT GCT ATG TGC GTA 
CCA GCT GCT TTA ATC 
Type I-cGnRH-R-HA-tag-R TCA GCA CAC CGT GTT AAC GGT T 
Type III-cGnRH-R-HA-tag-F GTT ATG TAT CCT TAT GAT GTT CCC AAC TAT GCT ATG GCC 
CGG CTC GGC 
Type III-cGnRH-R-HA-tag-R TCA CAG CGC ACT GCT CTG G 
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Variant GnRH ligand and receptor subtypes have been identified in a number 
of non-mammalian vertebrate species, however research into avian species 
GnRH systems is lacking.   Two isoforms of GnRH are present in the domestic 
chicken, the evolutionary conserved GnRH-II and cGnRH-I.  The expression of 
two GnRH ligands coincides with the two identified chicken GnRH receptor 
subtypes; cGnRH-R-I and a novel form I have designated as cGnRH-R-III.  The 
occurrence of two isoforms of the receptor in the chicken raises questions about 
their specific biological functions and interactions with the two ligands.  
Differential roles for these molecules in regulating gonadotrophin secretion or 
other functions are currently unclear.  To investigate this I cloned cGnRH-R-III 
cDNA from a broiler chicken anterior pituitary gland and compared its 
structure and expression with cGnRH-R-I.  The broiler cGnRH-R-III cDNA 
was 100% identical to the sequence recently reported in the red jungle fowl and 
white leghorn breed and had a 53% sequence identity with cGnRH-R-I in the 
protein coding region.  Expression profiling of cGnRH-R-III cDNA showed that 
it is predominantly expressed in the anterior pituitary, ~1400 times more 
abundant than cGnRH-R-I cDNA.  A pronounced sex and age difference 
existed, with higher pituitary transcript levels in sexually mature females versus 
juvenile females.  In contrast, higher expression levels occurred in juvenile 
males compared to sexually mature males.  Northern blot analysis indicated a 
single cGnRH-R-III transcript.  The research presented in this chapter, 
demonstrates the mRNA expression of a novel pituitary-predominant type III 
GnRH receptor homolog in the chicken.  The higher abundance of expression of 
cGnRH-R-III mRNA in the anterior pituitary when compared to cGnRH-R-I 
suggests it is probably the major mediator of pituitary gonadotroph function, 
and that tissue specific recruitment of cGnRH-R isoforms has occurred during 
evolution.   
 




Two GnRH isoforms are present in the chicken (cGnRH-I and GnRH-II) (Sharp and 
Ciccone, 2005).  There is no genomic DNA evidence for a third GnRH ligand in the 
chicken to date (Morgan and Millar, 2004).  Both cGnRH-I and GnRH-II stimulate 
luteinising hormone (LH) release from chicken pituitary in-vitro (Hattori et al., 
1986a; Millar et al., 1986) and in-vivo (Chou et al., 1985b; Hattori et al., 1986b; 
Proudman et al., 2006; Sharp et al., 1986).  LH secretion in response to GnRH-II is 
markedly greater than to cGnRH-I in mature laying hens. However, this is not the 
case in juvenile chickens of either sex, nor the mature male (Sharp et al., 1987).  
There is conflicting evidence for an effect of cGnRH-I or GnRH-II on follicle 
stimulating hormone release (FSH) in-vitro, (Hattori et al., 1986a; Millar et al., 1986) 
and in-vivo (Bruggeman et al., 1998; Dunn et al., 2003; Krishnan et al., 1993; 
Proudman et al., 2006). Probably, cGnRH-I does not directly stimulate FSH release, 
but may stimulate FSH biosynthesis, while a role for GnRH-II in FSH production has 
not been established (Dunn et al., 2003; Sharp and Ciccone, 2005).  Immunisation of 
laying hens against cGnRH-I, but not against GnRH-II, results in a complete 
regression of the reproductive system and a decrease in plasma LH (Sharp et al., 
1990), suggesting that gonadotrophin secretion is controlled by cGnRH-I rather than 
GnRH-II.  This  is consistent with the presence of cGnRH-I in the median eminence 
(Mikami et al., 1988a; Sharp et al., 1990) and the correlation between hypothalamic 
cGnRH-I peptide content and reproductive status (Sharp et al., 1990).  In contrast, 
abundant levels of GnRH-II (Mikami et al., 1988; Sharp et al., 1990; Vangils et al., 
1993) are not observed in the median eminence and no change in hypothalamic 
GnRH-II peptide content is seen in cockerels around the onset of puberty (Sharp et 
al., 1990).  However hypothalamic GnRH-II levels do decrease when the pre-
ovulatory release of LH is maximal or declining in the hen (Wilson et al., 1990). 
Thus GnRH-II may be involved in neuroendocrine events preceding ovulation or 
other non-neuroendocrine elements of reproduction.  In other avian species, GnRH-II 
affects reproductive behaviour in ring doves and soliciting behaviour in female song 
sparrows  (King and Millar, 1995; Maney et al., 1997).   
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The specific receptor types through which the GnRH ligands elicit biological 
responses in the chicken are not known.  Localisation of receptor gene expression 
using in-situ hybridisation would help to formulate hypothesis but such information 
is not available for the avian species.  Other clues to GnRH system organisation may 
be available from comparative anatomy, endocrinology, evolutionary biology and 
genomics.   
 
The divergence of amphibians and amniotes (reptiles, birds and mammals) is 
generally thought to have occurred approximately 350 million years ago (Elinson and 
Beckham, 2002), during the late Paleozoic Era (Elinson and Beckham, 2002).  Birds 
are a diverse group that evolved from reptiles during the Mesozoic Era about 150 
million years ago, with the crocodilian lineage being most closely related to birds 
(Rogers, 1999).  22,000 species of ray-finned fish share a common ancestor which 
experienced a large-scale gene or genome duplication event (Taylor et al., 2003) 
leading to tetraploidy in most fish species.  Most amphibians are also tetraploid as 
seen in Xenopus laevis (Hughes and Hughes, 1993), whereas some amphibians are 
diploid, with Xenopus tropicalis being the only  diploid species in the Xenopus 
genus, (Amaya et al., 1998; Fierro et al., 2007).  Reptilian genomes range in diploid 
chromosome number from 2n=20 in most lizards to 2n=68 in some turtles (Schmid et 
al., 1994).  Most avian karyotypes are composed of a diploid number of 78-82 
chromosomes (Federico et al., 2005).  Fewer GnRH ligand and GnRH receptor genes 
are retained in the genomes of mammals and birds compared to protochordates, fish 
and amphibians (Morgan and Millar, 2004).  
 
There is some evidence that GnRH systems exhibit species-specific recruitment of 
receptor subtypes and ligands within different tissues.  For example, the sea bass 
possesses five isoforms of GnRH receptor and all but one are expressed in the 
pituitary (Moncaut et al., 2005).  In goldfish, two subtypes of the GnRH receptor 
have been identified (Illing et al., 1999) and they are both expressed in the pituitary.  
In the bullfrog, three subtypes of GnRH receptor are expressed but only one 
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predominates in the pituitary (Wang et al., 2001a).  Two subtypes of GnRH receptor 
occur in the African clawed frog (Xenopus laevis) (Troskie et al., 2000), whereas the 
leopard gecko expresses three receptor subtypes in the pituitary, with one receptor 
subtype predominating in the anterior pituitary (Ikemoto and Park, 2007).  The 
pituitary-specific GnRH receptor subtypes expressed in the bullfrog (Wang et al., 
2001a), African clawed frog (Troskie et al., 2000) and leopard gecko (Ikemoto and 
Park, 2007) differ structurally, according to the nomenclature proposed by Millar et 
al., and by phylogenetic analysis (Flanagan et al., 2007; Millar et al., 2004; Tello et 
al., 2008).  The predominant pituitary GnRH receptor subtype expressed in the 
bullfrog is type III, in the African clawed frog is type I and in the leopard gecko is 
type III.  This suggests plasticity in evolutionary recruitment of GnRH receptor 
subtypes for regulation of pituitary gonadotrophin production.  There is also 
plasticity in the spatiotemporal expression patterns of GnRH receptor subtypes 
(Ikemoto and Park, 2007; Illing et al., 1999; Moncaut et al., 2005; Troskie et al., 
2000; Wang et al., 2001a).   
The promiscuity of receptor subtype activation by different endogenous GnRH 
ligands (Ikemoto and Park, 2007; Illing et al., 1999; Moncaut et al., 2005; Troskie et 
al., 2000; Wang et al., 2001a) suggests that a complex interplay between ligands and 
receptors may occur.  In this respect, the organisation of the avian GnRH system is 
distinct from those of teleosts, amphibians, reptiles or mammals, having two receptor 
subtypes for two GnRH ligands (Morgan and Millar, 2004).  Further characterisation 
of the avian GnRH system may therefore provide unique information to enable 
further comprehension of the interplay between GnRH ligands and their receptors in 
the control of reproduction. 
The first chicken GnRH-R (cGnRH-R) isoform to be cloned, cGnRH-R-I  is widely 
expressed (Sun et al., 2001a; Sun et al., 2001b) and GnRH-II has a higher binding 
affinity and is more potent in stimulating inositol phosphate accumulation than 
cGnRH-I at this receptor (Sun et al., 2001b).  This suggested that the chicken 
pituitary might contain an alternative GnRH receptor more selective for cGnRH-I, 
since this appears to be the GnRH isoform most likely to be biologically important 
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for regulation of LH production.  Therefore, the aims of this study were to clone the 
cDNA encoding the novel isoform of the cGnRH-R from a broiler chicken 
(commercial meat-type chicken) and undertake further characterisation of this second 
GnRH receptor isoform, including comparisons with the type I receptor.  The novel 
isoform of cGnRH-R was subsequently cloned by ourselves and others using RT-
PCR (Joseph et al., 2006; Shimizu and Bedecarrats, 2006) (Genbank AY895154.  
Using bioinformatics analysis, I confirmed that the novel cGnRH-R is a type III 
GnRH receptor homolog.  Critically, I have established the preponderance of 
cGnRH-R-III mRNA relative to cGnRH-R-I mRNA in the pituitary.   
 
3.3. Methods 
The detailed methodologies performed to generate the results presented in this 
chapter are described in chapter 2 (2.1-2.14.) 




The identification and cloning of the novel cGnRH receptor isoform is described in this 
chapter and was performed first in order to identify that the sequence was identical to the 
predicted GnRH receptor sequence identified by bioinformatic analysis in the Chicken 
Genome (Ensembl 2004) (results section 3.4.5 and 343.6).  It is presented after the RT-PCR 
amplification and tissue distribution (3.4.1), the Northern blot analysis to detect mRNA 
transcripts (3.4.2) and the real-time RT-PCR quantification in various tissues from birds in 
different physiological stages.  The results are presented in this manner for purposes of 
simplification.  In the results section and chapters that follow, the amino acid residues are 
refered to as the actual amino acid number as illustrated in Fig.3.8 and the Ballesteros and 
Weinstein ‘Numbering Convention’ was not adopted.  However, all residues have been 
converted to the Ballesteros and Weinstein Number and are available in the Appendix A.  
3.4.1. cGnRH-R-III cDNA is predominantly expressed in the pituitary 
The amplification of GnRH receptor cDNA was ensured by designing primers based 
on predicted cDNA sequence determined from the Gallus gallus gallus Genome 
(Ensembl 2004) subsequent to performing basic local alignment search tool 
‘BLAST’ analysis with other identified GnRH-R subtype cDNAs.  The retrieved 
cDNA sequence was latterly found to be identical to a published cGnRH-R subtype 
cDNA sequence (Accession Number AY895154).  The PCR primers were designed 
to extend over exon boundaries, therefore eliminating genomic DNA amplification 
(Fig. 3.1A).  Total RNA from dissected tissues was reverse transcribed as described 
in the methods chapter (2.5) to synthesize cDNA.  A single 238bp cDNA 
amplification product derived from exon 3 was detected in the anterior pituitary (Fig. 
3.1A).  The amplification of cGnRH-R-III cDNA was also detected in all the tissues 
tested (anterior pituitary, optic lobe, hind brain, cerebrum, cerebellum, median 
eminence, anterior hypothalamus, posterior hypothalamus, adrenal gland, olfactory 
bulb, kidney, small intestine, spleen, testes, liver) from pre-pubertal males and 
females although the intensity of the amplicons in the anterior pituitary was distinctly 
greater than any other tissue (Fig. 3.1B and 3.1C).   
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3.4.2. Single cGnRH-R-III transcript identified by Northern blot analysis 
Hybridisation of [γ-32P]-dATP labelled 73-120-cGnRH-R-III_anti-sense 
oligonucleotide probe designed to the 5’ upstream region of the translation start site 
in exon 1 of cGnRH-R-III was detected in samples from the anterior pituitary, but 
not from the small intestine or the testes of pooled Poly (A)+ RNA samples purified 
from ten 14-week old male birds of an advanced intercross of broiler and layer 
strains (AIL) (Fig. 3.2A) indicating a single cGnRH-R-III mRNA transcript.  [γ-32P]-
dATP 73-120-cGnRH-R-III_sense oligonucleotide used as a hybridisation negative 
control did not hybridise to the Poly (A)+ RNA samples as expected (data not 
shown).  Skeletal muscle actin-alpha-1 (ACTA1) 32P-dCTP labelled DNA probe 
hybridised to the pituitary, small intestine and testes samples (Fig. 3.2B), 
demonstrating equal RNA loading of samples and estimation cGnRH-R-III mRNA 
transcript size.  This ACTA1 gene whose full-length transcript size is 1736bp was 
used to estimate the size of the cGnRH-R-III mRNA transcript size, by overlapping 
the two Norhtern blots.  In another study, cGnRH-R-III mRNA of approximately 
1600bp bound the cGnRH-R-III_1210f-3217r-pBSK(+) riboprobe in sexually mature 
male and female white Leghorn layer type bird anterior pituitary samples, but not to 
cerebral cortex or to muscle RNA (Fig. 3.2C).  This confirmed the estimated size of 
the cGnRH-R-III transcript as estimated in (Fig. 3.2A).  There was no evidence for 
expression of cGnRH-R-III mRNA transcripts (splice variants) in any tissues, in 
either study. 
 
3.4.3. Comparative real-time RT-PCR quantification of cGnRH-R-I and 
cGnRH-R-III mRNA.   
The comparative quantification of cGnRH-R-I and cGnRH-R-III mRNA expression 
by real-time RT-PCR,  in 3 male and 3 female, 6 week old (pre-pubertal) Ross 
broiler type birds raised on 21 hours light period and 3 hours dark period (21L/3D) 
lighting and 3 male and 3 female, 24 week old (sexually mature) Ross broiler breeder 
birds raised on 14L/10D lighting, demonstrated that the overall expression of 
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cGnRH-R-III was greater than cGnRH-R-I in the median eminence, gonads and 
small intestine, but particularly so in the anterior pituitary where cGnRH-R-III 
expression was ~1373 times that of cGnRH-R-I (Fig. 3.3C). The data analysis was 
performed by applying an ANOVA analysis, as this data is composed of various 
explanatory variables (e.g. age, sex and tissue), and ANOVA analysis partitions the 
observed variance into components due to the different explanatory variables. 
ANOVA analysis demonstrated a significant relationship between tissue type on 
cGnRH-R-III concentrations (p<0.01).  This is primarily due to higher cGnRH-R-III 
mRNA expression in the anterior pituitary when compared to the median eminence, 
gonads and intestine (Fig. 3.3A).  Anterior pituitary expression of cGnRH-R-III was 
~92.5 times greater than in the testes or ovary.  No significant relation to tissue type 
was detected with cGnRH-R-I expression, where expression in the testes and ovary 
was ~1.4 times greater than in the anterior pituitary (Fig. 3.3B).  ANOVA analysis 
demonstrated a significant relationship between age and sex on pituitary cGnRH-R-
III mRNA expression (Fig. 3.3D).  Anterior pituitary cGnRH-R-III expression was 
~8.4 fold lower in sexually mature males compared to juvenile males whereas the 
reciprocal relationship was observed in females, with ~2.8 fold more anterior 
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Figure 3. 1 
 
Fig. 3.1.  Ethidium bromide stained agarose gels of cGnRH-R-III cDNA PCR 
amplification with primers cGnRH-R-III-713-735f (exon 2-3) and cGnRH-R-III-933-
952r generating a 238bp product which corresponds to exon 3 of cGnRH-R-III.  PCR 
cycle number = 40.  (A) cGnRH-R-III amplification; 1 = genomic DNA control, 2 = anterior 
pituitary complementary DNA, 3 = non-template control.  (B) cGnRH-R-III amplification on 
pre-pubertal female samples, (C) cGnRH-R-III amplification on pre-pubertal male samples, 
(D) GAPDH amplification.  (B, C and D) 1 = anterior pituitary, 2 = hind brain, 3 = 
cerebrum, 4 = cerebellum, 5 = median eminence, 6 = anterior hypothalamus, 7 = posterior 
hypothalamus, 8 = olfactory bulb, 9 = optic lobe, 10 = adrenal gland, 11 = kidney, 12 = small 
intestine, 13 = spleen, 14 = testes or ovary, 15 = liver, 16 = non-template control.   
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Figure 3. 2  
 
Fig. 3.2.  Northern blots of cGnRH-R-III mRNA indicating a single transcript 
detectable with both oligoprobes and riboprobes.  (A, B) Northern blot with pituitary (P), 
small intestine (SI) and testes (T) Poly (A)+ RNA samples (3µg) of 14 week old AIL male 
birds, hybridised with (A) cGnRH-R-III [γ-32P]-dATP 5’ end labelled oligoprobe and (B) 
Skeletal muscle alpha-actin-1 (ACTA1) 32P-dCTP random primer labelled DNA probe.  (C) 
Northern blot with pooled male and female cerebral cortex (C), pooled male and female 
muscle (M) and anterior pituitary glands (P1=female, P2=male) total RNA samples (15µg) of 
white Leghorn layer type birds.  Hybridised with GnRH-R-III antisense riboprobe spanning 
all 4 exons. The blot shows a single detectable band in the pituitaries and no detectable 
bands in the muscle or brain cortex tissues.  Millenium RNA size markers were added to the 
original gel and sizes were transferred to the image by interpolation. The position of the 28S 
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Figure 3. 3 
 
Fig. 3.3.  Comparative quantitative real-time PCR analysis of cGnRH-R-I and cGnRH-
R-III mRNA expression in tissues of pre-pubertal and sexually mature, male and 
female broiler chickens.  (A) cGnRH-R-III mRNA expression observed per milligram of 
tissue.  (B) cGnRH-R-I mRNA expression observed per milligram of tissue.  (C) Ratio of 
absolute expression of cGnRH-R-III over cGnRH-R-I mRNA.  The statistical significances 
in each experiment were caculated by applying an ANOVA to determine the effects of tissue 
type on cGnRH receptor expression.  In (A) and (C) values of p<0.01 are represented by two 
asterix (**) and represents statistical significance compared to all other tissues.  Values are 
mean (attomoles/milligram of tissue), represented as 1x10-18moles/milligram of tissue +/- 
SEM.  P = pituitary, ME = median eminence, SI = small intestine, T = testes and O = ovary.  
(No significant differences were detected between male and female gonads).  (D) 
Relationship between sex and age on pituitary cGnRH-R-III mRNA expression in pre-
pubertal (n=6) and sexually mature (n=6), male (n=6) (open columns) and female (n=6) 
(solid columns) broiler chickens.  Values are mean (attomoles/milligram of tissue) +/- SEM 
*p=<0.05, **p=<0.01. 
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3.4.4. Cloning of the type I GnRH receptor homolog cDNA into pcDNA 
I/Amp expression vector 
An expression construct containing cGnRH-R-I cDNA cloned into pcDNA1/Amp 
(Invitrogen, UK) eukaryotic expression vector was used (Sun et al., 2001b) in 
parallel studies.  The sequence of the cloned expression construct was confirmed by 
restriction enzyme digest (Fig 3.4A-D).  The expression construct contains the entire 
coding sequence and included 69bp upstream from the start codon through to the 
stop codon (Sun et al., 2001b). 
 
3.4.5. Cloning of the type III GnRH receptor homolog cDNA into 
pBluescript II SK(+) vector 
The sequence of the cGnRH-R-III_1210f-3217r-pBSK(+) construct, the cloned PCR 
product from broiler pituitary cDNA pool amplified with primers cGnRH-R(new)-
1210f and cGnRH-R(new)-3217r, was mapped by restriction digest (Fig. 3.5A-D). 
Automated sequencing of cGnRH-R-III_1210f-3217r-pBSK(+) construct using vector 
primers M13-Forward and M13-Reverse, indicated that the product from a meat type 
broiler strain was identical to the exons in the genomic DNA sequence from Gallus 
gallus gallus (Ensembl 2004) and White Leghorn strains (matching AY895154), 
following analysis with ClustalW sequence alignment software (Chenna et al., 2003).  
The expression construct contained the entire coding sequence and included 30bp 
upstream from the start codon through to 97bp after the stop codon (Fig. 3.5A-D).  
The cGnRH-R-III gene resides on chromosome 10 (UCSC Genome Browser Chr 10: 
20593844bp-20595762bp: Version_Feb2004), which is relatively close to the 
location of the cGnRH-R-I gene (UCSC Genome Browser Chr 10: 18495117bp-
18496853bp: Version_Feb2004) (Fig. 3.6). 
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3.4.6. Cloning of the type III GnRH receptor homolog cDNA into pcDNA 
3.1/myc-His-A expression vector 
The sequence of the cGnRH-R-III_1210f-3217r-pCDNA3.1/myc-His-A expression 
construct was mapped by restriction digestion (Fig. 3.7A-D) and determined by 
sequencing using vector primer T7-Forward. The expression construct contained the 
entire coding sequence and included 30bp upstream of the start codon through to 
97bp after the stop codon.  The myc-His epitope encoded in the expression vector 
was not utilised.   
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Figure 3. 4  
 
Fig 3.4.  Schematic representation of the construction of the cGnRH-R-I_pcDNA 
1/Amp construct as described in (Sun et al., 2001a; Sun et al., 2001b).  (A) The pcDNA 
1/Amp vector MCS.  Col E1 origin (1-587bp), M13 origin (588-1180bp), Ampicillin gene 
(1360-2303bp), CMV promoter (2304-2954bp), T7 primer sequence (2938-2957bp), 
Polylinker (2956-3074bp), Sp6 primer sequence (3075-3093bp), splice and PolyA (3798-
4693bp), SV40 origin (4634-4797).  (B)  The amplified anterior pituitary cDNA insert is as 
described (Sun et al., 2001a; Sun et al., 2001b).  The tranlation start site (58-60bp) and the 
translation termination site (1193-1195) are indicated in bold italics.  (C)  The restriction 
enzyme sites used to validate the integrity of the recovered construct.  The cut positions are 
with reference to the 5962bp cGnRH-R-I_pcDNA 1/Amp construct.                                    
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Figure 3. 5 
 
Fig 3.5.  Schematic representation of the construction of the cGnRH-R-III_1210f-
3217r-pBSK(+) plasmid.  (A) The pBluescript II SK(+) phagemid vector (accession 
#X52328) was linearised with EcoRV within the MCS  (C) pBluescript II SK(+) multiple 
cloning site region.  f1 (+) origin of ss-DNA replication (135-441bp); ß-galactosidase α-
fragment coding sequence (lacZ’) (460-816bp); multiple cloning site (MCS) (653-760bp); 
T7 promoter transcription initiation site (643); T3 promoter transcription initiation site 
(774bp); lac promoter (817-938bp); pUC origin of replication (1158-1825bp); ampicillin 
resistance (bla) ORF (1976-2833bp).  (B)  The amplified anterior pituitary cDNA insert 
sequence amplified with primers cGnRH-R(new)-1210f (1-18bp)  and cGnRH-R(new)-3217r 
(1367-1386bp).  The primer sequences are annotated in bold and underlined.  The translation 
start site (30-32bp) and the translation termination site (1289-1291) are indicated in bold 
italics.  (D)  The restriction enzyme sites used to validate the integrity of the construct cloned 
by inserting the cGnRH-R-III insert into the pBluescript II SK(+) linearised with ECORV 
within the MCS.  The cut positions are with reference to the 4347bp cGnRH-R-III_1210f-
3217r-pBSK(+) construct.                                    
Chapter 3                           Cloning, Characterisation and Expression of cGnRH-R-III
 
 100
Figure 3. 6 
 
Fig 3.6. UCSC Genome Browser focused on chicken Chromosome 10 position 
18,400,000-20,600,000 [Feb. 2004 Assembly]. (http://genome.ucsc.edu/cgi-bin/hgGateway).  
cGnRH-R-III (purple box and indicated with purple arrow) gene resides on chromosome 
10:20593844bp-20595762bp, which is close to the location of cGnRH-R-I (red box and 
indicated with red arrow) gene which resides on chromosome10:18495117bp-18496853bp.  
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Figure 3. 7 
 
Fig. 3. 7.  Schematic representation of the construction of the cGnRH-R-
III_pcDNA3.1/myc-His(-)A plasmid.  (A) The pcDNA 3.1/myc-His(-)A vector.  (C) 
pcDNA 3.1/myc-His(-)A multiple cloning site region.  CMV promoter (209-863bp), T7 
promoter/priming site (863-882bp), Multiple cloning site (895-1006bp), mycepitope (1007-
1036), Polyhistidine tag 1052-1069bp), BGH reverse priming site (1113-1130bp), BGH 
polyadenylation signal (1116-1343bp), f1 origin (1389-1817bp), SV40 promoter and origin 
(1844-2152bp), Neomycin resistance gene (2227-3021bp), SV40 polyadenylation signal 
(3195-3325bp), pUC origin (3708-4381bp), Ampicillin resistance gene (5426-
5386bp:complementary strand).  (B)  The insert sequence removed from cGnRH-R-
III_1210f-3217r-pBSK(+) construct, using restriction enzymes BamHI and HincII.  The 
regions of the removed pBSK(+) vector are annotated in bold.  The primer sequences used to 
amplify the original cGnRH-R-III_1210f-3217r insert are annotated in bold and underlined 
characters.  The translation start site (56-58bp) and the translation termination site (1315-
1318) are indicated in bold italics.  (D)  The restriction enzyme sites used to validate the 
integrity of the construct cloned by inserting the cGnRH-R-III-pBSK(+) insert into the 
pcDNA3.1/myc-His(-) vector between the BamHI and HincII sites of the MCS.  The base 
pair sites are numbered with reference to the 6892bp cGnRH-R-III_ pcDNA3.1/myc-His(-) 
A construct.        
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3.4.7. Type III GnRH receptor gene structure and amino acid sequence 
motif identification 
Bioinformatics comparisons of the chicken type III GnRH receptor cDNA and 
genomic DNA sequences confirmed that the predicted receptor sequence consists of 
a 419 amino acid protein encoded by 4 exons on chicken chromosome 10 linked to 
the type I GnRH receptor.  The amino acid sequence identity of the two cGnRH-Rs 
is 53% (Fig. 3.8A).  The amino acid sequences of both cGnRH-R receptors were 
compared with human, bullfrog, leopard gecko and African clawed frog GnRH 
receptor subtypes (Table 3.1).  The highest homology of cGnRH-R-I was with 
bullfrog-II GnRH-R.  The highest homology of cGnRH-R-III was with bullfrog-I and 
leopard gecko-I GnRH-Rs.  (Note: the existing nomenclature for the bullfrog and 
leopard gecko subtypes is confusing, as they have not been designated according to 
phylogenetic classification) (Table 3.1). Phylogenetic analysis (Fig. 3.8B) clearly 
classes this receptor as a type III GnRH receptor homolog, with a high bootstrap 
value (99%) supporting the classification between type II and type III GnRH receptor 
clusters.  The bullfrog-I GnRH-R and the leopard gecko-I cGnRH receptor 
homologue lie within the type III GnRH receptor homolog cluster.    
 
Using cDNA sequence alignment with genomic DNA sequence, the gene structure of 
cGnRH-R-III was determined.  The putative translation start codon is coded in exon 
1 and the stop codon in exon 4. The amino terminal extracellular domain is coded by 
exon 1 and exon 2.  Exon 2 also encodes transmembrane domain (TMD) 1, 
intracellular loop (ICL) 1, TMD2, extracellular loop (ECL) 1, TMD3, ICL2 and part 
of TMD4.  Exon 3 encodes the rest of TMD4, ECL2, TMD5 and part of ICL3.  Exon 
4 encodes the rest of ICL3, TMD6, ECL3, TMD7 and the C-terminal cytoplasmic 
domain (Fig. 3.8A).   Comparisons of functionally important amino acid residues and 
sequence micro-domains were performed using amino acid sequence alignment.  
cGnRH-R-III like cGnRH-R-I has aspartic acid residues (Asp/D) in both loci of the 
helix2/helix7 micro-domain (amino acid positions; cGnRH-R-I = 87 and 310, 
cGnRH-R-III = 113 and 345) (Fig 3.8A).  The arginine cage motif (DRXXX(I/V) and 
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alanine residue (Ala/A) in ICL3 are maintained in cGnRH-R-III at positions 164 and 
286 respectively (Fig 3.8A).  The two cGnRH-Rs exhibit conservation of the aspartic 
acid (Asp/D) (amino acid positions; cGnRH-R-I = 98 and cGnRH-R-III = 124) and 
asparagine (Asn/N) (amino acid positions; cGnRH-R-I = 102 and cGnRH-R-III = 
128) residues in TMD2 (Fig 3.8A).  The lysine (Lys/K) residue in TMD3 at position 
121 of cGnRH-R-I is conservatively substituted with an arginine (Arg/R) residue at 
position 147 of the cGnRH-R-III.  The glutamate (Glu/E) residue in ECL3 is not 
conserved in cGnRH-R-III at position 288 whereas it is present in cGnRH-R-I at 
position 328.  cGnRH-R-I has a PEY motif in ECL3 at position 291 - 293 whereas in 
cGnRH-R-III this motif is PPS at position (327-329) (Fig 3.8A).  The cytoplasmic 
tail domain of cGnRH-R-III is longer by an additional 8 residues (Fig 3.8A).   Three 
putative Src homology domain 3 (SH3) binding motifs were identified exclusively in 
the type III cGnRH receptor cytoplasmic C-terminal tail domain (sequence = EPEPP, 
EPPSP, GPHPP), which are not present in the type I cGnRH-R.  These motifs are 
located at amino acid positions 369-373, 370-375 and 398-402 encoded by exon four 
of cGnRH-R-III (Fig 3.8A).   
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Figure 3. 8 
 
Fig. 3.8A continued on next page 
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Fig. 3. 8.  (A) Alignment of human, bullfrog, leopard gecko, African clawed frog and chicken GnRH Receptor sequences, representative 
sequences of GnRH receptor types I, II and III.  Motifs in ECL3 are depicted in bold and underlined. Ubiquitously conserved amino acid residues are 
shown with dark background shading.  Boxed amino acids are as follows:  1 and 2 = aspartic acid residue in the functional helix2/helix7 micro-
domain of non-mammalian GnRH receptors, 3 and 4 = conserved coupling arginine cage motif and alanine residue, 5, 6, 7 and 8 = ligand binding 
residues; aspartic acid residue, asparagine residue, lysine residue and arginine residue respectively.  Predicted transmembrane domains (TMD 1-7) 
are indicated by a bold horizontal line.  GnRH receptor subtypes are labelled according to the published terminology and presented in Roman 
numerals (Ikemoto and Park, 2007; Wang et al., 2001a).  
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Fig. 3.8.  (B) A phylogenetic tree inferred using the neighbour joining method based on 
multiple sequence alignment of representative, reptilian, amphibian and avian GnRH 
receptor amino acid sequences.  Phylogenetic analyses were conducted in MEGA4 
(Tamura et al., 2007).  The bootstrap consensus tree inferred from 1000 replicates is taken to 
represent the evolutionary history of the taxa analyzed (Felsenstein, 1985). Branches 
corresponding to partitions reproduced in less than 50% bootstrap replicates are collapsed. 
The percentage of replicate trees in which the associated taxa clustered together in the 
bootstrap test (1000 replicates) are shown next to the branches (Felsenstein, 1985). The tree 
is drawn to scale, with branch lengths in the same units as those of the evolutionary distances 
used to infer the phylogenetic tree.  The evolutionary distances were computed using the 
Poisson correction method (Zuckerkandl and Pauling, 1965) and are in the units of the 
number of amino acid substitutions per site. All positions containing gaps and missing data 
were eliminated from the dataset (Complete deletion option). There were a total of 300 
positions in the final dataset. 
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Table 3. 1 
Comparison of the amino acid identities of GnRH-R subtypes.  The GnRH receptor 
names of the bullfrog and the leopard gecko are according to the published terminology of 
each receptor subtype, presented in Roman numerals (Ikemoto and Park, 2007; Wang et al., 
2001a). 
 
GnRH-R subtype Identity (%) with 
cGnRH-R-I 
Identity (%) with 
cGnRH-R-III 
 
Chicken I 100 53 
Chicken III 53 100 
Bullfrog I 51 65 
Bullfrog II 63 51 
Bullfrog III 51 60 
African clawed frog I 65 52 
African clawed frog II 51 61 
Leopard gecko I 50 65 
Leopard gecko II 69 51 
Leopard gecko III 51 58 
Human 42 43 
 
 
3.4.8. In-situ hybridisation to detect cGnRH-R-III mRNA 
In-situ hybridisation using Digoxigenin (DIG)-labelled RNA probes on 
whole tissues 
No DIG-specific staining could be identified in the 18 month old female layer (Fig. 
3.9A, C) pituitary gland hybridised with DIG-labelled cGnRH-R-III antisense RNA 
probe.  There was clear DIG-specific staining in the pituitary gland of an 18 month 
old female layer pituitary gland hybridised with DIG-labelled pro-opiomelanocortin 
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(POMC) antisense RNA probe used as a positive control (Fig 3.9B, D).  Whole-
mount pituitary glands (Fig were sectioned to try to identify the cellular localisation 
of DIG-specific labelling (Fig. 3.10A-D).  DIG-specific staining localised in the 
pituitary gland hybridised with DIG-labelled POMC antisense RNA probe (Fig. 
3.10C, D), demonstrating that the probe permeated only the outer surface of the 
tissue and the methodology used was optimal for detecting mRNA expression on the 
outer surface of the pituitary gland.  The expression of cGnRH-R-III mRNA was not 
detectable on the outer surface of the pituitary gland. 
 
In-situ hybridisation using DIG-labelled RNA probes on sectioned 
tissues 
DIG-specific staining was identified in 18 month old male layer bird (Fig. 3.11A-B) 
pituitary gland sections hybridised with DIG-labelled POMC antisense RNA probe.  
The DIG-labelled cGnRH-R-III sense RNA probe did not hybridise to 18 month old 
female layer pituitary gland sections (Fig. 3.11C-D).  There was no evidence of 
DIG-specific staining of sections hybridised with DIG-labelled cGnRH-R-III 
antisense RNA probe (Fig. 3.11E-F). 
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Figure 3. 9 
 
Fig. 3. 9.  18 month old female layer anterior pituitary gland whole-mount in-situ 
hybridisation with DIG-labelled cGnRH-R-III antisense RNA probe (A, C) and DIG-
labelled POMC antisense RNA probe (B, D).  (A, B) Dorsal view of cephalic (CE) and 
caudal (CA) lobes of the pituitary gland.  (C, D) Ventral view of cephalic (CE) and caudal 
(CA) lobes of the pituitary gland. 
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Figure 3. 10 
 
Fig. 3.10.  30µm sagittal sections of sectioned whole-mount chicken anterior pituitary 
gland in-situ hybridisation samples.  (Note: the whole-mount samples were sectioned 
subsequent to performing the in-situ hybridisation).  CE=cephalic lobe and CA-caudal 
lobe.  (A, C) DIG-labelled cGnRH-R-III antisense RNA probe.  (B, D) DIG-labelled POMC 
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Figure 3. 11 
 
Fig. 3.11.  18 month old male layer pituitary parasagittal sections hybridised with; (A, 
B) DIG-labelled POMC antisense RNA probe.  (C, D) DIG-labelled cGnRH-R-III sense 
RNA probe.  (E, F) DIG-labelled cGnRH-R-III anti-sense RNA probe.  The tissues were 
sectioned at 25µm thickness, and images were captured at 10X objective magnification.  
Cephalic lobe = CE, Caudal lobe = CA.   
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In-situ hybridisation using [35S] dATP(alphas) labelled oligonucleotide 
probes on sectioned tissues 
No obvious differences in the density of silver grains were detected in 26 week old 
broiler breeder pituitary sections hybridised with [35S]dATP labelled 73-120-
cGnRH-R-III_sense, 73-120-cGnRH-R-III_antisense, 1261-1290-cGnRH-R-
III_sense  or 1261-1290-cGnRH-R-III_antisense oligonucleotide probes exposed to 
photographic emulsion for 30 days (data not shown).  Silver grain distribution did 
suggest sites of transcript expression for cGnRH-R-III.  However, silver grains were 
present on both the area of the section and the slide, indicating that this represents the 
level of non-specific background.  Therefore in an attempt to amplify the signal, 
[35S]dATP cGnRH-R-III sense (73-120-cGnRH-R-III_sense + 1261-1290-cGnRH-
R-III_sense) negative control and [35S]dATP cGnRH-R-III antisense (73-120-
cGnRH-R-III_antisense + 1261-1290-cGnRH-R-III_antisense) oligonucleotide 
cocktail probes were used.  Hybridisation using [35S]dATP POMC oligonucleotide 
probes was detected abundantly in the cephalic lobe of the anterior pituitary sections 
of sexually mature advanced intercross layer (AIL) birds, reflected by a high and 
clustered silver grain density (Fig. 3.12E).  There was no increase in abundance of 
silver grains detected in the sections hybridised with [35S]dATP cGnRH-R-III sense 
cocktail (Fig. 3.12A, B) probes or [35S]dATP cGnRH-R-III antisense cocktail probes 
(Fig. 3.12C, D).  Although in one particular pituitary section hybridised with 
[35S]dATP cGnRH-R-III antisense probe (Fig. 3.12F, G, H) an abundance of silver 
grains distributed in a network pattern were evident, which potentially indicated 
detection of cGnRH-R-III mRNA.   
 
In another study, hybridisation of [35S]dATP POMC antisense oligonucleotide probe 
was detected abundantly in the cephalic lobe of 15µm thick anterior pituitary gland 
sections, reflected by a high silver grain density in both male (data not shown) and 
female (Fig. 3.13A, B) sexually mature birds of an advanced intercross lay (AIL) 
pedigree.  There was no evidence of the [35S]dATP cGnRH-R-III sense cocktail 
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probes hybridising to the anterior pituitary sections of both AIL male (data not 
shown) or female (Fig. 3.13C, D) sexually mature birds, as no clustering of silver 
grains was apparent.  There was no increase in abundance of silver grains in (Fig 
3.13E, F) compared to hybridisation of the cGnRH-R-III sense oligonucleotide 
cocktail probes (Fig. 3.13C, D).  Therefore, there was no evidence of hybridisation 
of the [35S]dATP cGnRH-R-III oligonucleotide antisense cocktail probes to the 
pituitary glands of sexually mature AIL male (data not shown) or female (Fig. 
3.13E, F) birds.  No increase in the abundance of silver grains was detected in 
sexually mature female (data not shown) or male AIL samples exposed to 
photographic emulsion for an additional 40 days of the [35S]dATP POMC antisense 
(Fig. 3.14A, B) oligonucleotide probe or either the [35S]dATP cGnRH-R-III sense 
(Fig. 3.14C, D) or antisense cocktail probes (Fig 3.14E, F).   
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Figure 3. 12 
 
Fig. 3.12.  In-situ hybridisation of cGnRH-R-III (sense and antisense) and POMC 
(antisense) [35S]dATPalphaS oligonucleotide probes to sexually mature AIL pituitary 
gland sections.  (A, B) cGnRH-R-III_sense oligonucleotide cocktail.  (C, D, F, G, H) 
cGnRH-R-III_antisense oligonucleotide cocktail.  (E) POMC antisense oligonucleotide.    
Images are in dark field to visualise silver grains. (B, D, E, F, H) and bright field to visualise 
Haemotoxylin and Eosin stained cells (A, C, G).  The slides were exposed to emulsion for 
16 days (E, F, G, H) and 30 days (A, B, C, D).  (G, H) 2x magnification of section captured 
in image (F).  The tissues were sectioned at 15µm thickness.  
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 Figure 3. 13 
 
Fig. 3.13  In-situ hybridisation of cGnRH-R-III sense and antisense and POMC anti-
sense [35S]dATPalphaS oligonucleotide probes to sexually mature (approximately 16 
weeks old) AIL female pituitary gland sections.  (A, B) POMC antisense oligonucleotide.  
(C, D) cGnRH-R-III_sense oligonucleotide cocktail. (E, F) cGnRH-R-III_antisense 
oligonucleotide cocktail.  Images are in dark field to visualise silver grains. (B, D, F) and 
bright field to visualise Haemotoxylin and Eosin stained cells (A, C, E).  The slides were 
exposed to emulsion for 7 days.  The tissues were sectioned at 15µm thickness.  
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Figure 3. 14 
 
Fig. 3.14.  In-situ hybridisation of cGnRH-R-III sense and antisense and POMC anti-
sense [35S]dATPalphaS oligonucleotide probes to sexually mature (approximately 16 
weeks old) AIL male pituitary sections.  (A, B) POMC anti-sense oligonucleotide.  (C, D) 
cGnRH-R-III_sense oligonucleotide cocktail. (E, F) cGnRH-R-III_antisense oligonucleotide 
cocktail.  Images are in dark field to visualise silver grains. (B, D, F) and bright field to 
visualise Haemotoxylin and Eosin stained cells (A, C, E).  The slides were exposed to 
emulsion for 47 days.  The tissues were sectioned at 15µm thickness.  
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3.4.9. Laser capture enrichment of fixed LH gonadotophs for cGnRH-R 
subtype RT-PCR quantification 
Rapid IHC detection of LH-specific gonadotrophs on sectioned pituitary 
glands 
Female ‘out of lay’, layer silkie cross birds were perfusion fixed with Zamboni’s 
fixative through the jugular vein or alternatively were dissected and fixed in acetone 
once sectioned.  No effects of the tissue fixation methods were observed on the 
sections stained with anti-LH-ß antibody (data not shown).  The optimal staining 
methodology was a 1:800 dilution of the primary anti-turkey LH-ß antibody 
incubated for 3 minutes.  Immuno-reactive positive cells were stained as dark brown 
in colour, and the immuno-negative cells were faint brown (Fig. 3.15).  Slides were 
kept in a box containing silica crystals to prevent re-hydration of the cells which 
inhibits Laser capture micro-dissection (LCM).  The smallest laser spot diameter of 
the Acturus PIX Cell III Laser Capture Instrument is 7µm and the average size of a 
gonadotroph is 10µm.  Thus it is theoretically possible to dissect out a pure 
gonadotroph.  However, due to the method in which the thermostatic film forms a 
protrusion that bridges the gap between the cap and the target cell when activated by 
the laser, the actual size of the site of contact between the melted thermostatic film 
and the target cell is larger than the set laser spot diameter size.  Additionally, lifting 
the cap results in the removal of the target cell which has adhered to the cap and at 
times is contaminated by fractions of adjacent cells.  Therefore, The LCM proved 
unsuccessful as the area dissected by LCM was greater than that of a gonadotroph, 
resulting in contamination from adjacent cell types.   
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Figure 3. 15 
 
Fig. 3. 15.  Immunohistochemistry of pituitary samples from a female ‘out of lay’, layer 
silkie cross bird. (A) Sagittal 20µm frozen section at 4x objective magnification to detect 
LH specific-gonadotrophs which are visible as dark brown clusters of cells (indicated with 
black arrows).  (B) Sagittal 20µm frozen sections to detect LH gonadotrophs which are 
visible as dark brown cells (indicated with black arrows).   




In this chapter, a novel chicken GnRH receptor cDNA expressed in the pituitary 
gland was cloned and sequenced (Fig. 3.5, 3.6, 3.7, and 3.8).  Birds, like certain 
mammals, possess two GnRH receptor subtypes in contrast to fish, reptiles and 
amphibians in which three types of receptor are generally found (Ikemoto and Park, 
2007; Morgan and Millar, 2004; Stewart et al., 2009).  The proximity of the two 
chicken GnRH receptor subtype genes on chromosome 10 (approximately 2Mb 
apart) and their high amino acid sequence identity (53%), suggests they may have 
been derived by gene duplication (Fig. 3.6) (Joseph et al., 2009).  Phylogenetic 
analysis indicates that the novel chicken GnRH receptor should be classified as a 
type III receptor.  There has been an inclination by many researchers to designate 
GnRH receptors that are selective for GnRH-II as type II GnRH receptors.  However, 
all non-mammalian receptors, regardless of their structural similarity appear to 
preferentially bind GnRH-II (Pfleger et al., 2002).  Other investigators have 
designated GnRH receptors by their tissue-specific expression (type I in 
pituitary/type II in brain).  This classification is also problematic as the predominant 
GnRH receptor expressed in bullfrog pituitary is structurally a type III receptor, 
(Wang et al., 2001a) while in African clawed frog it is a type I receptor (Troskie et 
al., 2000).  Thus it is evident that there is considerable plasticity in utilisation of a 
particular GnRH receptor in a particular tissue.  We therefore advocate that GnRH 
receptors should be designated names according to their structural and phylogenetic 
relatedness prior to assessing their physiological roles.  cGnRH-R-III was first 
designated as cGNRHR2 (Shimizu and Bedecarrats, 2006), whereas re-designation 
as cGnRH-R-III is appropriate according to phylogenetic classification (Fig. 3.8B)  
(Joseph et al., 2009). 
 
The first GnRH-R isoform to be cloned in the chicken, cGnRH-R-I  is expressed at 
the transcriptional level in various tissues including the pre-optic anterior 
hypothalamus, basal hypothalamus, anterior pituitary gland, brain cortex, cerebellum, 
testes, heart and spleen; but not the liver or kidney (Sun et al., 2001a; Sun et al., 
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2001b).  The widespread expression of cGnRH-R-I transcripts was confirmed in this 
study (Fig. 3.3A).  The novel cGnRH-R-III homolog was also shown to be widely 
transcribed (Fig. 3.1B, C) although levels are predominant in the anterior pituitary 
gland (Fig. 3.2A, B and Fig. 3.3B) (Joseph et al., 2009).  Critically, the relative 
abundance of the two receptors mRNA transcripts in relation to each other has been 
established in this thesis, with cGnRH-R-III mRNA being expressed at a higher 
molar concentration than cGnRH-R-I mRNA in all tissues tested (Fig. 3.3.C) (Joseph 
et al., 2009).  In another study, PCR amplification of cGnRH-R-III cDNA was shown 
to be pituitary-specific (Shimizu and Bedecarrats, 2006).  The comparison of the two 
cGnRH-R homolog cDNA expression patterns may be useful in determining the 
physiological importance of each receptor subtype.  However, this approach is based 
on the assumption that cDNA is translated into protein in proportional quantities (see 
Appendix B for additional data).  The higher expression (~1373 times) of cGnRH-
R-III mRNA compared to cGnRH-R-I mRNA in the anterior pituitary gland (Fig. 
3.3C), does suggest it is the physiologically important receptor in this organ.  
Although, more than one GnRH receptor subtype can be expressed within the same 
tissue, as seen in the sea bass (Moncaut et al., 2005) and goldfish (Illing et al., 1999) 
and now in the chicken (Fig. 3.3C) (Joseph et al., 2009).  In the bullfrog and leopard 
gecko however, as in the chicken (Fig. 3.3C) mRNA for one of the three GnRH-R 
subtypes predominates in the pituitary (Ikemoto and Park, 2007; Joseph et al., 2009; 
Wang et al., 2001a).  In this study presented in this chapter, sex-specific plasticity 
in the spatiotemporal expression patterns of GnRH receptor subtypes has been 
demonstrated.  The predominance of one receptor subtype (type III) over another 
receptor subtype (type I) in the chicken pituitary is similar to that of the closest 
evolutionary species within the amphibian and the reptilian orders (Ikemoto and 
Park, 2007; Illing et al., 1999; Moncaut et al., 2005; Troskie et al., 2000; Wang et al., 
2001a).  Interestingly, the pituitary-specific GnRH receptor subtypes expressed in the 
bullfrog (Wang et al., 2001a), African clawed frog (Troskie et al., 2000) and leopard 
gecko (Ikemoto and Park, 2007) and chicken (Fig. 3.8B) (Joseph et al., 2009) differ 
structurally, according to their phylogenetic classification (Flanagan et al., 2007; 
Joseph et al., 2009; Millar et al., 2004; Tello et al., 2008).  These observations lend 
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further support for the existence of plasticity in evolutionary recruitment of 
GnRH receptor subtypes for regulation of pituitary gonadotrophin production.   
 
In this study, pituitary cGnRH-R-III mRNA expression levels can be correlated with 
reproductive status, suggesting that cGnRH-R-III plays a role in the regulation of 
gonadotroph function (Joseph et al., 2009).  In contrast, no sex differences or 
changes in expression were detected for cGnRH-R-I mRNA (data not shown), 
compared to a pronounced reciprocal sex difference in pituitary cGnRH-R-III mRNA 
expression (Fig 3.3.D) (Joseph et al., 2009).  Higher cGnRH-R-III mRNA levels 
occur in adult females compared to adult males (Fig 3.3.D) (Joseph et al., 2009).  In 
contrast, in juvenile chickens, higher cGnRH-R-III mRNA levels occurred in males 
compared to females (Fig 3.3.D) (Joseph et al., 2009).  Differences in cGnRH-R-III 
mRNA expression levels between juvenile and mature males and females as seen in 
this study (Joseph et al., 2009) were not previously reported in another study 
(Shimizu and Bedecarrats, 2006).  This difference may be due to the precise age of 
animals used in different studies.  The sexual dimorphism in cGnRH-R-III mRNA 
expression, where levels of mRNA are higher in juvenile males compared to juvenile 
females, is consistent with the LH response to photo-stimulation seen in juveniles, 
where there is a robust response in males but not in females (Sreekumar and Sharp, 
1998).  In adult males and females, cGnRH-R-III mRNA expression levels are 
inversely related to sex differences in LH responsiveness to GnRH injection (Sharp 
et al., 1987).  When chicken pituitary fragments from adult males or juveniles of 
either sex are perifused, a large spike followed by a plateau in LH release in response 
to GnRH stimulation is observed (Liu et al., 1995).  Adult laying hens do not exhibit 
this rapid spike of LH release but do show the plateau phase (Liu et al., 1995).    The 
release of LH in adult hens is also much reduced compared to juvenile hens (Liu et 
al., 1995).  In general, our observations suggest that the level of GnRH-R-III mRNA 
may be inversely related to the capacity to release LH by gonadotrophs in adult 
females (Joseph et al., 2009).  It can be hypothesised that elevated levels of cGnRH-
R-III mRNA in the adult female may be reflective of expression of membrane 
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cGnRH-R-III receptor number and that increased levels of ovarian steroid or peptide 
hormones may act to diminish the LH response to GnRH at the gonadotroph, through 
down regulation of intracellular signalling pathways, including Ca2+ mechanism in 
these cells (Liu et al., 1995) (see Appendix B for additional data). 
 
In avian species, the two gonadotrophins, FSH and LH, are not expressed in the same 
cell type (Proudman et al., 1999; Puebla-Osorio et al., 2002).  Both cGnRH-I and 
GnRH-II stimulate LH release from chicken pituitary in-vitro (Hattori et al., 1986a; 
Millar et al., 1986) and in-vivo (Chou et al., 1985b; Hattori et al., 1986b; Proudman 
et al., 2006; Sharp et al., 1986) however, there is conflicting evidence for an effect of 
cGnRH-I or GnRH-II on FSH in-vitro, (Hattori et al., 1986a; Millar et al., 1986) and 
in-vivo (Bruggeman et al., 1998; Dunn et al., 2003; Krishnan et al., 1993; Proudman 
et al., 2006).  The quantification of the expression of cGnRH-R-I and cGnRH-R-III 
subtypes in the seperate populations of gonadotrophs would allow inference about 
the role of cGnRH-R subtypes in the control of production of each gonadotrophin 
and how the secretion of LH and FSH may be differentially controlled by GnRH.  
However, in this thesis concerted attempts to confirm the cellular localisation of 
cGnRH-R-III expression within the pituitary gonadotroph cells using in-situ 
hybridisation or laser capture enrichment of gonadotrophs proved unsuccessful.   
 
It was possible to detect POMC mRNA using in-situ hybridisation to chicken 
pituitary sections, indicating that the three methods used (DIG labelled RNA probes 
on whole-mount or cryostat sectioned pituitary glands and radiolabelled oligoprobes 
on sectioned pituitary glands) were effective (Fig. 3.9.B, D; Fig. 3.10.B, D; Fig. 
3.11.A, B; Fig. 3.12.E; Fig. 1.13.A, B and Fig. 3.14.A, B).  POMC is a peptide 
hormone precursor which contains sequences for melanocortins, lipotrophins and ß-
endorphin (Takeuchi et al., 1999), and is expressed in the cephalic lobe of  the 
chicken pituitary gland (Gerets et al., 2000).  High level expression of POMC in the 
cephalic lobes of the pituitary was confirmed in this study (Fig. 3.9.B, D; Fig. 
3.10.B, D; Fig. 3.11.A, B).  The DIG labelled cGnRH-R-III RNA probes 
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encompassed the entire cDNA fragment (~1300bp) (Fig. 3.9.A, C; Fig. 3.10.A, C; 
Fig. 3.11.C-F), and perhaps a smaller RNA probe may prove more successful due to 
greater tissue penetration and hybridisation efficiency.  However, in view of the fact 
that the oligoprobes, which were previously shown to hybridise to the mRNA (as 
shown in the Northern blots Fig. 3.2.A) did not yield a signal in in-situ 
hybridisation indicates that the cGnRH-R-III mRNA may not be expressed 
abundantly enough to be readily detected by in-situ hybridisation (Fig 3.12.A-D, F; 
Fig. 3.13.C-F; Fig. 3.14.C-F).  On two occasions however, the presence of silver 
grain clusters forming a network pattern (Fig. 3.12F, G, H) suggested cGnRH-R-III 
mRNA in pituitary cells, however, this was very difficult to reproduce (Fig. 3.14), 
and is likely to be an artefact, possibly due to cracking of the emulsion during drying.  
In addition to gonadotrophs, it is possible that GnRH receptors may be expressed in 
other pituitary cell types, including for example folliculo stellate (FS) cells.  A 
number of growth factors and peptides are expressed in FS cells and FS cells may 
have a role in paracrine communication in the anterior pituitary gland (Allaerts and 
Vankelecom, 2005).  It has been shown that activin which is expressed in FS cells 
may have a role in modulating GnRH-R expression (Kaiser et al., 1992; Rispoli and 
Nett, 2005).  Therefore, it is plausible that cGnRH-R-III homolog mRNA may be 
expressed in the FS cells.  More research into the expression of GnRH receptors in 
FS cells may prove beneficial in understanding cell-type specific expression of 
cGnRH-R subtypes.    
 
Semi-quantitative studies on GnRH and GnRH receptor mRNA in the sheep have 
shown that the receptor is expressed approximately 6 times less abundantly in the 
pituitary compared to the relative expression of GnRH in the hypothalamus (Dolan et 
al., 2003).  When comparing expression levels of genes, hypothalamic cGnRH-I in 
laying and incubating hens varies about 5 fold (between 38.7 and 7.7 x10-17 mols per 
hypothalamus) (Dunn et al., 1996) and is 10-50 fold higher than that of the pituitary 
expression of cGnRH-R-III which was quantified in this study to be   6.8x10-18 mol 
per mg of tissue (Fig. 3.3.A) (Joseph et al., 2009).  In general, mRNAs for G protein 
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coupled receptors are expressed at relatively low levels (Fraser et al., 1996).  There 
have been previous reports of in-situ hybridisation detection of cGnRH-R subtypes 
mRNA in a variety of tissues in other species (Bahk et al., 2008; Bing et al., 2003; 
Crumeyrollearias et al., 1994; Fraser et al., 1996; QuinonesJenab et al., 1996; 
WeiQuan et al., 2001).  However, in this study cGnRH-R-III mRNA was not 
detectable using the same methodology.  As mentioned, it is possible that the 
cGnRH-R-III mRNA is not expressed exclusively in gonadotrophs.  GnRH receptor 
mRNA has been previously shown to be expressed in lactotrophs of the rat anterior 
pituitary (Mertani et al., 1996).  This may explain why cGnRH-R-III mRNA was 
detectable in the anterior pituitary by Northern analysis (Fig. 3.2) but not by in-situ 
hybridisation (Fig. 3.9-Fig. 3.14).  Receptor transcripts might not be concentrated in 
one particular subtype of pituitary cells, but may be spread over a number different 
pituitary cell types.  However, it may have been more appropriate to use a GPCR as a 
positive control inorder to optimise the in-situ hybridisation methods, as POMC is 
expressed in much more abundant levels than GPCRs.  Therefore, the methodology 
may not have been optimised for in-situ hybridisation of a GPCR and the optimised 
methods may thus not have been optimised for detecting cGnRH-R-III mRNA 
expression.  This approach may be the focus of future investigations.      
 
An alternative method to measure the cellular localisation of cGnRH-R-III and 
cGnRH-R-I mRNA in pituitary gonadotrophs was attempted by the application of 
immunohistochemical techniques to detect LH gonadotrophs followed by laser 
capture enrichment of the isolated population of cells and real-time quantitative RT-
PCR (Fig. 3.14.A, B).  Theoretically this methodology is possible for the selective 
extraction of cells from heterogeneous tissues (Fend et al., 1999; Mojsilovic-Petrovic 
et al., 2004), and has previously been performed for pituitary cell type enrichment in 
cichlid fish in combination with post-capture micromanipulation to remove 
undesirable tissue around the periphery of the targeted cells (Parhar et al., 2005).  
However, it proved technically difficult for chicken gonadotroph cells in our hands.  
Although detection of LH stained gonadotrophs was successful, the laser capture of 
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pure gonadotrophs was impossible because the size limit for the micro-dissected area 
was greater than that of a single gonadotroph cell (Fig. 3.14.B).  It is plausible that 
this method could be applied to in-vitro dispersed pituitary cells in the future.  A 
more involved method of employing double immunohistochemistry to detect the co-
localisation of the cGnRH receptor subtypes in the gonadotroph cells may prove 
more effective at some point in the future.  
 
Using RT-PCR, two cGnRH-R-III splice variant transcripts have been identified 
(Shimizu and Bedecarrats, 2006), a pituitary-specific transcript (1065bp splice 
variant) (Shimizu and Bedecarrats, 2006), in addition to another 501bp splice variant 
that is expressed in different brain regions (Shimizu and Bedecarrats, 2006).  In this 
study, these cGnRH-R-III splice variant transcripts (Shimizu and Bedecarrats, 2006) 
were not detected by oligonucleotide probe or riboprobe using Northern blotting to 
pituitary gland RNA, (Fig. 3.2.A-C), suggesting that their in-vivo expression is 
relatively low and may be of little functional significance in the pituitary.  cGnRH-R 
subtype splice variants have been detected in the bullfrog, mouse, wallaby and 
human (Cheung and Hearn, 2003; Grosse et al., 1997; Illing et al., 1993; Wang et al., 
2001b; Zhou and Sealfon, 1994).   Of the identified cGnRH-R splice variants, only 
that of the bullfrog and sheep (Illing et al., 1993; Wang et al., 2001b) have been 
confirmed by Northern blotting (Cheung and Hearn, 2003; Grosse et al., 1997; Zhou 
and Sealfon, 1994).  Experimentally, GnRH-R splice variants were shown to possess 
inhibitory effects on the signalling of full-length receptors in the human and bullfrog 
(Grosse et al., 1997; Pawson et al., 2005; Wang et al., 2001b) and have been 
suggested to interfere with the function of the full-length receptors (Grosse et al., 
1997; Pawson et al., 2005; Wang et al., 2001b) possibly through the formation of 
homo-dimers and hetero-dimers (Cheung and Hearn, 2005).  The effects of the 
cGnRH-R-III splice variants on the function of the full length type III cGnRH 
receptor are investigated in Chapter 4.   
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Unlike mammalian GnRH receptors, which are encoded by 3 exons (Kakar, 1997; 
Zhou and Sealfon, 1994), both avian cGnRH-R-I and cGnRH-R-III are encoded by 4 
exons (Fig. 3.8.A).  The presence of functionally important residues and micro-
domains in cGnRH-R-III were assessed.  cGnRH-R-III like cGnRH-R-I has aspartic 
acid residues in both loci of the helix2/helix7 micro-domain (Fig. 3.8.A), an 
arrangement unique to non-mammalian GnRH receptors (Flanagan et al., 1999; Zhou 
et al., 1994), like other GPCRs.  Conservation of important coupling motifs and 
residues, the arginine cage motif (Ballesteros et al., 1998) and alanine in ICL3 
(Myburgh et al., 1998) is maintained in cGnRH-R-III at amino acid positions 164 
and 286 respectively (Fig. 3.8.A).  The two cGnRH-Rs exhibit conservation of the 
aspartic acid (Flanagan et al., 2000) and asparagine (Davidson et al., 1996) ligand-
binding residues in TMD2 (Fig. 3.8.A).  The lysine in TMD3 of the cGnRH-R-I 
(Zhou et al., 1995) is substituted with an arginine residue in cGnRH-R-III (Fig. 
3.8.A).  This conservative change is believed to preserve agonist binding to the 
receptor (Zhou et al., 1995).  The glutamate residue in ECL3 at position 301 in the 
mouse which was shown to possess a role in receptor recognition of Arg8 in 
mammalian GnRH (Flanagan et al., 1994) is not conserved in cGnRH-R-III (Fig. 
3.8.A) whereas it is present in cGnRH-R-I (Sun et al., 2001b).  ECL3 of each 
receptor type has a distinctive sequence motif which has a key influence on receptor 
selectivity (Millar et al., 2004).  cGnRH-R-I has a PEY motif in ECL3 whereas in 
cGnRH-R-III this motif is PPS (Fig. 3.8.A).  The conservation of these motifs 
suggests that the two cGnRH-R receptor homologs may have similar ligand 
selectivity to endogenous cGnRH ligands.  This is investigated in Chapter 4 
 
The C-terminal cytoplasmic domain of GnRH-Rs has been shown to be involved in 
receptor mediated internalisation, receptor expression, phosphorylation and 
desensitization (Blomenrohr et al., 1999; Heding et al., 1998; Pawson et al., 1998b; 
Willars et al., 1999).  The C-terminal cytoplasmic tail domain of cGnRH-R-III is 
longer by an additional 8 residues compared to cGnRH-R-I (Fig. 3.8.A).  The effect 
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of the additional 8 residues on the rate of ligand induced receptor internalisation is 
investigated in Chapter 4.   
 
Three putative SH3 binding motifs were identified in the type III cGnRH receptor C-
terminal cytoplasmic tail domain which are not present in the type I cGnRH-R.  SH3 
binding proteins contain proline rich regions, with at least one PXXP motif (Cohen et 
al., 1995).  These motifs are located at amino acid positions 369-373, 370-375 and 
398-402 encoded by exon four of the cGnRH-R-III gene (Fig. 3.8.A).  The 
occurrence of SH3 binding motifs suggest the potential for differential coupling of 
cGnRH-R-III to the mitogen activated protein kinase (MAPK) cascade (Millar et al., 
2004), which is investigated in Chapter 5.  
 
As the information on GnRH systems is incomplete in avian and reptilian species 
(Morgan and Millar, 2004), this thesis provides a new insight into the interplay 
between GnRH ligands and their receptors in the control of reproduction at a 
particular branch in the evolutionary tree.  To date, there have been no other studies 
on GnRH receptors in avian species other than the chicken (Joseph et al., 2009; 
Shimizu and Bedecarrats, 2006; Sun et al., 2001a; Sun et al., 2001b).  With the recent 
release of the Zebrafinch genome (Ensembl Genome Browser, June 2009) however, 
it has been possible to search for homologous regions of the genetic loci expected to 
contain GnRH receptor subtypes.  Although the current release of the genome is not 
complete, a putative type III zebrafinch GnRH receptor gene resides on chromosome 
10, at location 463841-465318 and a putative type I Zebrafinch GnRH receptor 
resides on chromosome 10, at location 18405095-18405990.  Comparisons of the 
sequence identity of chicken and zebrafinch GnRH receptors will be of particular 
interest for future investigations.  
 
Based on the species-specific variation in GnRH receptor subtype predominantly 
expressed in the anterior pituitary observed in the bullfrog (Wang et al., 2001a), 
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African clawed frog (Troskie et al., 2000), leopard gecko (Ikemoto and Park, 2007) 
and here in the chicken (Fig. 3.8B) (Joseph et al., 2009) it is evident that there is 
likely to be plasticity in pituitary utilisation of GnRH receptor subtypes for 
functional regulation of gonadotrophin production and secretion.  There is also 
plasticity in the recruitment of GnRH isoforms for tissue regulation, as seen in the 
goldfish, where GnRH-II is a regulator of pituitary function (Yu et al., 1998).  This 
plasticity of ligand and receptor recruitment during evolution provides a new 
perspective on our understanding the interplay between GnRH ligands and their 
receptors in the control of reproduction.  Delineation of ‘cognate’ ligand/receptor 
pairing requires the assessment of receptor protein expression in the target cell 
and assessment of ligand isoform delivery to that cell.  In the chicken there is 
good evidence that cGnRH-I targets the gonadotroph (Mikami et al., 1988a; Sharp et 
al., 1990; Vangils et al., 1993).  In view of the ~1400 fold higher levels of cGnRH-R-
III mRNA in the pituitary (Fig. 3.3.A) and its changes in relation to sexual maturity 
(Fig. 3.3.D) the cognate pituitary receptor for cGnRH-I and the mediator of 
gonadotroph regulation is likely to be cGnRH-R-III.   
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3.6. Connective Statement 
Expression of cGnRH-R-III mRNA was ~1400 fold higher than cGnRH-R-I mRNA 
in the anterior pituitary gland suggesting that cGnRH-R-III is the predominant 
regulator of gonadotrophin synthesis and secretion in chickens.  However, the 
capacity of cGnRH-R-III to bind the different cGnRH ligands is unknown.  
Measurement of the ligand selectivity of the cGnRH-R-III subtype for the 
endogenous ligands, cGnRH-I and GnRH-II, may help to elucidate the physiological 
significance of the receptor subtypes.  Furthermore, the development of GnRH 
analogs that differentially promote or inhibit activation of either receptor subtype 
may be valuable tools for deciphering the role of receptor subtypes in terms of 
effects on gonadotrophin production or other neuroendocrine functions.  Therefore in 
Chapter 4, using cGnRH-R-I and cGnRH-R-III cDNA expression constructs 
transiently transfected into COS-7 cells, the pharmacological profiling of cGnRH-R-
III in terms of ligand selectivity and activation of inositol phosphate production is 
described in comparison with the pharmacological profile of cGnRH-R-I.   
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The expression of two GnRH receptor subtypes, cGnRH-R-I and the more 
recently discovered cGnRH-R-III, in the chicken coincides with the presence of 
two chicken GnRH ligands, cGnRH-I and GnRH-II.  Expression of cGnRH-R-
III mRNA was ~1400 fold higher than cGnRH-R-I mRNA in the anterior 
pituitary gland, suggesting that cGnRH-R-III is the predominant regulator of 
chicken gonadotrophin synthesis and secretion (Chapter 3).  However, the 
ability of cGnRH-R-III to bind the endogenous ligands was uncharacterised.  
Determination of ligand-binding selectivity and the extent of activation of the 
cGnRH-R-III subtype to the endogenous ligands, cGnRH-I and GnRH-II, may 
help to elucidate the physiological roles of the receptor subtypes.  Additionally, 
the development of GnRH analogs that differentially promote or inhibit 
activation the of receptor subtypes will be valuable tools for determining the 
role of receptor subtypes in the regulation of gonadotrophin production or in 
other functions in the central nervous system or peripheral tissues.  To 
investigate this, pharmacological profiling of cGnRH-R-III in terms of ligand-
binding selectivity and inositol phosphate production in response to ligand-
receptor activation was investigated in comparison with the pharmacological 
profile of cGnRH-R-I.  Functional studies in transfected COS-7 cells indicated 
that cGnRH-R-III has a higher ligand-binding affinity for GnRH-II than 
cGnRH-I (IC50: 0.57 v 19.8 nM) with more potent stimulation of inositol 
phosphate production (EC50: 0.8 v 4.38 nM).  Similar results were found for 
cGnRH-R-I, (IC50: 0.51 v 10.8 nM) and (EC50: 0.7 v 2.8 nM).  Effects of GnRH 
antagonists were compared at the two receptors.  Mammalian antagonist 27 
distinguished between cGnRH-R-I and cGnRH-R-III (IC50: 2.3 v 351 nM), and 
application of this synthetic peptide may allow delineation of receptor subtype 
function in-vitro and in-vivo.  In addition, the initial rate of receptor 
internalisation was faster for cGnRH-R-III than cGnRH-R-I (26%.min-1 v 
15.8%.min-1).  Also, although cGnRH-R-III splice variants do not bind GnRH 
ligands independently, cGnRH-R-III_SV2 significantly decreased maximal 
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ligand-binding of cGnRH-R-III by approximately 30%, suggesting that it may 
impair the expression of the full-length type III cGnRH receptor.  The research 
presented in Chapter 4, demonstrates that cGnRH-R-III, like cGnRH-R-I, has a 
higher ligand-binding selectivity and induction of inositol phosphate 
accumulation with GnRH-II than with cGnRH-I, although cGnRH-I is the 
physiological regulator of gonadotroph function.  These results suggest that 
evolutionary recruitment of ligand-receptor pairing for particular physiological 
processes does not correlate with properties such as highest ligand-binding 
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4.2.  Introduction 
4.2.1. Ligand selectivity and G protein coupling of cGnRH-Rs to 
endogenous ligands 
Two GnRH isoforms, cGnRH-I and GnRH-II are present in the chicken (Sharp and 
Ciccone, 2005).  cGnRH-I differs from mammalian GnRH-I (mGnRH-I) by the 
substitution of an arginine (Arg) by a glutamine (Gln) residue in position 8 of the 
decapeptide, while the structure of  GnRH-II (His5-Trp7-Tyr8-GnRH) is conserved 
in all jawed vertebrate classes (Miyamoto et al., 1984).  It is firmly established that 
GnRH-II (relative to GnRH-I) has the highest ligand-binding affinity for all non-
mammalian vertebrate receptors irrespective of receptor classification based on 
structural similarities (Pfleger et al., 2002).  The promiscuity of receptor subtype 
activation in-vitro by different endogenous GnRH ligand isoforms, as seen in teleost 
fish (Illing et al., 1999; Moncaut et al., 2005), amphibians (Troskie et al., 2000; 
Wang et al., 2001a) and reptilian (Ikemoto and Park, 2007) species, suggests that a 
complex interplay between ligands and receptors may occur in-vivo.  Hence, the 
occurrence of two GnRH ligands and two GnRH receptors expressed in the chicken, 
cGnRH-R-I (Sun et al., 2001a; Sun et al., 2001b) and cGnRH-R-III (Chapter 3-Fig. 
3.1, 3.2, 3,3, 3.6.) (Joseph et al., 2009; Shimizu and Bedecarrats, 2006), poses 
questions concerning the interactions of the two ligands at either receptor subtype.  
The presence of functionally important residues and micro-domains in cGnRH-R-III 
were assessed and compared with those in cGnRH-R-I and other GnRH receptors 
expressed in vertebrate species (Chapter 3-3.3.7, Fig. 3.8).  It was established in 
Chapter 3 that; (A) cGnRH-R-III like cGnRH-R-I has aspartic acid residues in both 
loci of the helix2/helix7 micro-domain, which regulates GPCR coupling and 
expression (Flanagan et al., 1999; Zhou et al., 1994).  (B) Conservation of other 
important coupling motifs and residues such as the arginine cage motif 
(DRXXX(I/V)) which resides at the cystolic end of TMD3 (Ballesteros et al., 1998) 
and alanine in ICL3 (Myburgh et al., 1998), are maintained in cGnRH-R-III  like 
cGnRH-R-I.  (C) The two cGnRH-Rs exhibit conservation of the aspartic acid 
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(Flanagan et al., 2000) and asparagine (Davidson et al., 1996) ligand-binding 
residues in TMD2.  (D) The lysine in TMD3 of the cGnRH-R-III (Zhou et al., 1995)  
is conservatively substituted with an arginine residue and this is believed to preserve 
agonist binding to the receptor (Zhou et al., 1995) (Fig. 3.8A).  The conservation of 
these motifs suggests that the two cGnRH-R receptor isoforms may have similar 
pharmacological profiles in response to endogenous ligands.   
Interestingly, ECL3 of each receptor type has a distinctive motif and this has a key 
influence on ligand-receptor selectivity (Millar et al., 2004).  Mammalian type I 
receptors possess S-E/D-P motifs whereas non-mammalian type I receptors have P-
X-S/Y motifs (Millar et al., 2004; Wang et al., 2004).  A mutagenesis study has 
shown that the residues surrounding the glutamic acid residue (E) are important for 
differential ligand-binding selectivity (mGnRH-I v GnRH-II) between mammalian 
and non-mammalian GnRH receptors (Wang et al., 2004).    cGnRH-R-I has a PEY 
motif in ECL3 whereas in cGnRH-R-III this motif is PPS.  The presence of these 
motifs suggests that the two cGnRH-R receptor homologs may function similarly in 
response to endogenous chicken GnRH ligand stimulation with a preference for 
GnRH-II (although cGnRH-I differs from mGnRH).   
 
Previous pharmacological studies in COS-7 cells expressing chicken GnRH receptors 
showed that cGnRH-R-I has a higher ligand-binding affinity for GnRH-II (Ki = 
0.6nM) than cGnRH-I (Ki = 5.3nM) and GnRH-II is more potent in stimulating 
inositol phosphate accumulation (ED50 = 0.04nM) than cGnRH-I (ED50 = 2.7 nM) 
(Sun et al., 2001b).  Earlier studies on cultured pituitary cells showed that GnRH-II is 
more potent than cGnRH-I (ED50 = 0.055 v 0.28 nM) in stimulating LH release and 
in stimulating FSH release from dispersed chicken pituitary cells (ED50 = 0.034  v 
0.37 nM)  (Millar et al., 1986).  This was confirmed in later studies on cultured 
pituitary cells with GnRH-II exhibiting an ED50 of 0.35nM compared to an ED50 of 
1.8nM for cGnRH-I in LH releasing activity (Millar et al., 1989).  In-vivo injection 
studies showed that LH secretion in response to GnRH-II is markedly greater than to 
cGnRH-I in mature laying hens, however, this is not the case in juvenile chickens of 
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either sex, nor the mature male (Sharp et al., 1987).  There is conflicting evidence for 
an effect of cGnRH-I or GnRH-II on FSH release in-vitro, (Hattori et al., 1986a; 
Millar et al., 1986) and in-vivo (Bruggeman et al., 1998; Dunn et al., 2003; Krishnan 
et al., 1993; Proudman et al., 2006).  Probably as derived from other species, cGnRH 
may stimulate FSH biosynthesis, although there is no evidence of FSH release on 
cGnRH-I stimulation, while a role for GnRH-II in FSH production has not been 
established (Dunn et al., 2003; Sharp and Ciccone, 2005). 
 
Research into second messenger systems involved in the control of LH secretion in 
the avian pituitary is relatively scant when compared to other species.  Early studies 
suggested a role of cAMP in the release of LH (Bonney and Cunningham, 1977b).  
Later studies showed the requirement for PKC and calcium mobilisation (Davidson 
et al., 1987a; Davidson et al., 1987b), which confirmed other studies establishing the 
requirement for elevated intracellular Ca2+ (Bonney and Cunningham, 1977a; Luck 
and Scanes, 1980).  More recent research however has provided clear evidence for 
cAMP, PKC activation and the requirement for Ca2+ in regulation of cGnRH-I 
induced LH secretion from chicken pituitary gonadotrophs (Johnson and Tilly, 1991) 
confirming earlier reports.  However, this data also demonstrates the complexity of 
signal transduction mechanisms regulating LH secretion, in that intracellular calcium 
is sufficient, cAMP is not a prerequisite for and additional signalling molecules 
mediate the effects of PKC activation on cGnRH-I induced LH secretion.  Thus 
multiple signalling mechanisms exist to control the LH secretion from avian pituitary 
gonadotrophs (Johnson and Tilly, 1991).  
 
It was anticipated that identifying the ligand selectivity and potency of cGnRH-R-III 
activation in response to endogenous ligands, cGnRH-I and GnRH-II, may elucidate 
the physiological roles of the receptor subtypes, given that in-vitro studies could be 
performed with dispersed pituitary cells expressing both cGnRH-R-I and cGnRH-R-
III.  Interaction between cGnRH-I and GnRH-II and the release of LH is sexually 
differentiated in the domestic chicken (Sharp et al., 1987).  Elucidating the ligand 
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selectivity and the potency of cGnRH-I and GnRH-II at individual chicken GnRH 
receptor homologs would increase understanding of the functional significance of 
cGnRH-R-I and cGnRH-R-III in terms of sex-specific responses to the endogenous 
ligands.  Alternatively it could be hypothesised that since cGnRH-R-III is 
predominantly expressed in the pituitary (Chapter 3) it may be more functionally 
“selective” for cGnRH-I, since this appears to be the GnRH isoform released from 
the hypothalamus to the pituitary.   
 
In addition to quantifying cGnRH receptor subtype mRNA abundance and ligand-
binding selectivity, determining receptor signalling (e.g. in terms of G protein 
coupling or receptor protein-protein complex formation) is important for elucidating 
the functional capacity of each GnRH receptor subtype.  GnRH receptors 
preferentially couple to Gαq protein in pituitary gonadotrophs (Grosse et al., 2000; 
Hsieh and Martin, 1992; Naor et al., 1986), but evidence shows that GnRH receptors 
can also couple to Gαi and Gαs proteins (Hawes et al., 1993; Liu et al., 2002; 
Stanislaus et al., 1998).  It is important however to take into account the cell system 
in which the coupling of the G protein is being studied, as variations in G protein 
complement suggest that coupling of GnRH receptors is “cell-context dependent” 
(Dobkin-Bekman et al., 2006; Naor, 2009; Ruf et al., 2003).  In this chapter the 
ligand induced potency of Gαq coupling of cGnRH-R-III was assessed by measuring 
the production of inositol phosphates in transfected COS-7 cells in comparison with 
cGnRH-R-I. 
 
4.2.2. Activity of GnRH analogs  
Mammalian GnRH receptor antagonists 27, 135-18 and 135-25 have been previously 
shown to have decreased affinities for cGnRH-R-I compared to the human GnRH 
receptor (Sun et al., 2001b).  The binding affinities of the GnRH analogs, 27, 135-18 
and 135-25 at cGnRH-R-I were 61nM, 703nM and 4900nM, respectively (Sun et al., 
2001b).  In cells expressing cGnRH-R-I, the GnRH analog 135-18 acted as a high 
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potency full agonist (ED50 = 33nM), whereas GnRH analog 135-25 was a weak 
partial agonist (ED50 = 1300nM) and GnRH analog 27 showed antagonistic 
properties (IC50 = 177nM) (Sun et al., 2001b).  This confirmed previous studies 
performed with cultured chicken pituitary cells measuring the ability of GnRH 
analogs to inhibit the GnRH induced LH release (Jacobs et al., 1995).  In these 
studies GnRH analog 27 acted as a pure antagonist, and had an IC50 of 137nM, 
whereas GnRH analog 135-18 acted as a pure agonist (Jacobs et al., 1995).  
Considering the 53% amino acid sequence identity of the two chicken GnRH 
receptor subtypes (Chapter 3-Fig. 3.8) and taking into consideration the expression 
of both chicken GnRH receptors in the pituitary (Chapter 3-Fig 3.3), it was 
hypothesised that identifying a GnRH analog that differentially binds and activates 
one of the chicken GnRH receptor homologs may be valuable.  This would facilitate 
in-vivo and in-vitro studies to allow delineation of the role of each cGnRH-R subtype 
in terms of gonadotrophin synthesis and release.   
 
4.2.3. cGnRH-R-III splice variants  
In addition to full-length GnRH receptors, several splice variant (SV) mRNAs of 
GnRH receptors have been identified in the bullfrog, mouse, sheep, wallaby and 
human (Cheung and Hearn, 2003; Cheung and Hearn, 2005; Grosse et al., 1997; 
Illing et al., 1993; Wang et al., 2001b; Zhou and Sealfon, 1994).  Although their 
physiological significance is unclear, it has been suggested that the proteins they 
encode may interfere with full-length receptor function.  In experimental systems, 
expression of human and bullfrog GnRH-R SVs elicits inhibitory effects on the 
signalling of full-length receptors (Grosse et al., 1997; Pawson et al., 2005; Wang et 
al., 2001b).  Cellular trafficking of truncated receptors varies, as seen in studies 
performed with the bullfrog and the human GnRH-R SV constructs (Pawson et al., 
2005; Wang et al., 2001b).  Carboxyl-terminal GFP-tagged bullfrog GnRH-R SVs 
are either localised exclusively in the intracellular compartment, or alternatively in 
both the intracellular compartment and at the cell surface in HeLa cells depending on 
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the type of SVs (Wang et al., 2001b).  A human GnRH-R-SV could not be detected 
in COS-7 cell membranes (Pawson et al., 2005) although, non-functional natural 
mutants of the human GnRH-R were shown to promote retention of the native 
receptor in the endoplasmic reticulum, thus reducing ligand-binding ability and 
inositol phosphate accumulation (Brothers et al., 2004).  The inability of receptors to 
be properly trafficked to the cell surface is often the result of protein misfolding and 
misrouting (e.g. to lysosome), as demonstrated by several studies (Brothers et al., 
2004; Janovick et al., 2002; Leanos-Miranda et al., 2002).  This may be due to 
hetero-oligomerization between the wild type and mutant proteins (Brothers et al., 
2004).   
 
A PCR based study has shown that there is expression of two cGnRH-R-III SVs in 
the chicken, a pituitary-specific transcript (1065bp SV) (cGnRH-R-III_SV2), in 
addition to another 501bp SV that is expressed in different brain regions (cGnRH-R-
III_SV1) (Shimizu and Bedecarrats, 2006).  cGnRH-R-III_SV1 mRNA lacks exon II 
and III, resulting in a predicted 253 amino acid deletion from part of the N-terminal 
to part of intracellular loop 3. cGnRH-R-III_SV2 mRNA lacks part of exon II, 
resulting in a predicted 65-amino acid deletion from part of the extracellular domain 
to part of transmembrane domain 1.  Both SVs are unable to signal independently 
through Gαq (Shimizu and Bedecarrats, 2006),  and their RNA expression is not 
detectable by Northern blot analysis (Chapter 3-Fig. 3.2) (Joseph et al., 2009), 
suggesting that their expression may be of little functional significance.  Only the 
bullfrog and sheep GnRH receptor SVs (Illing et al., 1993; Wang et al., 2001b) have 
been detected by Northern blot analysis, whereas other GnRH-R SV s have been 
detected by PCR amplification and subsequent sequencing (Cheung and Hearn, 
2003; Grosse et al., 1997; Zhou and Sealfon, 1994).  However, studies on the 
bullfrog, mouse and human GnRH-R (Grosse et al., 1997; Pawson et al., 2005; Wang 
et al., 2001b) show that the SVs (Shimizu and Bedecarrats, 2006) might alter 
function of the full-length cGnRH-R-III although their endogenous expression has 
not been confirmed by Northern blot analysis (Chapter 3-Fig. 3.2).  Thus, in this 
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chapter, the ability of the cGnRH-R-III SVs to bind to cGnRH ligands and their 
effects on full-length receptor expression were evaluated.  These studies were 
performed alongside studies in a collaborator’s laboratory (Prof. Gregoy 
Bedecarrates, University of Guelph, Canada), where evaluation of the ability of the 
SVs to be translated into functional proteins and influence second messenger 
signalling of the full-length receptor were determined. 
 
4.2.4. Ligand induced internalisation of cGnRH-Rs 
The C-terminal tail of GnRH-Rs has been shown to be involved in receptor mediated 
internalisation and desensitisation (Blomenrohr et al., 1999; Heding et al., 1998; 
Pawson et al., 1998a; Willars et al., 1999).  Receptor desensitisation is caused by 
sustained stimulation of the receptor and can be a consequence of receptor 
phosphorylation (McArdle et al., 2002).  Phosphorylation can stabilise ß-arrestin 
association with GPCRs resulting in the inhibition of G protein binding and 
subsequent uncoupling from effector proteins (McArdle et al., 1999; McArdle et al., 
2002).  The phosphorylation of amino acids in the C-terminal-tail facilitates ß-
arrestin association with the GnRH-Rs (McArdle et al., 2002),  although other 
residues may facilitate ß-arrestin binding  (Ferguson, 2001).  Chicken gonadotroph 
cells were stimulated with antagonists and no effects on desensitization were 
observed, whereas cGnRH-I desensitized gonadotroph response measured by LH 
release at a more rapid rate than determined in mammalian cells.  This 
desensitisation was shown to be dependent on intracellular calcium stores (King et 
al., 1986).  The rate of internalisation of radioligand [His5-D-Tyr6]-GnRH-I is 
11.3%.min-1 at the chicken type I cGnRH receptor in COS-1 cells, which is much 
more rapid than at the human GnRH-R (0.71%) (Pawson et al., 1998a).  This 
internalisation was demonstrated to be through a caveolae-like, dynamin dependent 
mechanism and cysteine328 and the threonine369threonine370 doublet are crucial for 
rapid internalisation (Pawson et al., 2003).  The region crucial for receptor 
internalisation of cGnRH-R-I is distal to or including Ser337 (Pawson et al., 1998a).  
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The highly conserved arginine residue in the cystolic region of TM3 and the highly 
conserved tyrosine residue of the N/DPXXY motif in TM7 have all been shown to be 
important for GnRH-R internalisation in the mouse (Arora et al., 1996; Arora et al., 
1997).  Interestingly mammalian GnRH-Rs lack a cytoplasmic C-terminal domain 
and internalise more slowly than non-mammalian GnRH-Rs (Millar et al., 2004).  
The possibility that cGnRH-R-III may differ from cGnRH-R-I in the rate of ligand-
induced internalisation was considered because 8 additional residues occur in the 
cytoplasmic C-terminal tail of cGnRH-R-III (Chapter 3-Fig. 3.8A), a domain which 
predisposes GnRH-Rs to rapid rates of internalisation (Pawson et al., 1998a).  
Therefore the ligand-induced internalisation of cGnRH-R-III was investigated in this 
chapter.  
 
4.2.5. Summary  
The aims of this study were to compare and further characterise the pharmacological 
properties of the chicken type III cGnRH receptor with the type I cGnRH receptor.  
This included analysis of ligand-binding and potency of inositol phosphate 
production in response to cGnRH-I and GnRH-II and a small panel of GnRH analogs 
in an attempt to identify a GnRH analog that may be applied to examine the 
differential effects of receptor subtypes on gonadotrophin synthesis and release.  The 
effect of the cGnRH-R-III splice variants on cGnRH-R-III receptor binding was also 
examined.  Additionally, the ligand induced internalisation of both receptors was 
compared.   
 
4.3. Methods 
The methodologies used to generate the results presented in this chapter are 
described in chapter 2 (2.15-2.20.).  The primary structures of the synthetic peptide 
GnRH analogs used in all experiments presented in this chapter are described in 
Table 4.1. 




Primary structure of GnRH analogs.   
Table 4. 1 
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The IC50 values derived in these experiments are the concentration of the competing 
ligand required to displace 50% of the specific radioligand binding.  In all results 
presented in this chapter, IC50 values derived from competitive binding assays are 
used as a measure of relative binding affinity of each ligand to make a comparison 
comparison between the two receptors ( cGnRH-R-I and cGnRH-R-III).    
4.4.1. cGnRH-R-III, like cGnRH-R-I, has a higher ligand-binding affinity 
for GnRH-II than for cGnRH-I. 
COS-7 cells transiently transfected with cGnRH-R-III and cGnRH-R-I expression 
constructs, bound cGnRH-I and GnRH-II (Table 4.2) and showed displacement of 
125I-[His5-D-Tyr6]-GnRH-I with both cGnRH-I and GnRH-II in a concentration 
dependent fashion.  The binding affinities for cGnRH-I and GnRH-II were similar at 
cGnRH-R-I and cGnRH-R-III (Fig 4.1).  GnRH-II has a higher binding affinity (35-
fold) for cGnRH-R-III than cGnRH-I (IC50:0.57 vs 19.8 nM) (Table 4.2).  The ligand 
selectivity was similar with cGnRH-R-I, where a higher binding affinity for cGnRH-
II (35-fold) than cGnRH-I was observed (IC50: 0.51 vs 10.8 nM) (Table 4.2).  These 
finding are similar to previous reports (Sun et al., 2001b).  cGnRH-R-I showed a 1.8-
fold higher ligand-selectivity for cGnRH-I compared to cGnRH-R-III, whereas the 
ligand-selectivity for GnRH-II at the two receptors was similar.   
 
4.4.2. GnRH-II elicits inositol phosphate accumulation at cGnRH-R-III 
and cGnRH-R-I more potently than cGnRH-I. 
cGnRH-I and GnRH-II stimulated inositol phosphate production in cGnRH-R-I and 
cGnRH-R-III transfected COS-7 cells (Fig 4.2).  GnRH-II was more potent in 
stimulation of inositol phosphate production at cGnRH-R-III than cGnRH-I (EC50: 
0.8 vs 4.38 nM).  Similar results were found for cGnRH-R-I, where GnRH-II was 
more potent in stimulating inositol phosphate production than cGnRH-I (EC50 0.7 vs 
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2.8 nM).  The potency of GnRH-II at both receptors was much higher than for 
cGnRH-I, in accordance with their relative binding affinities.  In cGnRH-R-III 
transfected cells, the potency of GnRH-II stimulation was 6-fold higher than with 
cGnRH-I (Table 4.2).  GnRH-II was 4-fold more potent than cGnRH-I for 
production of inositol phosphate via activation of cGnRH-R-I (Table 4.2).   
 
4.4.3. Binding affinity of sGnRH-III and GnRH analogs-135-18, 135-25 
and 27 at cGnRH-R-I and cGnRH-R-III. 
sGnRH-III bound cGnRH-R-III and cGnRH-R-I with similar affinities (IC50: 9.31 
and 8.40 nM, respectively) (Table 4.2).  Because there was no genomic evidence for 
a GnRH-III isoform in the chicken, the binding affinity of sGnRH-III was tested as 
an alternative.  GnRH-II exhibited a 16-fold higher affinity than sGnRH-III at 
cGnRH-R-III and cGnRH-R-I, and sGnRH-III exhibited a higher affinity than 
cGnRH-I at both receptors (Table 4.2).  Mammalian antagonists 27, 135-18 and 135-
25 bound cGnRH-R-III and cGnRH-R-I (Table 4.2).  Similar binding affinities were 
observed for all GnRH analogs and mammalian antagonists at either receptor except 
for mammalian antagonist 27.  Mammalian antagonist 135-18 and 135-25 showed 
respectively a 3.5- and 0.6-fold higher binding affinity at cGnRH-R-I compared to 
cGnRH-R-III.  Remarkably, mammalian antagonist 27 had a much higher affinity for 
cGnRH-R-I (IC50: 0.38nM) than cGnRH-R-III (IC50: 21.4nM).  
 
4.4.4. Stimulation of inositol phosphate accumulation in cGnRH-R-I and 
cGnRH-R-III expressing COS-7 cells by mammalian antagonists 
Mammalian antagonist 27 displayed inverse agonist properties at both receptors at 
10µM concentration, decreasing inositol phosphate production below basal levels 
(Table 4.2), (Fig 4.2A, C).  However, at concentrations <10µM this ligand displayed 
agonistic activity at both recepeptors (Fig 4.2A, C).  Mammalian antagonist 135-25 
induced only weak stimulation of inositol phosphate production in transfected COS-7 
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cells: cGnRH-R-I (EC50: 5970nM) and cGnRH-R-III (EC50: 4860nM) (Table 4.2), 
(Fig 4.3A, C).  Mammalian antagonist 135-18 also induced a weak stimulation of 
inositol phosphate production in transfected COS-7 cells; cGnRH-R-III (EC50: 
1510nM), but no stimulation of inositol phosphate was detected in cGnRH-R-I 
transfected cells (Fig 4.4A, C).   
 
4.4.5. Inhibition of inositol phosphate accumulation in cGnRH-R-I and 
cGnRH-R-III expressing COS-7 cells by mammalian antagonists 
GnRH-II was used as an agonist to test antagonistic activity of mammalian 
antogonists, as this would facilitate comparisons with previous publications where 
cGnRH-R-I was researched (Sun et al., 2001b).  Mammalian antagonist 135-18 was 
able to antagonise stimulation of inositol phosphate production by 1nM GnRH-II.  
This effect was most potent in cells transfected with cGnRH-R-I (IC50: 2330 nM) 
than those transfected with cGnRH-R-III (IC50: 3890 nM) (Fig 4.4B, D).  
Mammalian antagonist 135-25 acted as an agonist in cGnRH-R-III transfected cells 
in the presence of 1nM GnRH-II, with its potency of inositol phosphate stimulation 
increasing from EC50: 4860nM in the absence of GnRH-II to EC50: 20.1nM in the 
presence of GnRH-II (Fig 4.3D).  Antagonistic properties for mammalian antagonist 
135-25 were observed at cGnRH-R-I transfected cells as this compound decreased 
the inositol phosphate stimulation seen with 1nM GnRH-II, but with weak effect 
(IC50: 245 nM) (Fig 4.3B).  Surprisingly, mammalian antagonist 27 exhibited large 
differences in antagonistic potency at cGnRH-R-I (IC50: 2.3 nM) compared to 
cGnRH-R-III (IC50: 351nM) (Fig 4.2B, D). 
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Figure 4. 1 
 
Figure 4.1: (A) Ligand binding of cGnRH-R-I and cGnRH-R-III.  Competitive 
displacement of 125I-[His5-D-Tyr6]-GnRH with serial dilutions (10-11M to 10-6M) of cGnRH-I 
(solid squares ■) and (10-11M to 10-6M) GnRH-II (open squares □) in COS-7 cells transiently 
transfected with cGnRH-R-I (dashed lines) and cGnRH-R-III (solid lines) expression 
constructs. The data presented is from four independent experiments each performed in 
triplicate.  Non-specific binding, determined in un-transfected cells was subtracted from 
cpm.  (B) Inositol phosphate production in response to (10-11M to 10-6M) cGnRH-I (solid 
squares ■) and GnRH-II (open squares □) in COS-7 cells transiently transfected with 
cGnRH-R-I (dashed lines) and cGnRH-R-III (solid lines) expression constructs.  The data is 
from four independent experiments performed in triplicate.   
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Figure 4. 2 
 
Fig. 4.2. Inositol phosphate production in response to (10-10M to 10-5M) mammalian 
antagonist 27 (A, C) in COS-7 cells transiently transfected with cGnRH-R-I (filled squares 
■ (A)) and cGnRH-R-III (open squares □ (C)).  The ability to inhibit inositol phosphate 
formation by mammalian antagonist 27 (B, D) in the presence of 1nM GnRH-II stimulation 
was measured in COS-7 transiently transfected with cGnRH-R-I (filled circles ● (B)) and 
cGnRH-R-III (open circles ○ (D)). Inositol phosphate production in response to 10-8M 
GnRH-II stimulation (asterisks *).  Non-stimulated basal inositol phosphate accumulation 
(♦).  The data are the mean +/-SEM of three independent experiments performed in 
triplicate.  
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Figure 4. 3 
 
Fig. 4.3. Inositol phosphate production in response to (10-10M to 10-5M) mammalian 
antagonist 135-25 (A, C) in COS-7 cells transiently transfected with cGnRH-R-I (filled 
squares ■ (A)) and cGnRH-R-III (open squares □ (C)).  The ability to inhibit inositol 
phosphate formation by mammalian antagonist 135-25 (B, D) in the presence of 1nM 
GnRH-II stimulation was measured in COS-7 transiently transfected with cGnRH-R-I (filled 
circles ● (B)) and cGnRH-R-III (open circles ○ (D)). Inositol phosphate production in 
response to 10-8M GnRH-II stimulation (asterisks *).  Non-stimulated basal inositol 
phosphate accumulation (♦).  The data are the mean +/-SEM of three independent 








Figure 4. 4 
 
Fig. 4.4. Inositol phosphate production in response to (10-10M to 10-5M) mammalian 
antagonist 135-18 (A, C) in COS-7 cells transiently transfected with cGnRH-R-I (filled 
squares ■ (A)) and cGnRH-R-III (open squares □ (C)).  The ability to inhibit inositol 
phosphate formation by mammalian antagonist 135-18 (B, D) in the presence of 1nM 
GnRH-II stimulation was measured in COS-7 transiently transfected with cGnRH-R-I (filled 
circles ● (B)) and cGnRH-R-III (open circles ○ (D)). Inositol phosphate production in 
response to 10-8M GnRH-II stimulation (asterisks *).  Non-stimulated basal inositol 
phosphate accumulation (♦).  The data are the mean +/-SEM of three independent 
experiments performed in triplicate.  
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Table 4. 2 
Receptor binding and peptide-stimulated inositol phosphate accumulation in response to GnRH analogs in COS-7 cells expressing cGnRH-I 
and cGnRH-R-III 
 Ligand binding IP Production 
Analog cGnRH-R-I cGnRH-R-III cGnRH-R-I cGnRH-R-III 
 IC50 (nM)a EC50 (nM)b IC50 (nM)c EC50 (nM)b IC50 (nM)c 
cGnRH-I 10.8 ± 1.59 d 19.8  ± 3.56 d 2.8 ± 0.20 d  4.38 ± 0.18 d  
GnRH-II 0.51 ± 0.07 d 0.57 ± 0.15 d 0.7 ± 0.14 d  0.8 ± 0.14 d  
sGnRH-III 8.40 ± 1.21 e 9.31 ± 4.31 e 10.3 ± 4.5 d  21 ± 0.2 d*  
27 0.38 ± 0.09 e 21.4 ± 4.86 e Inverse agonist e 2.3 ± 0.3 e Inverse agonist e 351 ± 114 e 
135-18 2090 ± 156 e 7260 ± 105 e None d 2330 ± 134 d 1510 ± 216 d 3890 ± 2027 d 
4860 ± 807 d 245 ± 207 d 5970 ± 2510 d 8560 ± 3402 e 135-25 14200 ± 1515 e *None d 
a IC50 values (relative binding affinities) for GnRH analogs 
b EC50 values for agonist activity of GnRH analogs 
c IC50 values for antagonism of IP production stimulated by 1nM GnRH-II 
d Data are mean ± SE of three to four experiments 
e Data are mean ± SE of two to three experiments 
All experiments were performed on up to four separate occasions in triplicate 
*20.1 ± 8.9 = agonistic effect of peptide in presence of 1nM GnRH-II 
C
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4.4.6. cGnRH-R-III_SV2 significantly affects cell surface expression of 
cGnRH-R-III when co-expressed with cGnRH-R-III. 
Co-transfections were performed as described in the methods section (2.16) and were 
controlled for to ensure that co-transfection with splice variant constructs (cGnRH-
R-III_SV1 and cGnRH-R-III_SV2) did not result in reduced transcription of the full-
length construct (cGnRH-R-III).  A titration of varying quantities of full-length 
cGnRH-R-III cDNA (3µg-10µg) were transfected and the maximal binding of 125I-
[His5-D-Tyr6]-GnRH-I was determined.  There were no differences in the maximal 
binding of 125I-[His5-D-Tyr6]-GnRH-I to cGnRH-R-III in cells transfected with 3µg 
of cDNA versus those transfected with 10µg of cDNA (data not shown).  In all 
cases the total amount of transfected cDNA was standardised to 10µg with the 
addition of empty pcDNA3.1.  Independently transfected cGnRH-R-III SVs in COS-
7 cells, displayed no binding to 125I-[His5-D-Tyr6]-GnRH-I (Fig. 4.5A, B).  A 
significant reduction (p<0.01) in the maximum binding of 125I-[His5-D-Tyr6]-GnRH-
I to the full-length cGnRH-R-III was observed when co-transfected with the cGnRH-
R-III_SV2 (Table 4.3).  A small, but significant increase in the maximum binding of 
125I-[His5-D-Tyr6]-GnRH-I was observed when cGnRH-R-III_SV1 was co-
transfected with cGnRH-R-III (Table 4.3).  Cells transfected with cGnRH-R-III 
alone or in combination with cGnRH-R-III_SV1 or cGnRH-R-III_SV2 bound 
cGnRH-I and GnRH-II (Table 4.3) and showed displacement of 125I-[His5-D-Tyr6]-
GnRH-I with both cGnRH-I and GnRH-II in a concentration dependent fashion and 
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Table 4. 3 
Maximum binding and IC50 values calculated from competitive binding assay 











cGnRH-R-III 7.90 ± 0.02 
(12.59nM) 
100.0 ± 2.9a 
cGnRH-R-III_SV1 No binding No binding 
cGnRH-R-III_SV2 No binding No binding 
cGnRH-R-III + 
cGnRH-R-III_SV1 
7.70 ± 0.03 
(19.95nM) 




7.90 ± 0.05 
(12.59nM) 
70.2 ± 2.2b 
cGnRH-R-III 9.10 ± 0.01 
(0.79nM) 
100.0 ±2.3a 
cGnRH-R-III_SV1 No binding No binding 
cGnRH-R-III_SV2 No binding No binding 
cGnRH-R-III + 
cGnRH-R-III_SV1 
9.10 ± 0.01 
(0.79nM) 




9.30 ± 0.02 
(0.50nM) 
66.6 ± 0.9c 
* Data correspond to mean ± SEM of three independent assays.  The   statistical 
significances were calculated by appling a Student’s t –test between each maximum binding 
value detemined as a % of cGnRH-R-III transfected cells.  a,b Different superscript letters 
indicate significant differences within column for each ligand (p < 0.05). 
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Figure 4. 5 
 
Fig. 4.5.  Ligand binding to cGnRH-R-III in cells co-transfected with cGnRH-R-III 
Splice Variants.  Competitive displacement of 125I-[His5-D-Tyr6]-GnRH with serial dilutions 
of (A) cGnRH-I and (B) GnRH-II in COS-7 cells transiently transfected with cGnRH-R-III 
(filled squares ■), cGnRH-R-III & SV1 (filled up-turned triangles ▲), cGnRH-R-III & SV2 
(filled down-turned triangles ▼), SV1 (filled diamond ♦) and SV2 (filled circle ●) 
expression constructs.  Data are presented as mean ± SEM total counts per minute corrected 
for non-specific binding from three independent experiments performed in triplicate. 
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4.4.7. Ligand-induced internalisation of 125I-[His5-D-Tyr6]-GnRH-I bound 
to cGnRH-R-I and cGnRH-R-III. 
cGnRH-R-I internalised 125I-[His5-D-Tyr6]-GnRH-I at an initial rate of 15.8%.min-1 
±1.57 which was significantly less (p<0.005) than the initial rate of internalisation of 
26.0%.min-1 ± 2.33  at cGnRH-R-III.  The percent maximal internalisation of cGnRH-
R-I was 78.2% versus 68.9% for GnRH-R-III (Fig 4.6).  
 
Figure 4. 6 
 
Fig. 4.6. cGnRH-R-I and cGnRH-R-III ligand induced internalisation rate.  Percent 
internalisation of 125I-[His5-D-Tyr6]-GnRH-I ligand mediated by cGnRH-R-I (solid triangle 
▲) and cGnRH-R-III (solid square ■).  Data points are the mean +/-SEM of four 
independent experiments each performed with 6 replicates.  Background binding, determined 
in un-transfected cells was accounted for.  The statistical significance was calculated by 
applying a Student’s t-test to the initial rates of internalisation for each individual experiment 
performed.   




4.5.1. Ligand binding selectivity and G protein coupling of cGnRH-Rs 
The occurrence of two or three forms of GnRH peptide hormone in different 
vertebrate species suggested the possibility that cognate receptors respond differently 
to distinguish between the different ligands.  However, the analysis performed in this 
chapter comparing the pharmacological profiles of both cGnRH-R-I and cGnRH-R-
III illustrate that the chicken receptors have similar pharmacological profiles in 
relation to the endogenous GnRH peptides in the chicken (Fig. 4.1A, B).  cGnRH-R-
III, like cGnRH-R-I has a similar GnRH binding selectivity for GnRH-II over 
cGnRH-I (Fig 4.1A).  The results confirm a previous observation on ligand 
selectivity at cGnRH-R-I, where cGnRH-R-I was shown to have a higher binding 
selectivity for GnRH-II rather than cGnRH-I (Sun et al., 2001b).  The ligand 
selectivity of cGnRH-I for cGnRH-R-I was relatively high (Fig 4.1A) despite 
cGnRH-I lacking a folded ß-II’ turn conformation (Sun et al., 2001b).  The major 
ligand binding sites identified in mammalian GnRH receptors; Asp(98) (Flanagan et 
al., 2000), Asn(102) (Davidson et al., 1996) are conserved in cGnRH-R-III and in 
cGnRH-R-I, whilst the lysine in TMD3 of cGnRH-R-I is conservatively substituted 
with an arginine residue in cGnRH-R-III, preserving agonist binding to the receptor 
(Chapter 3-Fig. 3.8) (Zhou et al., 1995).  The conservation of these residues is 
consistent with the observed similarity in binding affinities of the two receptors to 
cGnRH-I and GnRH-II.  These receptor residues are believed to interact with amino 
and COOH terrminal residues of the GnRH ligands (Davidson et al., 1996; Flanagan 
et al., 1994; Zhou et al., 1995).  It has been proposed that cGnRH-R-I is configured 
such that the spatial arrangement of the receptor binding sites accommodates binding 
of configured and non-configured ligands, supported by the presence of  aspartic acid 
in both loci of the functional helix2/helix7 micro-domain (Sun et al., 2001b).  These 
residues are also conserved in cGnRH-R-III (Chapter 3-Fig. 3.8).  Preferential 
selectivity for GnRH-II is emerging as a general phenomenon for non-mammalian 
GnRH receptors irrespective of their classification based on structural features.  This 
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phenomenon appears to be due to the preconfigured ß-II’ turn of GnRH-II (Pfleger et 
al., 2002).  The GnRH-II structure is conserved in vertebrates and it has been 
proposed this results from a co-ordinated evolutionary selection of residues for 
binding and for ligand configuration resulting in a high affinity binding for all 
receptors (Pfleger et al., 2002).  The current study supports this concept in that both 
cGnRH-Rs maintain higher ligand selectivity for GnRH-II (Fig. 4.1).  However, this 
situation presents an apparent conundrum because cGnRH-I is thought to be the 
hypothalamic peptide responsible for regulating the pituitary gonadotroph (Mikami 
et al., 1988a; Sharp et al., 1990).   
 
In accordance with the ligand-binding selectivity of cGnRH-R-III (Fig. 4.1), GnRH-
II was more potent (4-fold) at stimulating inositol phosphate production at cGnRH-
R-III than cGnRH-I (Fig. 4.1B) consistent with previous data (Shimizu and 
Bedecarrats, 2006; Sun et al., 2001b).  Due to the conservation of aspartic acid in 
both loci of the helix2/helix7 micro-domain (Sun et al., 2001b), alanine in IC3 
(Myburgh et al., 1998), and the arginine cage motif that resides at the cytosolic end 
of TMD3 (Ballesteros et al., 1998) (Chapter 3-Fig. 3.8A), all of which are known to 
be important for receptor G protein coupling and signal transduction, it is not 
surprising that cGnRH-R-III, like GnRH-R-I (Sun et al., 2001b) stimulates inositol 
phosphate production.  Since inositol phosphate and DAG are generated by the 
recruitment of the Gαq protein and subsequent activation of PLC-ß (Ruf et al., 2003; 
Stojilkovic et al., 1994), cGnRH-R-III can activate the Ca2+ and PKC signalling 
pathways which are the predominant mediators of LH and FSH biosynthesis and 
secretion (Conn and Crowley, 1994; Sealfon et al., 1997).  Additionally, recent 
research using a cAMP responsive element (CRE) luciferase reporter construct 
suggests that cGnRH-R-I and cGnRH-R-III can couple to GαS (Shimizu M et al., 
2008).  However, it should be recognised that CRE-luc can also be activated by the 
stimulation of more than one second messenger signalling pathway (Naor, 2009).  
For example, studies show that there is a possible crosstalk between PLC and AC 
pathways and two isoforms of PKC (PKCΔ and PKCε) may activate AC, resulting in 
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increased cAMP levels (Lariviere et al., 2007).  In COS-7 cells, the human GnRH-R 
can stimulate cAMP production via Ca2+/calmodulin crosstalk when AC-I is 
introduced (Grosse et al., 2000).  Similarly, it has also been reported that activation 
of Gαq and the resulting increase in intracellular Ca2+, can lead to the stimulation of 
CRE-binding protein (CREB) (Matthews et al., 1994).  Thus cGnRH-I stimulation of 
cGnRH-R-I and cGnRH-R-III may result in additional CRE-binding protein 
activation by mechanisms involving the coupling of several G proteins.  An 
investigation into the precise mechanisms would prove beneficial in future studies.  
The potency of the endogenous ligands in inducing cAMP in these experiments was 
in accordance with the determined ligand-binding selectivity shown in (Fig. 4.1A).  
cGnRH-II had a higher potency in cAMP induction at cGnRH-R-I and cGnRH-R-III 
(ED50  2.09 and 3.2nM respectively) compared with cGnRH-I (ED50  26.8 and 22. 
91nM respectively) (Shimizu M et al., 2008).   
 
The results suggest that receptor ligand selectivity measured in-vitro does not 
necessarily reflect the likely in-vivo role of GnRH receptor isoforms nor does it 
necessarily determine the designation of ‘cognate’ receptors. Evolutionary 
recruitment of ligand-receptor pairing for particular physiological processes is 
not always determined by selection according to the highest affinity for ligand-
binding or potency in inositol phosphate production, but can be determined by 
tissue-specific expression of ligand and receptor in particular instances.  As in 
the chicken where cGnRH-I is the only ligand that activates the pituitary cGnRH 
receptors, as GnRH-II is not present in the median eminence (Mikami et al., 1988b; 
Sharp et al., 1990).  However, there may be an adaptive advantage of lower 
affinity/potency pairing.  It can by hypothesised that a ligand (e.g. GnRH-I) having a 
lower affinity with a receptor (cGnRH-R-I and cGnRH-R-III) will correlate with a 
greater dissociation of the ligand and the receptor.  This would allow a greater 
proportion of available receptors in a given time-frame of receptor activation.  
Additionally, lower affinity/potency paring will enable receptor activation with lower 
pulses of GnRH and remove the requirement of large pulses to produce and effect.  
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In contrast, lower affinity/potency pairing may result in less receptor desensitisation 
on GnRH pulse activation, enabiling a more prolonged affect of the ligands.   
 
4.5.2. Activity of GnRH analogs at chicken receptors  
Mammalian antagonist 27 has significantly higher binding affinities for cGnRH-R-III 
and cGnRH-R-I compared with mammalian antagonists 135-18 and 135-25 (Table 
4.2).  Although, the binding affinities of the mammalian antagonists were much 
lower at both chicken GnRH receptor homologs than previous observations at the 
human GnRH receptor (Sun et al., 2001b).  Mammalian antagonist 27 showed a 56-
fold higher binding affinity for GnRH-R-I than for cGnRH-R-III (Table 4.2).  The 
D-α-Me-4-Cl-Phe in position 2 of mammalian antagonist 27 may enhance its binding 
affinity to both receptors compared to the other mammalian antagonists (Sun et al., 
2001b).  The lysine (Lys/K) in TMD3 at position 121 of the cGnRH-R-I is 
conservatively substituted with an arginine (Arg/R) residue in cGnRH-R-III at 
position 147 (Chapter 3, Fig. 3.8.A) (Joseph et al., 2009),  although this preserves 
agonist binding to the receptor (Zhou et al., 1995), it may contribute to the altered 
binding affinity of mammalian antagonist 27 (Table 4.2.).  
 
The observed low binding affinities of mammalian antagonists 135-25 and 135-18 
(Table 4.2) are translated into similarly low potencies in their capacity to stimulate 
or inhibit inositol phosphate accumulation (Fig. 4.3A-D, Fig. 4.4A-D).  The sizes of 
these effects are too small to distinguish between the two receptor subtypes.  The 
agonistic and antagonistic effects of 135-25 and 135-18 are extremely small, and this 
is reflected in the size of standard error values observed (Table 4.2).  The 
concentrations of mammalian antagonists 135-25 and 135-18 required to bind both 
cGnRH-R-I and cGnRH-R-III and to exert an agonistic or antagonistic effect are 
large, making an accurate estimation of the EC50 and IC50 values difficult (Table 
4.2).  Mammalian antagonist 135-18 behaved as an extremely weak agonist (EC50 = 
1510nM) and also antagonised GnRH-II activation of cGnRH-R-III (IC50 = 3890nM) 
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(Fig. 4.4C, D).  At cGnRH-R-I, mammalian antagonist 135-18 acted as a full 
antagonist (IC50 = 2330nM) with no agonistic effects (Fig. 4.4A, B).  This 
contradicts previous observations, where mammalian antagonist 135-18 was shown 
to behave as a full agonist at cGnRH-R-I (EC50 = 33nM) (Sun et al., 2001b).  
Mammalian antagonist 135-25 acted as a very weak agonist at cGnRH-R-III (EC50 = 
4860nM) and cGnRH-R-I (EC50 = 5970nM) (Fig. 4.3C, D).  However, while this 
ligand was able to weakly antagonise GnRH-II activation of cGnRH-R-I (IC50 = 
245nM) (Fig. 4.3A, B), no antagonism was seen at cGnRH-R-III.  Interstingly, the 
potency of this ligand appeared to be increased in the presence of GnRH-II.  Co-
operativity may be a possible explanation for the observed effects.  It is feasible that 
in the presence of GnRH-II, mammalian antagonist 135-25 displayed increased 
potency in inositol phosphate production of cGnRH-R-III due to conformational 
changes of the receptor.  This data confirms previous observations where mammalian 
antagonist 135-25 was shown to have agonist and antagonist effects at cGnRH-R-I 
(EC50 = 1300nM and IC50 = 4100nM) (Sun et al., 2001b).   
 
Differences in binding affinity were translated into differences in antagonistic effects 
at the receptors, with antagonist 27 showing a 153-fold higher antagonistic effect at 
cGnRH-R-I than cGnRH-R-III (Table 4.2) (Fig. 4.2B, C).  The difference in binding 
affinity of Antagonist 27 was 56-fold higher at cGnRH-R-I than cGnRH-R-III 
(Table 4.2).  Although it behaved as an agonist at low concentrations, mammalian 
antagonist 27 acted as an inverse agonist at both cGnRH-R-I and cGnRH-R-III at 
10µM concentration (Fig 4.2A, C).  Mammalian antagonist 27 was also able to 
strongly antagonise GnRH-II stimulation of cGnRH-R-I (IC50 = 2.3nM) and cGnRH-
R-III (IC50 = 351nM) (Fig 4.2B, D).  This is an extremely valuable finding in terms 
of distinguishing between the receptors in terms of their pharmacology.  Therefore, 
it may be possible to utilise antagonist 27 to preferentially block chicken type I 
GnRH receptor function in-vivo in order to study physiological roles of the 
chicken type III GnRH receptor.  This data confirms previous observations, where 
mammalian antagonist 27 acted as a pure antagonist (IC50 = 177nM) (Sun et al., 
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2001b) at cGnRH-R-I, although previously it was not shown to have inverse 
agonistic effects, as shown in this study (Fig. 4.2A, C).     Antagonist 27 displayed a 
binding affinity of 0.38nM at cGnRH-R-I and 21.nM at cGnRH-R-III (Table 4.2), 
however, inverse agonist effects were only observed at 10µM at both receptors, 
therefore it is plausible that the observed inverse agonism is not receptor-specific 
mediated effect.  It is feasible that the antagonist 27 or the vehicle is effecting the 
production of inositol phosphate at these concentrations irrespective of the receptor 
expression.   
 
Analysis of the mammalian antagonist sequences revealed that both 135-25 (which 
has agonistic activity at cGnRH-R-I and GnRH-R-III) and 135-18 (which has 
agonistic activity at cGnRH-R-III) have a basic D-amino acid substitution (D-Ipr-Lys) 
in place of Gly6 and differ only by the amino acid in position 5 (Table 4.1).  Previous 
studies showed that agonism at cGnRH-R-I is conferred by D-lys or D-Ipr-Lys in 
position 6 of the GnRH analog interacting with ECL2 of the receptor by stabilising 
the receptor active conformation (Sun et al., 2001b).  Stabilisation of the active 
conformation of cGnRH-R-I by 135-18 was not supported by the observation made 
in this study, where 135-18 was shown to have antagonistic effects at cGnRH-R-I in 
the concentration range used (Fig 4.4A, B).  Additionally, the large aromatic side 
chain (1-MePal) (Table 4.1) was suggested to prevent 135-25 acting as a full agonist 
at cGnRH-R-I (Sun et al., 2001b) by changing the orientation of the adjacent D-Lys 
moiety such that its ability to interact with the cognate receptor amino acid is 
impaired.  This observation is maintained in terms of GnRH-R-I; however the data 
from the present study suggests that the large aromatic side chain of 135-25 does not 
interfere with the interaction of cGnRH-R-III.  However, the smaller aromatic side 
chain (Ile) (Table 4.1) at position 5 of mammalian antagonist 135-18 was suggested 
to allow this analog to act as a full agonist at cGnRH-R-I (Sun et al., 2001a), 
however in the current study, this compound acted as a pure antagonist at cGnRH-R-
I ((Fig 4.4A, B), making structure-function interpretations for these analog sequences 
difficult.    
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4.5.3. cGnRH-R-III splice variants  
In these experiments the maximum binding of the co-transfected full-length and 
splice variant contructs to 125I-[His5-D-Tyr6]-GnRH-I was used a measure of receptor 
expression at the cell surface.  The maximum binding of 125I-[His5-D-Tyr6]-GnRH-I 
in the absence competing ligand between the two experiments (Fig 4.5) should not 
differ as transfected cells were derived from the same transfection reaction, and they 
are not dependent on the competing ligand.  The differences observed between the 
two experiments (Fig 4.5) are due to interplate variation attributable to the 
experimental procedure. Although there is a significant increase in the maximum 
binding observed for cGnRH-R-III when co-transfected with cGnRH-R-III_SV1 
(Table 4.3), the size of the effect is small (increases of 2.0 and 9%), this may suggest 
that co-transfection with cGnRH-R-III_SV1 may result in increased trafficking of the 
full-length receptor to the cell membrane; although the effect is very small.  The 
significant reduction in maximum binding (decreases 29.8 and 33.4%)  observed for 
cGnRH-R-III when co-transfected with cGnRH-R-III_SV2 (Table 4.3 and Fig. 
4.5A, B) may be a result of cGnRH-R-III_SV2 reducing the trafficking of the full-
length receptor to the cell membrane, as seen in a study with the full-length and 
splice variants of the human GnRH-R (Pawson et al., 2005).  Alternatively, cGnRH-
R-III_SV2 could potentially dimerize with the full length receptor, as shown in a 
study using wallaby GnRH receptors, where the GnRH-Rs formed homodimers as 
well as heterodimers with SVs without agonist stimulation (Cheung and Hearn, 
2005).  Dimerisation of the full length cGnRH-R-III and cGnRH-R-III_SV2 may 
induce allosteric conformational changes in the full length cGnRH-R-III, resulting in 
a disruption of ligand binding sites (N. Joseph et. al., in preparation).  This 
complements observations made in a collaborator’s laboratory (Prof Gregoy 
Bedecarrats, University of Guelph), where it has been demonstrated that both SV 
mRNAs are translated and trafficked in a similar way to the full-length receptor and 
that a substantial proportion of cGnRH-R-III splice variants (particularly cGnRH-R-
III_SV2) co-localize with the full-length receptor in co-transfected COS-7 cells.  
Expression of cGnRH-RIII_SV2 resulted in a decrease in maximum inositol 
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phosphate accumulation in COS-7 cells and in CRE-luc activity in GH3 cells 
transfected with the full-length receptor, while no effect was observed on EC50 
values. Interestingly, the effect of cGnRH-R-III_SV2 was more pronounced on 
cAMP production than on inositol phosphate accumulation, suggesting that 
inhibition by this variant is more effective on the Gαs pathway.  While the decreased 
maximal binding induced by co-transfection of cGnRH-R-III_SV2 can explain the 
decreased ligand stimulation of inositol phosphate and CRE-luc activity, cGnRH-R-
III_SV1 had no effect on binding when transfected in COS-7 cells at a ratio of 2:1 to 
full-length receptor cDNA.  However, it did impair inositol phosphate generation in 
the same cells under these conditions. This implies that cGnRH-R-III_SV1 associates 
with the full-length receptor to cause uncoupling from Gαq protein (N. Joseph et. al., 
in preparation).  Therefore, it is plausible that cGnRH-R-III splice variants may 
modulate cGnRH-R-III activity and may be physiological regulators if 
expressed at sufficient levels. 
 
4.5.4. Ligand induced internalisation of cGnRH-Rs 
Considering the primary structural differences between the two chicken receptors, 
the possibility that the rate of ligand-induced internalisation between the two 
receptors may differ was considered due to the presence of 8 additional residues in 
the C-terminal tail of cGnRH-R-III (Chapter 3-Fig. 3.8).  A slightly greater rate of 
internalisation was measured for cGnRH-R-III compared to cGnRH-R-I (Fig. 4.6).  
The region crucial for receptor internalisation of cGnRH-R-I is distal to residue 336 
in cGnRH-R-I (Pawson et al., 1998a).  In cGnRH-R-III this region contains all 8 of 
the additional residues that comprise the elongated tail (Fig. 4.7).  The cysteine328 
residue of cGnRH-R-I, which was shown to be crucial for internalisation rate is 
conserved in cGnRH-R-III (Fig. 4.7).  The putative threonine369threonine370 
phosphorylation doublet of cGnRH-R-I, known to be critical for internalisation 
(Pawson et al., 2003), is not conserved in cGnRH-R-III (Fig. 4.7). However, in 
cGnRH-R-III, a different phosphorylation doublet (serine doublet) exists near the 
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carboxyl terminus (Fig. 4.7).  Therefore, this serine doublet probably maintains the 
internalisation rate of cGnRH-R-III.  The highly conserved arginine residue in the 
cystolic region of TM3 and the highly conserved tyrosine residue of the N/DPXXY 
motif in TM7 are important for GnRH receptor internalisation in the mouse (Arora et 
al., 1996; Arora et al., 1997) and are conserved in both chicken receptors (Chapter 
3-Fig. 3.8), although these features are also conserved throughout the rhodopsin 
family of GPCRs.  It is possible that the spatial arrangement of amino acid residues 
in the carboxyl-terminus region of cGnRH-R-III may contribute to the increase in 
internalisation rate when compared to the internalisation rate of cGnRH-R-I (Fig. 
4.6). 
 
Figure 4. 7 
 
Fig. 4.7. Alignment of the cytoplasmic C-terminal tails of cGnRH-R-I and cGnRH-R-
III.  The amino acid residues that are important for receptor internalisation are boxed.  [1] 
Region crucial for cGnRH-R-I internalisation is distal to residue 336.  [2] Threonine369 and 
threonine370 doublet of cGnRH-R-I, known to be critical for internalisation.  [3] Serine-serine 
doubled of cGnRH-R-III presenting a phosphorylation doublet near the carboxyl terminus.  
[4] Conservation of cGnRH-R-I cysteine328 residue with cGnRH-R-III.  The C-tail domain is 
poorly conserved (~14% sequence identity between the type I and type III cGnRH 
receptors). 
 
The length of the cytoplasmic tail has also been suggested to contribute to the cell 
surface expression of the receptor (Pawson et al., 2003), but transient gene 
expression of both receptors following transfection by electroporation of a standard 
quantity of cDNA was similar in COS-7 cells (data not shown), suggesting that 
extension of the tail beyond a critical minimum does not further enhance expression 
at the cell surface.  The length of the cytoplasmic tail probably effects cell surface 
expression by changing the conformation of the receptor.  The internalisation of 
cGnRH-R-I was suggested to be through a caveolae-like, dynamin-dependent 
manner (Pawson et al., 2003).  The internalisation kinetics of the two receptors were 
Chapter 4                         Pharmacological profiling of cGnRH-R-I and cGnRH-R-III
 
 163
measured in COS-7 cells (Fig. 4.6) which have low endogenous levels of  ß-arrestin 
(Menard et al., 1997).  A further investigation into the mechanisms of internalisation 
of cGnRH-R-III will prove valuable as internalisation of the receptors may be 
influenced by cell-type-specific factors.  Although unlikely, the receptors may 
internalise through different mechanisms which would result in differential effects in 
different tissue cell types.  Agonist induced receptor desensitisation has been studied 
in chicken pituitary cells (King et al., 1986) although no analysis of agonist induced 
desensitisation of chicken receptor isoforms has been performed.  Such studies may 




In summary, I compared the in-vitro pharmacological properties of cGnRH-R-I and 
cGnRH-R-III, and found both receptors to be similar in relation to endogenous 
chicken GnRH ligands.  Pharmacological profiling of the type I and type III GnRH 
receptors has established that GnRH-II is more selective and more potent in the 
induction of inositol phosphate accumulation at both receptors than cGnRH-I.  
cGnRH-R-III has a slightly more rapid internalisation rate than cGnRH-R-I.  This 
may be important in determining the dynamics of cellular responses to receptor 
activation.  Activation and inhibition by GnRH analogs acting on cGnRH-R-I and 
cGnRH-R-III were characterised using a range of ligands (sGnRH-III, mammalian 
antagonist 27, 135-18 and 135-25), furthering the pharmacological profile of both 
receptor subtypes. Major differences between the two receptors were only seen with 
mammalian antagonist 27.  A decrease in expression of cGnRH-R-III by co-
transfections with cGnRH-R-III_SV2 was measured and the implications of cGnRH-
R-III splice variants on signal transduction was discussed. 
The findings presented in this chapter encompassing ligand-binding selectivity, G 
protein coupling and internalisation of cGnRH-R-III suggest that it could 
theoretically function similarly to cGnRH-R-I to regulate gonadotrophin synthesis.  
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However the predominant levels of cGnRH-R-III mRNA in the pituitary gland 
(~1400 fold more than cGnRH-R-I), and the changes in expression patterns with age 
and sex suggest a distinct functional capacity of cGnRH-R-III compared to cGnRH-
R-I (Chapter 3).  The application of GnRH analogs such as antagonist 27 which has 
been shown to differentially affect GnRH receptor subtype function in transfected 
cells will be valuable for determining the physiological roles of different ligands and 
receptor subtypes in-vivo. Our studies suggest that evolutionary plasticity in the 
tissue-specific adoption of GnRH ligand and receptor subtypes for regulation of 
particular physiological functions may have occurred in birds.  Birds appear to 
have adopted a strategy to regulate gonadotrophin synthesis and release which 
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4.6. Connective Statement 
Expression of cGnRH-R-III mRNA was ~1400 fold higher than cGnRH-R-I mRNA 
in the anterior pituitary gland suggesting that cGnRH-R-III is the predominant 
regulator of gonadotrophin synthesis and secretion (Chapter 3).  Both cGnRH-R 
subtypes have similar in-vitro pharmacological properties in relation to endogenous 
ligands, cGnRH-I and GnRH-II (Chapter 4) which does not further enhance our 
understanding of the roles of the cGnRH-R-I and cGnRH-R-III in terms of regulation 
of gonadotrophin biosynthesis.  However a GnRH analog was identified that may be 
applied to differentially promote or inhibit activation of each cGnRH receptor 
subtype, providing a valuable tool for deciphering the role of receptor subtypes in 
terms of gonadotrophin regulation or other putative functions.  In an attempt to 
discover differential functional capacities of the cGnRH-R subtypes, an in-depth 
study of the GnRH receptor activated MAPK signalling cascade was undertaken 
(Chapter 5).  A number of primary structural differences were identified between 
the two receptors.  Of particular interest are the putative Src Homology 3 (SH3) 
binding motifs identified exclusively in cGnRH-R-III.  Identifying if cGnRH-R-I and 
cGnRH-R-III differentially target signalling pathways may help to elucidate 
differential physiological roles for the receptor subtypes.  Therefore in Chapter 5 
using the cGnRH-R-I and cGnRH-R-III  expression constructs, SH3 binding motif 
mutants and HA epitope-tagged cGnRH-R subtype constructs transiently transfected 
into COS-7 cells, the activation and interaction of the cGnRH-R subtypes with an 
array of signalling pathway mediators is described.   











MAPK Signalling Activated via Type I 
and Type III cGnRH Receptors 
 




The expression of two GnRH receptor subtypes, cGnRH-R-I and cGnRH-R-III, 
coincides with the occurrence of two chicken GnRH ligands (cGnRH-I and 
GnRH-II).  Despite the ~1400 fold higher level of mRNA encoding cGnRH-R-III 
in pituitary compared to cGnRH-R-I mRNA, there was no obvious functional 
difference of cGnRH-R-III compared to cGnRH-R-I when pharmacological 
properties were compared using endogenous ligands.  cGnRH-R-III, like 
cGnRH-R-I, had a preferential ligand-binding selectivity and induction of 
inositol phosphate production in response to GnRH-II compared with cGnRH-I, 
although cGnRH-I is believed to be the physiological regulator of gonadotroph 
function.  It was anticipated that the two cGnRH-R subtypes may have 
differential roles in the regulation of LH and FSH transcription through 
differential activation of second messenger pathways.  Characterisation of 
signalling cascades activated by the two cGnRH-R subtypes may help to 
elucidate the existence of differential roles for the receptor subtypes.  With this 
in mind, three putative Src homology domain 3 (SH3) binding motifs were 
identified in the type III cGnRH receptor cytoplasmic C-terminal tail domain 
(sequence = EPEPP, EPPSP, GPHPP) which are not present in the type I 
cGnRH receptor.  This suggested the potential for differential coupling to the 
mitogen-activated protein kinase (MAPK) cascade.  Therefore to investigate this 
possibility, activation of the MAPK cascade via cGnRH-R-III and cGnRH-R-I 
was determined by quantifying phosphorylated ERK (pERK 1/2) produced in 
response to GnRH.  Studies performed in COS-7 cells showed a 4-6 fold 
increase in ERK1/2 phosphorylation via the type I and type III cGnRH 
receptors within 10 minutes of cGnRH-I or GnRH-II stimulation, indicating 
that both receptors signal through the ERK pathway.  The effects were dose 
dependent at cGnRH-R-I and cGnRH-R-III.   Effects of pre-treatment with 
phospholipase C (PLC) inhibitor or c-Src inhibitor showed that both cGnRH-Rs 
can activate pERK 1/2 possibly independently of PLC but dependently upon c-
Src.  However, it must be noted that 100% of the PLC activity was not inhibited 
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by PLC inhibitor as measured by inositol phosphate production at 60 minutes, 
and the PLC inhibitor has not been shown to inhibit PLC in the same time 
frame used for the pERK experiments.  Mutagenesis of the individual SH3 
binding motifs of cGnRH-R-III was performed by substituting an alanine codon 
for the first proline codon of each SH3 binding motif, and the effects on pERK 
1/2 activation were quantified.  The results indicated that the individual SH3 
binding motifs of cGnRH-R-III do not contribute to MAPK activation when 
compared to the native cGnRH-R-III.  Both cGnRH-R-I and cGnRH-R-III were 
HA epitope-tagged (HA-cGnRH-R-I and HA-cGnRH-R-III) to facilitate 
characterisation of receptor protein-protein complexes isolated by immuno-
precipitation using western blotting, following transient transfection of COS-7 
cells.  Both HA-tagged receptors retained ligand-binding and coupling to PLC.  
Several size forms of HA-cGnRH-R-III were detectable and the composition of 
the immuno-precipitated protein complexes can be analysed in detail in future 














5.2.1. The mitogen-activated protein kinase (MAPK) cascade influences 
gonadotrophin gene expression 
Four groups of MAPK are currently known in mammals; extracellular signal-related 
kinase (ERK), Jun N-terminal kinase (JNK), p38MAPK (p38) and big MAPK 
(BMK) (Naor et al., 2000).  GnRH activates all four of the MAPK cascades, 
although the mechanisms involved in GnRH stimulation of the MAPK cascade via 
GnRH receptors are dependent on “cell-context” (Dobkin-Bekman et al., 2006).  
Activation of the MAPK cascade results in gene transcription regulation, as certain 
components are able to translocate to the nucleus (Dobkin-Bekman et al., 2006; Naor 
et al., 2000).  Variation in the frequency of GnRH pulses and in the level of GnRH 
receptors (which affects signal intensity) have been implicated in the differential 
regulation of gonadotrophin subunit gene expression (Haisenleder et al., 1991; 
Kaiser et al., 1995).   These variables may lead to differential signalling (Dobkin-
Bekman et al., 2006).  Mediation of effects through PKC, ERK, JNK, c-Src Ca2+ and 
PKA, PKC, ERK, JNK, Ca2+ have been implicated in the transcriptional regulation 
of the common gonadotrophin alpha subunit and LH beta subunit respectively, 
although some studies show that p38, JNK and PKC, ERK, Ca2+ are not implicated 
in the transcriptional regulation of the common gonadotrophin alpha subunit and LH 
beta subunit respectively (Call and Wolfe, 1999; Fowkes et al., 2002; Harris et al., 
2003; Roberson et al., 1999; Saunders et al., 1998; Weck et al., 2000; Weck et al., 
1998; Xie et al., 2005; Yokoi et al., 2000).  FSH beta subunit gene regulation appears 
to be mediated by PKC, ERK, JNK, p38 and c-Src but not Ca 2+ (Bonfil et al., 2004).  
These conflicting results may reflect the different cell types, gene promoters from 
different species and cell culture conditions used experimentally (Naor, 2009).  
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5.2.2. MAPK signalling activated by the GnRH receptor through a G 
protein dependent mechanism 
GnRH receptors primarily couple to Gαq in pituitary gonadotrophs (Grosse et al., 
2000; Hsieh and Martin, 1992; Naor et al., 1986; Naor et al., 2000), but evidence 
shows that GnRH receptors can also couple to Gαi and Gαs (Hawes et al., 1993; Liu 
et al., 2002; Stanislaus et al., 1998).  However, GnRH receptors interact with 
multiple G proteins in a ‘cell-context’ dependent manner (Dobkin-Bekman et al., 
2006).  In pituitary gonadotrophs a consensus signalling mechanism has emerged 
which activates the MAPK cascade, with Gαq activating PLC which generates DAG 
and IP3 which subsequently activate PKC and Ca2+ mobilisation, resulting in 
activation of ERK, JNK, and p38 (Dobkin-Bekman et al., 2006; Naor et al., 2000).  
In rat pituitary cultures, ERK activation is PKC dependent and dependent on Ca2+ 
influx, whereas JNK activation is PKC independent and dependent on Ca2+ 
mobilisation (Mulvaney and Roberson, 2000; Mulvaney et al., 1999).  In αT3-1 
(mouse embryo gonadotroph) cells, GnRH stimulated ERK, JNK and p38 activation 
is dependent on PKC activation [8, 35, 36].  ERK activation has been further studied 
and shown to be dependent on c-Src, dynamin, Ras and Ca2+ influx (Benard et al., 
2001), whereas JNK activation is additionally dependent on c-Src and CDC42/Rac1 
(Levi et al., 1998).  In HEK293 (human embryo kidney) cells, GnRH stimulation of 
GnRH receptor transfected cells results in ERK activation dependent on focal 
adhesion kinase (FAK) and c-Src at focal adhesion complexes (sites of integrin-ECM 
adhesion) mediated by Rac (Davidson et al., 2004).  In COS-7 (African Green 
monkey kidney) cells, Gαi modulates EGFR resulting in c-Src activation and 
subsequent ERK activation mediated via Ras, and JNK activation mediated by PI3K 
(Kraus et al., 2003).   
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5.2.3. MAPK signalling activated by GPCRs through a G protein 
independent mechanism  
It was shown that heptahelical receptors may directly interact with multiple 
intracellular signalling proteins (Hall et al., 1999) such as ß-arrestin, GPCR kinases 
(GRKs) SH2, SH3 or PDZ (protein-protein interaction motifs) containing proteins, 
PTKs, small GTPases and other proteins (Naor et al., 2000).  The complexes formed 
act as a scaffold or platform for interaction with additional signalling molecules.  
These protein-protein interactions mediate signal transduction that activates the 
MAPK cascade independently of the G proteins (Naor et al., 2000).  ß-arrestins serve 
as scaffolds and adaptors for GPCR signalling (Miller and Lefkowitz, 2001).  A 
recent publication demonstrated an interaction of c-Src with β2-adrenergic receptor 
through the proline-rich region of ß1-arrestin (Miller et al., 2000).  The C-terminal 
tail of GPCRs serve as phosphorylation sites which facilitate ß-arrestin binding 
(McArdle et al., 2002).  The activation of c-Src can subsequently lead to the 
recruitment of Shc, Grb2, SOS and RAS which may activate the MAPK cascade 
(Kraus et al., 2001; McArdle et al., 2002; Miller and Lefkowitz, 2001).  Presence of 
SH3 binding motifs in the C-terminal tail domain suggests the potential for 
differential coupling to the MAPK cascade (Millar et al., 2004).   Carboxyl terminal 
tails of non-mammalian GnRH receptors have been implicated as sites for 
interactions with regulators of G protein signalling proteins (Castro-Fernandez and 
Conn, 2002).  The possiblility of direct interactions between accessory proteins, 
poly-proline binding proteins, receptor-activity modifying proteins and members of 
the scaffolding family of proteins and the GnRH receptor has been hypothesised, 
although the micro-domains or structural motifs within the GnRH receptors required 
for these interactions have not been identified (Millar et al., 2004).  
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5.2.4. c-Src interaction with MAPK signalling complexes and GPCRs 
Activation of the MAPK cascade is often dependent on c-Src interactions (Benard et 
al., 2001; Davidson et al., 2004; Gutkind, 1998; Kraus et al., 2003; Levi et al., 1998; 
Luttrell et al., 1999).  PKC activated via Gαq can modulate the activity of non-
receptor PTKs e.g. c-Src family kinases (Levi et al., 1998).  Additionally Gαi 
coupling may lead to activation of c-Src family of PTKs which in turn lead to MAPK 
activation (Gutkind, 1998; Luttrell et al., 1999).  In αT3-1, HEK293 and COS-7 cells 
GnRH stimulated ERK activation is c-Src dependent along with other second 
messengers (Benard et al., 2001; Davidson et al., 2004; Kraus et al., 2003).  In αT3-
1, JNK activation is also shown to be c-Src dependent (Levi et al., 1998).   
 
5.2.5. Signalling cascades involved in regulation of gonadotrophin 
gene expression in the chicken 
Characterisation of second messenger systems involved in the control of LH 
secretion in the avian pituitary is scant.  It has been established that cAMP, PKC 
activation and elevated intracellular Ca2+ are involved in cGnRH-I induced LH 
secretion from chicken pituitary gonadotrophs (Bonney and Cunningham, 1977a; 
Bonney and Cunningham, 1977b; Davidson et al., 1987a; Davidson et al., 1987b; 
Johnson and Tilly, 1991; Luck and Scanes, 1980).  However it was also shown that 
increases in intracellular Ca2+ are sufficient for secretion of stored LH, whilst 
elevated cyclic cAMP is not essential for LH secretion (Johnson and Tilly, 1991).  
Each second messenger may be required to elicit different effects of gonadotroph 
function following stimulation with GnRH.  Thus multiple signalling mechanisms 
co-exist to activate and sustain LH secretion from pituitary gonadotrophs (Johnson 
and Tilly, 1991).  Previously, there have been no studies examining the signalling 
mechanisms involved in the regulation of gonadotrophin gene transcription in the 
chicken.  In this thesis, it has been established that GnRH-II was more potent at 
stimulating inositol phosphate production at cGnRH-R-III than cGnRH-I (Chapter 4 
- Fig. 4.1B) (Joseph et al., 2009).  Similarly, GnRH-II stimulates inositol phosphate 
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production more potently at cGnRH-R-I than cGnRH-I (Chapter 4 - Fig. 4.1B), 
consistent with previous data (Joseph et al., 2009; Shimizu and Bedecarrats, 2006; 
Sun et al., 2001b).  Since inositol phosphate and DAG are generated by the 
recruitment of the Gαq protein and subsequent activation of PLC-ß (Ruf et al., 2003; 
Stojilkovic et al., 1994), cGnRH-R-III and cGnRH-R-I can activate the Ca2+ and 
PKC signalling pathways which are the predominant mediators of LH and FSH 
biosynthesis and secretion (Conn and Crowley, 1994; Sealfon et al., 1997).  Recent 
research using a cAMP responsive element (CRE) luciferase reporter construct 
suggests that cGnRH-R-I and cGnRH-R-III couple to GαS (Shimizu M et al., 2008).  
However as mentioned in Chapter 4, it should be recognised that CRE-luc can also 
be activated by the stimulation of more than one second messenger signalling 
pathway (Naor, 2009).  The potency of the endogenous ligands in inducing cAMP 
was in accordance with the GnRH receptor ligand-binding selectivity (Chapter 4 - 
Fig. 4.1A).  GnRH-II had a higher potency at cGnRH-R-I and cGnRH-R-III (ED50 = 
2.09 and 3.2nM respectively) compared with cGnRH-I (ED50 = 26.8 and 22. 91nM 
respectively) (Shimizu M et al., 2008).  Coupling to other G protein subtypes by the 
cGnRH-R isoforms has not been studied as yet, and to date no G protein independent 
signalling has been examined using the chicken GnRH receptors.   
 
5.2.6. Research Objectives 
Three putative Src homology domain 3 (SH3) binding motifs were identified in the 
type III cGnRH receptor (sequence = EPEPP, EPPSP, GPHPP) cytoplasmic C-
terminal tail domain which are not present in the type I cGnRH-R.  SH3 binding 
motifs contain proline-rich regions with at least one PXXP motif (Cohen et al., 
1995).  Putative functional motifs are located at amino acid positions 369-373, 370-
375 and 398-402 encoded by exon four of cGnRH-R-III (Chapter 3 - Fig 3.8A).  
The occurrence of SH3 binding motifs suggest the potential for differential coupling 
to the MAPK cascade (Millar et al., 2004).  Determining whether cGnRH-R-I and 
cGnRH-R-III differentially target signalling pathways may help to elucidate 
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differential physiological roles for the receptor subtypes.  Therefore in this chapter, a 
study of the GnRH receptor-activated MAPK signalling cascade was undertaken.  
Experiments were performed to test the hypothesis that the type III GnRH receptor 
may differentially interact with SH3 domain-containing proteins through the SH3 
binding motifs. 
 
5.3. Methods  
The methodologies used to generate the results in this chapter are described in 
Chapter 2 (2.21-2.27) 
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5.4. Results  
Note: In all results and diagrams that follow the phosphorylation of ERK 1/2 is 
denoted as ‘pERK’ for simplification.  The antibody used to immuno-blot for pERK 
(Cell Signaling, Danvers, USA) detects endogenous levels of ERK1/2 when 
phosphorylated either individually or dually at Thr202 and 204 of ERK1 (Thr and 
Tyr of ERK2) .Control experiments were carried out to ensure that no pERK 
increases occurred in non-transfected COS-7 cells treated with vehicle (0.2% 
propylene glycol) or 1µM GnRH-II (data not shown).   
 
5.4.1. cGnRH-I and GnRH-II induce cGnRH-R-I and cGnRH-R-III 
mediated pERK activation in a dose-dependent and time-dependent 
manner 
Experiments showed that cGnRH-I and GnRH-II induced pERK activation via 
cGnRH-R-I and cGnRH-R-III in a dose-dependent manner (Fig. 5.1A-D).  At each 
increment in concentration of cGnRH-I and GnRH-II, there was an increase in the 
level of pERK via cGnRH-R-I and cGnRH-R-III.  The maximum pERK levels in 
COS-7 cells transiently transfected with cGnRH-R constructs were as high as 12 fold 
when compared to basal (data not shown).  The data presented in (Fig. 5.1A-D) 
were calculated as a fold response over non-stimulated or basal pERK level.  
cGnRH-I stimulation of cGnRH-R-I elicited a significant increase in pERK level 
when applied at 10nM (p<0.01), 100nM (p<0.01) and 1µM concentrations (p<0.05) 
(Fig. 5.1A).  Similarly stimulation of cGnRH-R-I with GnRH-II elicited a significant 
increase in pERK level when applied at 10nM (p<0.01), 100nM (p<0.05) and 1µM 
concentrations (p<0.05) (Fig. 5.1B).  cGnRH-I stimulation of cGnRH-R-III elicited a 
significant increase in pERK level when applied at 10nM (p<0.05), 100nM (p<0.01) 
and 1µM concentrations (p<0.05) (Fig. 5.1C).  Similarly stimulation of cGnRH-R-III 
with GnRH-II elicited a significant increase in pERK level when applied at 10nM 
(p<0.01), 100nM (p<0.01) and 1µM concentrations (p<0.01) (Fig. 5.1D).   
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In addition, cGnRH-I and GnRH-II induced ERK activation in a time-dependent 
manner via cGnRH-R-I or cGnRH-R-III, with a maximum response observed after 
15 minutes of stimulation (Fig. 5.2A-D).  At each time point from 5-15 minutes with 
either cGnRH-I or GnRH-II, there was an increase in the pERK level whereas after 
30 minutes of stimulation there was a decrease in pERK level (Fig. 5.2A-D).  A 
significant increase in ERK activation via cGnRH-R-I using cGnRH-I stimulation 
was observed at 5 (p<0.01), 10 (p<0.001), 15 (p<0.001) and 30 (p<0.05) minutes and 
when using GnRH-II stimulation increases were also observed at 5 (p<0.001), 10 
(p<0.001), 15 (p<0.001) and 30 (p<0.05) minutes (Fig. 5.2A-B).  A significant 
increase in ERK activation via cGnRH-R-III using cGnRH-I stimulation was 
observed at 5 (p<0.01), 10 (p<0.001), 15 (p<0.001) and 30 (p<0.05) minutes and 
when using GnRH-II stimulation increases were also observed at 5 (p<0.01), 10 
(p<0.05), 15 (p<0.05) and 30 (p<0.01) minutes (Fig. 5.2C-D). 
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Figure 5. 1  
 
Fig. 5.1.  cGnRH-I and GnRH-II induce phosphorylation of ERK via cGnRH-R-I and 
cGnRH-R-III in a dose-dependent manner.  (A-D) COS-7 cells expressing chicken 
GnRH-R receptors were stimulated for 10 minutes with varying concentrations of cGnRH-I 
or GnRH-II (1nM-1µM) or left non-stimulated (NS) as indicated.  Representative western 
blots of NP40 cell lysates are shown.  Data from at least three independent experiments 
performed in triplicate or duplicate (as shown above) were quantified (using total ERK 
(tERK) immunoblot as a loading control) and the mean relative level of increase in pERK +/- 
S.E. is presented graphically below the corresponding blot.  The statistical significance of 
changes in level was calculated by applying a Student’s t-test between the non-stimulated 
and each individual dose stimulated.  Values of p<0.05 are represented by an asterisk * and 
p<0.01 are represented by two asterisks **.  These represent statistically significant 
differences compared to NS control levels. 
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Figure 5. 2 
 
Fig. 5.2.  cGnRH-I and GnRH-II induce pERK via cGnRH-R-I and cGnRH-R-III in a 
time-dependent manner.  (A-D) COS-7 cells expressing chicken GnRH-R receptors were 
stimulated with 100nM cGnRH-I or GnRH-II for different periods of time (5-30mins) or left 
un-stimulated as indicated.  Representative western blots of NP40 cell lysates are shown.  
Data from at least three independent experiments performed in triplicate or duplicate (as 
shown above) were quantified (using tERK immunoblot as a loading control) and the mean 
relative level of increase in pERK +/- S.E. is presented graphically below the corresponding 
blot.  The statistical significance of changes in level was calculated by applying a Student’s 
t-test between the non-stimulated and each individual dose stimulated.  Values of p<0.05 are 
represented by an asterisk * and p<0.01 are represented by two asterisks ** and p<0.001 are 
represented by three asterisks ***.  These represent statistically significant differences 
compared to NS control levels. 
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5.4.2. PLC inhibitor (U73122) inhibits cGnRH-I and GnRH-II induced 
inositol phosphate production (at 60 minutes stimulation) but does not 
inhibit ERK activation via cGnRH-R-I and cGnRH-R-III (at 10 minutes 
stimulation) 
COS-7 cells transfected with cGnRH-R-III expression constructs were pre-incubated 
for 45 minutes with 20µM U73122, a specific inhibitor of PLC, prior to stimulation 
with 100nM cGnRH-I for 10 minutes.  Following treatment, pERK levels and 
inositol phosphate production were quantified.  The method used to measure inositol 
phosphate production is only just sensitive enough to detect the response to cGnRH-I 
after 10 minutes stimulation (Fig. 5.3A).  However, there was a significant increase 
(p<0.01) in the production of inositol phosphate after 10 minutes of 10nM and 1µM 
cGnRH-I stimulation (Fig. 5.3A).  The size of the increase in inositol phosphate 
production was small (3.42% at 10nM and 22.01% at 1µM cGnRH-I compared to 
basal).  These data were not sufficient to accurately measure stimulation compared to 
pre-inhibited samples (Fig. 5.3A).  Therefore stimulation with GnRH was prolonged 
to 60 minutes, at which time a clear increase of inositol phosphate production can be 
observed (up to 284% compared to basal) (Fig. 5.3B).  Large significant increases in 
inositol phosphate production were observed in the absence of U73122 after 60 
minutes of 10nM and 1µM cGnRH-I and GnRH-II stimulation (p<0.01) but pre-
incubation with U73122 ‘effectively blocked’ accumulation of inositol phosphate 
production by ~70-80% (Fig. 5.3B).  A significant increase (p<0.05) in inositol 
phosphate production following 10nM and 1µM cGnRH-II stimulation for 60 
minutes was observed in cGnRH-R-III transfected COS-7 cells pre-treated with 
U73122 (Fig. 5.3B), however, the size of the effect is small (28.9% at 10nM and 
18.8% at 1µM cGnRH-II) in comparison to the non-inhibited controls. 
The cell surface expression of cGnRH-R-III following DNA transfection was 
quantified by measuring the maximal specific-binding of His5-D-Tyr6-GnRH-I (Fig. 
5.4A) to ensure that the cells expressed a sufficient amount of receptor to be able to 
measure the stimulation and inhibition.  Quantification of pERK was determined 
(Fig. 5.4B-C) and showed that there is no inhibition of ERK activation in cGnRH-R-
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III transfected cells pre-incubated with U73122 and stimulated with 100nM cGnRH-I 
or 100nM GnRH-II when compared to those that were not pre-incubated with 
U73122.  In the presence of U73122, ERK activation via cGnRH-R-III was 
detectable, on 100nM cGnRH-I (p<0.01) stimulation or 100nM GnRH-II (p<0.01) 
stimulation (Fig. 5.4B-C), suggesting PLC-independent activation of the MAPK 
cascade.      
Figure 5. 3 
 
Fig. 5.3. The effects of PLC inhibitor (U73122), on inositol phosphate production in 
cGnRH-R-III expressing cells.  COS-7 cells were  transfected with cGnRH-R-III 
expression constructs and either incubated for 10 minutes with 20µM U73122 prior to 
stimulation with 100nM cGnRH-I and 100nM cGnRH-II for (A) 10 or (B) 60 minutes or 
directly stimulated without a pre-incubation with U73122.  The amount of inositol phosphate 
production was then quantified and presented as fold over basal level present in non-
stimulated cells.  Data is from a single experiment preformed in triplicate.  The significance 
was calculated by applying a Student’s t-test between the non-stimulated and each individual 
stimulated time point.  Values of p<0.05 are represented by an asterisk * and p<0.01 are 
represented by two asterisks ** and represent statistical significance compared to basal 
controls.  
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Figure 5. 4  
 
Fig. 5.4. Measure of cell surface cGnRH-R-III expression and the effects of PLC 
inhibitor (U73122) on pERK activation in cGnRH-R-III expressing cells.  (A) The 
maximal binding and displacement of His5-D-Tyr6-GnRH-I with 10nM and 1µM cGnRH-I 
or GnRH-II in COS-7 cells expressing cGnRH-R-III.  (B, C)  COS-7 cells were  transfected 
with cGnRH-R-III expression constructs and either incubated for 10 minutes with 20µM 
U73122 prior to stimulation with 100nM cGnRH-I and 100nM cGnRH-II for 10 minutes or 
directly stimulated without a pre-incubation with U73122.  (B) Representative blots of NP40 
cell lysates are shown.  (C) Data presented from one experiment performed in duplicate were 
quantified (using tERK immuno-blot as a loading control) and the mean-fold over control +/- 
S.E. presented graphically below the corresponding blot.  The significance was calculated by 
applying a Student’s t-test between the basal control and each individual stimulated time 
point.  Values of p<0.05 are represented by an asterisk * and p<0.01 are represented by two 
asterisks ** and represent statistical significance compared to basal control. 
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5.4.3. cGnRH-I and GnRH-II induced ERK activation via cGnRH-R-I and 
cGnRH-R-III possibly via a PLC independent and c-Src dependent 
mechanism 
COS-7 cells transfected with cGnRH-R-I and cGnRH-R-III expression constructs 
were pre-incubated for 45 minutes with 20μM U73122, a specific inhibitor of PLC  
and/or 5μM PP2, an inhibitor of the Src family of tyrosine kinases, prior to 
stimulation with 100nM cGnRH-I for 10 minutes.  Following treatment, the ERK 
activation was quantified in the NP40 cell lysates using western blotting.  There was 
no inhibition in ERK activation in cGnRH-R-I (Fig 5.5A) and cGnRH-R-III (Fig. 
5.5B) transfected cells pre-treated with U73122 and stimulated with 100nM cGnRH-
I when compared to those stimulated with 100nM cGnRH-I alone.  Compared to the 
non-stimulated or basal controls, there was a significant (p<0.05 or p<0.01) increase 
in pERK level via cGnRH-R-I (Fig. 5.5A) and via cGnRH-R-III (Fig. 5.5B) in both 
the U73122 pre-inhibited and non-inhibited treatments.  Therefore, despite there 
being an inhibition in inositol phosphate production in cGnRH-R-I and cGnRH-R-III 
transfected cells pre-treated with U73122 and subsequently stimulated for 60 minutes 
(Fig. 5.3), the pERK activated on 10 minute stimulation via cGnRH-R-I and cGnRH-
R-III transfected cells pre-treated with U73122 was not inhibited.  Interestingly, 
however, compared to the non-stimulated controls, there was no increase in the 
pERK via cGnRH-R-I (Fig. 5.5A) and cGnRH-R-III (Fig 5.6B) in transfected COS-
7cells pre-incubated with PP2.  There was a clear inhibition of ERK activation in 
cGnRH-R-I (Fig. 5.5A) and cGnRH-R-III (Fig. 5.5B) transfected cells pre-treated 
with PP2 when compared to those stimulated with 100nM cGnRH-I alone.  
Therefore, ERK activation via cGnRH-R-I and cGnRH-R-III was inhibited by PP2.   
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Figure 5. 5  
 
Fig. 5.5.  The effects of PLC inhibitor (U73122) and c-Src inhibitor (PP2) on levels of 
pERK in (A) cGnRH-R-I and (B) cGnRH-R-III expressing cells.  Data presented from 
four experiments performed in duplicate were quantified (using tERK immunoblot as a 
loading control) and the mean-fold elevation compared to control +/- S.E.  The significance 
was calculated by applying a Student’s t-test between the basal control and each individual 
stimulated time point.  Values of p<0.05 are represented by an asterisk * and p<0.01 are 
represented by two asterisks ** and represent statistical significance compared to basal 
control. 
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5.4.4. Mutagenesis of the cGnRH-R-III SH3 binding motifs does not alter 
cGnRH-I induced pERK activation 
Synthesis of cGnRH-R-III SH3 binding motif mutants in pcDNA 3.1/myc-His-A 
vector was performed as described in the methods section Chapter 2-2.20.  The 
sequence of the SH3 binding motif mutants, i.e. mutagenesis of the target proline (P) 
codon to an alanine (A) codon was confirmed by DNA sequencing.  The expression 
construct contained the exact sequence of the original cGnRH-R-III_1210f-3217r-
pCDNA3.1/myc-His-A DNA but with the targeted mutated residues.  No random 
mutations were generated during the reaction.  A schematic representation of the 
cGnRH-R-III SH3 binding motif mutants, P317A-cGnRH-R-III, P319A-cGnRH-R-
III and P346A-cGnRH-R-III is presented (Fig.5.6). 
 
Figure 5. 6 
 
 
Fig. 5.6. Illustration of the cGnRH-R-III SH3 binding motif mutants.  (A) The 
cytoplasmic-terminal tails of cGnRH-R-I (grey text) and cGnRH-R-III (coloured text), 
indicating that the putative SH3 binding motif in the cytoplasmic-tail of cGnRH-R-III (red 
text = small and hydrophobic, blue = acidic, magenta = basic, green = hydroxyl + amine + 
basic).  (B) The putative SH3 binding motifs.  (C)  The SH3 binding motifs, P317A-cGnRH-
R-III, P319A-cGnRH-R-III and P346A-cGnRH-R-III mutated by site directed mutagenesis, 
by substituting the proline (P) residue (red text) with an alanine (A) residue (black text). 
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No reduction or increase in the maximum His5-D-Tyr6-GnRH-I binding of P317A-
cGnRH-R-III, P319A-cGnRH-R-III and P346A-cGnRH-R-III was observed when 
compared to the native cGnRH-R-III (Fig. 5.7A-B).  Although a full displacement 
curve was not generated, the binding affinity can be assumed to be similar for 
P317A-cGnRH-R-III, P319A-cGnRH-R-III and P346A-cGnRH-R-III when 
compared to cGnRH-R-III as no difference in the displacement of 125I-[His5-D-Tyr6]-
GnRH-I with 10nM and 1µM cGnRH-I (Fig. 5.7A) or GnRH-II (Fig. 5.7B) was 
observed between receptor constructs.  In accordance with observed higher ligand-
binding affinity for GnRH-II compared to cGnRH-I at cGnRH-R-III (Chapter 4-
Fig.4.1), the displacement of 125I-[His5-D-Tyr6]-GnRH-I with 10nM and 1µM 
GnRH-II (Fig. 5.7B) was greater than that of 10nM and 1µM cGnRH-I (Fig. 5.9A) 
for all cGnRH-R-III SH3 binding motif mutants. 
There were no significant differences between the maximal cGnRH-I induced pERK 
activation in the individual cGnRH-R-III SH3 binding motifs mutants (P317A-
cGnRH-R-III, P319A-cGnRH-R-III and P346A-cGnRH-R-III) when compared to 
the native cGnRH-R-III at either 5 or 10 minute time-points.  The data (Fig. 5.8A-B) 
are calculated as a fold response over non-stimulated pERK levels for each receptor 
construct transfected (Fig. 5.8B).   
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Figure 5. 7  
 
Fig. 5.7.  Mutagenesis of the individual SH3 binding motifs of cGnRH-R-III does not 
alter the cell surface receptor expression.  Competitive displacement of 125I-[His5-D-Tyr6]-
GnRH with 10nM and 1µM of (A) cGnRH-I (B) and GnRH-II in COS-7 cells transiently 
transfected with cGnRH-R-III and SH3 binding motif mutants; P317A-cGnRH-R-II, P319A-
cGnRH-R-III and P346A-cGnRH-R-III. The data presented is from three independent 
experiments each performed in triplicate. 
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Figure 5. 8  
 
 
Fig. 5.8.  Mutagenesis of the individual SH3 binding motifs of cGnRH-R-III does not 
alter cGnRH-I induced pERK activation.  COS-7 cells expressing native chicken GnRH-
R receptors or cGnRH-R-III SH3 binding motif mutants (P317A-cGnRH-R-III, P319A-
cGnRH-R-III and P346A-cGnRH-R-III) were stimulated with 100nM cGnRH-I for 5 and 10 
minutes or left non-stimulated as indicated.  (A) Representative blots of the NP40 cell lysates 
are shown.  (B) Data from at least three independent experiments performed in duplicate 
were quantified (using tERK immunoblot as a loading control) and a graph depicting the 
mean-fold over control +/- S.E. is presented below the blots.  The statistical significance was 
calculated by applying a Student’s t-test between cGnRH-R-I, P317A-cGnRH-R-III, P319A-
cGnRH-R-III and P346A-cGnRH-R-III versus the native cGnRH-R-III at each specific time 
point (5 and 10 minutes).  No statistical significant differences were detected. 
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5.4.5. Analysis of protein-protein interactions made by cGnRH-R-III or 
cGnRH-R-I 
The sequences of the HA epitope-tagged cGnRH-R-I and cGnRH-R-III expression 
constructs generated as described in methods section (Chapter 2: 2.20) were 
confirmed by automated DNA sequencing and restriction enzyme digest.  The 
expression construct contained the entire coding sequence and included a nucleotide 
sequence encoding a Kozak translation initiation sequence (GTT ATG) and a 
Hemagglutinin (HA) epitope-tag (TAT CCT TAT GAT GTT CCC AAC TAT GCT) 
immediately upstream of the usual receptor start codon through to the stop codon of 
either cGnRH-R-I or cGnRH-R-III cDNA sequences (Fig. 5. 9).   
 
Critically for comparative studies, both HA epitope-tagged cGnRH receptors showed 
similar maximum binding (Fig. 5.10A-B), indicating that the HA epitope-tagged 
cGnRH-R receptors exhibit cell surface expression comparable with native cGnRH 
receptors.  The binding affinity (measured as IC50) of GnRH II for HA-cGnRH-R-I 
and HA-cGnRH-R-III were 0.43nM and 0.25nM respectively.  Thus ligand-binding 
selectivity at HA-cGnRH-R-I and HA-cGnRH-R-III are comparable with those of 
the native cGnRH receptor homologs in respect to GnRH-II (Chapter 4-Table 4.2). 
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Figure 5. 9  
 
Fig. 5.9.  Schematic representation of the construction of HA epitope-tagged cGnRH-R-
I and cGnRH-R-III pcDNA 3.3 vector.  (A) The pcDNA 3.3 vector.  (B) The features of 
the pcDNA 3.3 vector (C) The cGnRH-R-I  cDNA sequence, and (D), the cGnRH-R-III 
amplified with HA-tag primers (Table 2.1) The primer sequences used to amplify the 
original cDNA  insert are annotated in bold, inclusive of the Kozak consensus (bold) and the 
HA epitope-tag (bold and underlined).  The usual receptor translation start site (56-58bp) and 
the transcription termination site (1315-1318) are indicated in bold italics.  (D)  The 
restriction enzyme sites used to validate the integrity of the construct cloned by inserting the 
cGnRH-R-I or cGnRH-R-III epitope-tagged insert into the pre-linearised pcDNA3.3 vector.  
The base pair cut positions refer to the insert sequence.   
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Figure 5. 10 
 
Fig. 5.10.  HA-cGnRH-R-I and HA-cGnRH-R-III have similar cell surface expression 
to native cGnRH-R-I and cGnRH-R-III.  Competitive displacement of 125I-[His5-D-Tyr6]-
GnRH-I with serial dilutions (10-11M to 10-5M) of GnRH-II in COS-7 cells transiently 
transfected with (A) HA-cGnRH-R-I (filled columns) and (B) HA-cGnRH-R-III (filled 
colums) expression constructs.  (A,B) The maximal binding of the native cGnRH-R-I and 
cGnRH-R-III (checkered filled columns) is used as a measure of expression at the cell 
surface.  The data presented is from one experiment performed in triplicate.   
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Attempts were made to optimise the immuno-precipitation of HA-GnRH-R-I and 
HA-cGnRH-R-III.  It was possible to immuno-precipitate a human HA epitope-
tagged GnRH-R construct (HA-hGnRH-R), although detection of HA-cGnRH-R-I 
and HA-cGnRH-R-III was not apparent (Fig. 5.11).  The HA-hGnRH-R construct 
was kindly provided by Dr R. Forfar, MRC, HRSU, Edinburgh, for use as a positive 
control.  In an attempt to verify the translation of the HA coding sequence of the 
chicken GnRH receptors, an immuno-blot was performed on NP40 cells lysates with 
anti-HA 3F10 antibody.  However, due to the excessive number of bands 
representing non-specific binding of the antibody to the solubilised cell lysates, it 
was not possible to detect specific bands representing HA protein (data not shown).  
An anti-cGnRH-R-III antibody was kindly provided by Prof. G. Bedecarrats, 
University of Guelph as part of collaborative work to validate the antibody and to 
detect expression of the cGnRH-R-III splice variants (Chapter 3).  Detection of 
cGnRH-R-III in NP40 cell lysates of transiently transfected COS-7 cells expressing 
cGnRH-R-III by immuno-blotting with this anti-cGnRH-R-III antibody yielded three 
bands for both cGnRH-R-III and HA-cGnRH-R-III at approximately 40-45 
kiloDaltons (Fig 5.12). 
Attempts to immuno-precipitate the cGnRH-R-III and HA-cGnRH-R-III proteins 
produced by transient transfection of COS-7 cells using anti-cGnRH-R-III followed 
by immuno-blotting with either anti-cGnRH-R-III or anti-HA 3F10 yielded 
numerous non-specific bands (data not shown).   
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Figure 5. 11  
 
Fig. 5.11. Immuno-blot of HA epitope-tagged GnRH receptors immuno-precipitated 
with anti-HA-3F10.  COS-7 cells were transiently transfected with HA epitope-tagged 
GnRH receptors and precipitated from NP40 solubilised cell lysates.  The presence of the 
receptor in the precipitate was analysed using immuno-blotting with anti-HA-12CA5 
antibody.   1 = HA-cGnRH-R-I, 2 = HA-cGnRH-R-III, 3 = HA-hGnRH-R, 4 = cGnRH-R-
III, 5 = Non-transfected control (NTC).  Bracket indicates receptor tagged protein.   
 
Figure 5. 12 
 
Fig 5.12. Immuno-blot of NP40 cell lysates of transiently transfected COS-7 cells 
expressing GnRH receptors.  COS-7 cells were transiently transfected with HA epitope-
tagged cGnRH receptor or un-tagged cGnRH receptor constructs and NP40 solubilised cell 
lysates prepared as described in the methods section 2.22.  The presence of the receptor 
proteins in solubilised NP40 cell lysates was analysed using immuno-blotting with anti-HA-
12CA5 (green) and anti-cGnRH-R-III antibody (red).  1 = cGnRH-R-I, 2 = cGnRH-R-III, 3 
= HA-cGnRH-R-I, 4 = HA-cGnRH-R-III, 5 = HA-hGnRH-R, 6 = Non-transfected control 
(NTC).  Arrowed brackets indicate detection of cGnRH-R-III tagged protein. 
 
The membrane localisation of cGnRH-R-III and HA-cGnRH-R-III protein was 
quantified by isolating the membranes of COS-7 cells expressing cGnRH-R-III in 
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parallel with radioligand binding assays.  Receptor expression detected by 
quantifying the maximal binding of His5-D-Tyr6-GnRH-I in whole cell radioligand 
binding assays showed that equal amounts of either cGnRH-R-III protein was 
expressed.  However, the immuno-blots (Fig. 5.13 and Fig. 5.14) showed detection 
of cGnRH-R-III but less protein expression of HA-cGnRH-R-III using anti-cGnRH-
R-III antibody.  HA-cGnRH-R-III was not detectable using anti-HA 3F10 for 
immuno-blotting, although HA-hGnRH-R was detectable using anti-HA 3F10 for 
immuno-blotting.  Therefore, the number of cGnRH-R-III transfected COS-7 cells 
used to immuno-precipitate the cGnRH-R-III using anti-HA 3F10 antibody was 
increased in subsequent experiments.  Immuno-blotting the immuno-precipitated 
proteins with anti-cGnRH-R-III indicated 3 bands specific for cGnRH-R-III, 
corresponding to a protein of approximately 40-45 kiloDaltons (Fig 5.15.A-B).  
However, immuno-blotting the immuno-precipitated samples with anti HA-3F10 
yielded a number of non-specific bands (data not shown).   
 
Figure 5. 13 
 
Fig 5.13. Immuno-blot of cell membrane proteins from transiently transfected COS-7 
cells expressing GnRH receptors.  COS-7 cells were transiently transfected with HA 
epitope-tagged and native GnRH receptors and the membranes isolated by high speed 
centrifugation.  The presence of the GnRH receptors in the isolated membranes was analysed 
using immuno-blotting with anti-HA-12CA5 (green) and anti-cGnRH-R-III anti-body (red).  
1 = HA-cGnRH-R-I, 2 = HA-cGnRH-R-III, 3 = HA-hGnRH-R, 4 = cGnRH-R-III, 5 = Non-
transfected control (NTC).  Arrowed brackets indicate GnRH-R protein.   
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Figure 5. 14 
 
Fig 5.14. Immuno-blot of cell membrane proteins from transiently transfected COS-7 
cells expressing GnRH receptors.  COS-7 cells were transiently transfected with HA 
epitope-tagged and native GnRH receptors and the membranes isolated by high speed 
centrifugation.  The presence of the GnRH receptors in the isolated membranes was analysed 
using immuno-blotting with anti-cGnRH-R-III anti-body (red).  1 = cGnRH-R-I, 2 = 
cGnRH-R-III, 3 = HA-cGnRH-R-I, 4 = HA-cGnRH-R-III, 5 = HA-hGnRH-R, 6 = Non-
transfected control (NTC).  Arrowed brackets indicate cGnRH-R-III protein.   
 
Figure 5. 15 
 
Fig. 5.15. Immuno-blot of HA epitope-tagged GnRH receptors immuno-precipitated 
with anti-HA-3F10. COS-7 cells were transiently transfected with HA epitope-tagged 
GnRH receptors and precipitated from NP40 solubilised cell lysates.  The presence of the 
receptor in the precipitate was analysed using immuno-blotting with anti-cGnRH-R-III anti-
body (red). 1 = HA-cGnRH-R-I, 2 = HA-cGnRH-R-III, 3 = Non-transfected control (NTC).  
Brackets indicate cGnRH-R-III protein.  (A,B) represent two occasions illustrating different 
intensities of cGnRH-R-III protein. 




cGnRH-I and GnRH-II stimulate inositol phosphate production in COS-7 cells 
expressing cGnRH-R-I and cGnRH-R-III (Chapter 4 - Fig. 4.1B) (Joseph et al., 
2009; Shimizu and Bedecarrats, 2006; Sun et al., 2001b).  Since inositol phosphate 
and DAG are generated by the recruitment of the Gαq protein and subsequent 
activation of PLC-ß (Ruf et al., 2003; Stojilkovic et al., 1994), cGnRH-R-III and 
cGnRH-R-I can activate the Ca2+ and PKC signalling pathways which are the 
predominant physiological mediators of LH and FSH biosynthesis and secretion 
(Conn and Crowley, 1994; Sealfon et al., 1997).  cAMP and PKC activation and Ca2+ 
are involved in the regulation of cGnRH-I induced LH secretion from chicken 
pituitary gonadotrophs (Bonney and Cunningham, 1977a; Bonney and Cunningham, 
1977b; Davidson et al., 1987a; Davidson et al., 1987b; Johnson and Tilly, 1991; 
Luck and Scanes, 1980).  However it was also shown that increases in intracellular 
Ca2+ is sufficient for secretion of stored LH, whilst elevated cyclic cAMP is not 
essential for LH secretion and PKC activates a variety of signalling molecules 
(Johnson and Tilly, 1991).  The downstream signal transduction of Ca2+ and PKC 
and the factors translocated to the nucleus with subsequent transcriptional regulation 
of gonadotrophins in the chicken remain to be elucidated.  GnRH release is probably 
pulsatile in birds and, in support of this view, chicken plasma LH levels are 
episodically modulated (Senthilkumaran et al., 2006; Vizcarra et al., 2004).  
Additionally, downstream signalling may be involved in sustaining LH production to 
meet the demands of pulsatile secretion.  As PKC and Ca2+ mediate the activation of 
the MAPK cascade in pituitary gonadotrophs, (Dobkin-Bekman et al., 2006; Naor et 
al., 2000) it is feasible that the transcriptional regulation of the gonadotrophins in the 
chicken is mediated by the MAPK cascade and modulated via the type I and/or the 
type III cGnRH receptors.  Research into signalling through the MAPK cascade via 
the chicken GnRH receptors subtypes has not been investigated to date but it may be 
expected to be similar to what has been established in mammals but perhaps with 
some species-specific differences.  Three putative SH3 binding motifs were 
identified in the cytoplasmic C-terminal tail of cGnRH-R-III (Chapter 3), and it was 
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hypothesized that the type III GnRH receptor may differentially interact with SH3 
domain-containing proteins through the SH3 binding motifs.   In an attempt to 
elucidate the physiological roles of the receptor subtypes and attribute a differential 
functional capacity to cGnRH-R-III, the affects of the SH3 binding motifs in terms of 
activation of the MAPK signalling cascade were investigated in this chapter. 
 
COS-7 cells do not endogenously express GnRH receptors and vehicle or GnRH 
treatment of non-transfected COS-7 cells did not affect levels of pERK (data not 
shown).  Dose responses and time-dependent responses to cGnRH-I and GnRH-II 
were quantified in cGnRH-R-I and cGnRH-R-III expressing COS-7 cells to elucidate 
whether there were any differences in pERK activation via the two cGnRH receptor 
subtypes.  The dose response of cGnRH-I and GnRH-II induced pERK activation via 
cGnRH-R-I and cGnRH-R-III clearly indicate that an increase in concentration of 
either cGnRH-I or GnRH-II results in an increase of the pERK activated by both 
cGnRH-I and cGnRH-R-III (Fig. 5.1A-D).  cGnRH-I and GnRH-II induced pERK 
activation via cGnRH-R-I and cGnRH-R-III in a time-dependent manner with a 
maximal response observed at 15 minutes of stimulation (Fig. 5.2A-D).  There is a 
clear decrease in pERK activation when cGnRH-R-I and cGnRH-R-III are stimulated 
with cGnRH-I and GnRH-II for 30 minutes when compared to the 15 minute 
stimulation (Fig. 5.2A-D).  Both cGnRH-I and GnRH-II treatment resulted in pERK 
activation via cGnRH-R-I and cGnRH-R-III in a similar dose (Fig. 5.1A-D) and time 
(Fig. 5.2A-D) dependent manner despite the presence of three putative SH3 binding 
motifs identified in the cytoplasmic C-terminal tail of cGnRH-R-III.  However, the G 
protein dependent activation of the MAPK cascade via PKC may mask any 
differences in Src mediated MAPK signalling via cGnRH-R-I and cGnRH-R-III or 
the effects elicited by SH3 domain binding proteins as previously suggested in a 
comparison between type I and type II GnRH receptors in which effects of β-arrestin 
mediated MAPK signalling were investigated (McArdle et al., 2002; Miller et al., 
2000).  Additionally, GnRH receptors interact with multiple G proteins in a ‘cell-
context’ dependent manner and may form different signal transduction protein 
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complexes in these cell types (Dobkin-Bekman et al., 2006), as shown in studies 
where GnRH stimulated ERK activation is dependent on PKC, c-Src, dynamin, RAS 
and Ca2+ influx (Benard et al., 2001), or dependent on FAK and c-Src at focal 
adhesion complexes (integrins) mediated by Rac (Davidson et al., 2004) or 
alternatively activation of the EGFR resulting in c-Src activation and subsequent 
ERK activation mediated by Ras (Kraus et al., 2003).  The existence of multiple and 
different MAPK protein complexes reflect properties of different cell types, gene 
promoters, species-specific effects and differences in cell culture conditions 
(Dobkin-Bekman et al., 2006; Karnoub and Weinberg, 2008; Naor, 2009; Omerovic 
et al., 2007).  Perhaps therefore, it is necessary to compare the mechanism by which 
cGnRH-R-I and cGnRH-R-III signal to the MAPK cascade in more detail, prior to 
comparing the level of pERK activation elicited by the two receptors, as the two 
receptors may induce similar overall pERK activation, but they may signal to the 
MAPK cascade through different protein complexes.  It is feasible that multiple and 
different MAPK protein complexes may couple to the two receptors resulting in 
pERK activation.  The type III cGnRH-R may for instance predominantly signal 
through a protein complex which involves c-Src.  
 
Therefore in an attempt to elucidate the process mediating pERK activation via 
cGnRH-R-I and cGnRH-R-III in COS-7 cells, the effects on pERK activation during 
inhibition of PLC and c-Src were investigated.  In pituitary gonadotrophs a 
consensus signalling mechanism has emerged which activates the MAPK cascade, 
with Gαq activating PLC which generates DAG and IP3 which subsequently activate 
PKC and Ca2+ mobilisation, resulting in activation of ERK, JNK, and p38 (Dobkin-
Bekman et al., 2006; Naor et al., 2000).  Therefore, determining the dependency on 
PLC of the two cGnRH-Rs may inform on the Gαq dependency of ERK activation 
via the two cGnRH-Rs.  Dependency on c-Src was also investigated, as it was 
anticipated that the two cGnRH receptors may mediate pERK activation through 
different second messenger pathways due to the SH3 binding motifs identified in the 
type III GnRH receptor which may differentially interact with SH3 domain-
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containing proteins.  Activation of the MAPK cascade is often dependent on c-Src 
interactions (Benard et al., 2001; Davidson et al., 2004; Gutkind, 1998; Kraus et al., 
2003; Levi et al., 1998; Luttrell et al., 1999).  PKC activated via Gαq can modulate 
the activity of non-receptor PTKs e.g. c-Src family kinases (Levi et al., 1998).  In 
αT3-1, HEK293 and COS-7 cells GnRH stimulated ERK activation is c-Src 
dependent along with other second messengers (Benard et al., 2001; Davidson et al., 
2004; Kraus et al., 2003).  In αT3-1, JNK activation is also shown to be c-Src 
dependent (Levi et al., 1998).  Therefore, determination of the dependency on c-Src, 
may potentially elaborate the function of the SH3 binding motifs in cGnRH-R-III.   
 
Validation of the PLC inhibitor (U73122) action was performed by demonstrating 
that pre-incubation with U73122 effectively blocked accumulation of inositol 
phosphate production on 60 minutes of GnRH stimulation (Fig. 5.3A-B).  Although 
the subsequent stimulations with cGnRH-I and GnRH-II to detect pERK activation 
were for 10 minutes in duration, stimulations required to measure inositol phosphate 
production were prolonged to 60 minutes (Fig. 5.3B) to clearly demonstrate an 
inhibition of inositol phosphate production.  There was a clear increase in inositol 
phosphate production in response to cGnRH-I and GnRH-II via cGnRH-R-III when 
compared to the U73122 treated cGnRH-R-III transfected cells (Fig. 5.3B).  The 
results demonstrate that despite an inhibition in inositol phosphate accumulation with 
U73122 with 60 minute GnRH stimulation (Fig. 5.3B) there was no inhibition of 
pERK activation via cGnRH-R-III and cGnRH-R-I in response to cGnRH-I and 
GnRH-II (10 minute stimulations) (Fig. 5.4B-C and Fig. 5.5A-B).  This suggested 
that cGnRH-I and GnRH-II induced pERK via cGnRH-R-I and cGnRH-R-III 
independently of PLC.  However, there was a small but significant increase (p<0.05) 
in the accumulation of inositol phosphate production in response to GnRH-II 
stimulation via cGnRH-R-III transfected cells that were pre-treated with U73122 
(Fig. 5.3B).  Therefore, 20µM U73122 does not completely inhibit PLC.  
Addtionally, the effects of U73122 inhibitor on PLC were only shown on 60 minutes 
of GnRH stimulation by measuring the production of inositol phosphate, whereas the 
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pERK was quantified on 10 minutes of GnRH stimulation.  Therefore, the PLC 
inhibitor has not been shown to inhibit PLC in the time frame used for the pERK 
experiments.  The effects of PLC inhibitor were compared alongside the effects of c-
Src inhibition on GnRH-I induced pERK activation via cGnRH-R-I (Fig 5.5A) and 
cGnRH-R-III (Fig. 5.5B).  The results confirm previous observations (Fig 5.4B-C) 
demonstrating that cGnRH-I induced pERK activation via cGnRH-R-I and cGnRH-
R-III may be PLC independent.  The cGnRH-I induced pERK activation via cGnRH-
R-I and cGnRH-R-IIII is c-Src dependent (Fig. 5.5A-B).  Gαq coupling primarily 
activates PLC which produces IP3 which induces Ca2+ and DAG (Naor et al., 2000).  
As PLC and hence IP3, Ca2+ and DAG are may not be not essential for pERK 
activation (Fig. 5.4B-C and 5.5A-B), the possible signal transduction mechanisms 
discussed thus far in GPCRs may not apply.  These include mediation through (1) the 
free Ca2+ activating CaM kinase II which phosphorylates and inhibits RAS-GTPase-
activating protein (RAS-GAP) inducing RAS and subsequently MAPK activation 
(Chen et al., 1998).  (2)  Ca2+ and DAG activated PKC or through Ca2+/RAS-GEF 
and RAS activation leading to MAPK activation (Farnsworth et al., 1995; Naor et al., 
2000; Nishizuka, 1992) (3) PKC activating c-RAF which is partially dependent on 
RAS resulting in stimulation of the ERK cascade (Kolch et al., 1993) (4) Ca2+ and 
PKC inducing activation of PTK (Zhang et al., 1996) which possibly facilitated by 
integrin interaction leads to MAPK activation (Naor et al., 2000).  However, both 
receptors are coupled to Gαq (Chapter 4 - Fig. 4.1B) (Joseph et al., 2009; Shimizu 
and Bedecarrats, 2006; Sun et al., 2001b) and possibly GαS (Shimizu M et al., 
2008).  GnRH induced pERK activation via cGnRH-R-I and cGnRH-R-III may be 
mediated by either G protein or the Gβγ complexes which can signal through PI3K to 
activate the MAPK cascade (Naor et al., 2000).  Additionally, there may be residual 
PLC activity, as inositol phosphate production was not completely inhibited by 
application if PLC inhibitor (U73122) (Fig. 5.3B).  Furthermore, pERK activation 
via cGnRH-R-I and cGnRH-R-III may be facilitated by other signalling components 
of the cGnRH-R-I and cGnRH-R-III signalling complex (Karnoub and Weinberg, 
2008).  pERK activation via cGnRH-R-I and cGnRH-R-III may be similar to the 
JNK activation observed in rat pituitary cultures, where it was shown to be PKC 
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independent and dependent on Ca2+ mobilisation (Mulvaney and Roberson, 2000; 
Mulvaney et al., 1999).  As pERK activation via the two cGnRH receptors, is c-Src 
dependent (Fig 5.5A-B), it is more likely that the pERK activation via the two 
receptors is mediated in a fashion similar to HEK293 cells, where GnRH stimulation 
of GnRH receptor expressing cells results in ERK activation dependent on FAK and 
c-Src at focal adhesion complexes (intergrins) mediated by Rac (Davidson et al., 
2004).  Although, in COS-7 cells, Gαi affects EGFR, resulting in c-Src activation and 
subsequent ERK activation mediated by Ras and JNK activation mediated by PI3K 
(Kraus et al., 2003).  This mechanism may possibly involve Gαq or Gαs coupling and 
may also be the mechanism in which the cGnRH-R-III mediates pERK activation.  
Or additionally, as in DU-145 cells, GnRH activation of ERK may involve, c-Src and 
EGFR trans-activation, which is mediated by the shedding of the heparin binding-
EGF (HB-EGF) (Kraus et al., 2004). 
 
As no receptor-subtype-specific differences in pERK activation were detected in 
terms of dose-response (Fig. 5.1), or time-course (Fig5.2), or inhibitor-probed 
mechanisms (Fig. 5.5), it was necessary to investigate the influence of SH3 binding 
motifs to further test the hypothesis that cGnRH-R-III has an additional capacity to 
signal through the MAPK signalling cascade through a direct interaction involving 
putative SH3 binding motifs (Chapter 3).  Therefore mutagenesis of the SH3 
binding motifs in the cGnRH-R-III cDNA receptor construct was performed to 
enable in-vitro studies (Fig 5.6).  The SH3 binding motif mutants, P317A-cGnRH-R-
III, P319A-cGnRH-R-III and P346A-cGnRH-R-III expressed in transfected COS-7 
cells were compared, and the results showed that there are no changes in the maximal 
binding of His5-D-Tyr6-GnRH-I displacement with cGnRH-I and GnRH-II between 
the SH3 binding motif mutants and the native cGnRH-R-III (Fig. 5.7A-B).  This 
demonstrated that the mutations did not alter the cell surface expression of the 
receptor.  The displacement of His5-D-Tyr6-GnRH-I with 10nM and 1µM cGnRH-I 
and cGnRH-II demonstrate that the ligands have the same affinity to P317A-cGnRH-
R-III, P319A-cGnRH-R-III, P346A-cGnRH-R-III compared to cGnRH-R-III (which 
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was as previously determined Chapter 4-Fig. 4.1).  The features of pERK activation 
via P317A-cGnRH-R-III, P319A-cGnRH-R-III and P346A-cGnRH-R-III in response 
to cGnRH-I and GnRH-II were similar to both the native cGnRH-R-III and cGnRH-
R-I (Fig 5.8A-B).  Therefore, there appears to be no additional pERK activation via 
cGnRH-R-III as a result of direct coupling through the SH3 binding motifs.  
Capacity for further increases in pERK levels are possible in the COS-7 cell assay, as 
the maximum pERK levels in COS-7 cells transiently transfected with cGnRH-R 
constructs has been observed as high as 12 fold when compared to basal (data not 
shown).  Therefore, the pERK assay did not obtain the maximum pERK levels 
feasible such that enhanced pERK activation would be detected if present.  However, 
G protein dependent activation of the MAPK cascade may mask any differences in c-
Src mediated MAPK signalling via cGnRH-R-I and cGnRH-R-III involving the SH3 
binding motif mutants. 
 
Therefore testing the hypothesis that cGnRH-III directly interacts with c-Src through 
the SH3 binding motifs was investigated.  In order to test this hypothesis, the 
cGnRH-R-I and cGnRH-R-III receptor cDNA constructs were modified to encode an 
HA epitope-tag that would facilitate the immuno-precipitation of the receptors (Fig 
5.9) and the protein complexes which they form.  The HA epitope-tagged receptors 
did not exhibit any differences in receptor expression (Fig 5.10) in comparison with 
native cGnRH-R-I and cGnRH-R-III transfected cells (Chapter 4 and Fig 5.7).  
Additionally the ligand-binding selectivity at HA cGnRH-R-I and cGnRH-R-III (Fig 
5.10) was comparable with that of the native cGnRH receptor homologs (Chapter 4- 
Table 4.1) in response to GnRH-II. 
 
Initial attempts to immuno-precipitate the HA epitope-tagged chicken type I and type 
III GnRH receptors were unsuccessful despite the successful immuno-precipitation   
of a human HA epitope-tagged GnRH receptor used as a positive control (Fig. 5.11).  
This suggested that the methodology used was optimal for immuno-precipitation of 
the GnRH receptors, whilst the HA epitope-tag of the chicken GnRH receptors may 
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not have been efficiently translated.  Using the anti-cGnRH-R-III antibody to 
immuno-blot NP40 cell lysates (Fig. 5.12), demonstrated that it is possible to detect 
the HA-cGnRH-R-III protein.  In an attempt to enrich the HA-cGnRH-R-I and HA-
cGnRH-R-III proteins, cell membranes were prepared by high speed centrifugation 
and immuno-blotted with anti-HA 3F10 and anti-cGnRH-R-III antibodies (Fig. 5.13 
& 5.14).  The detection of HA-hGnRH-R in enriched cell membrane protein 
samples, with anti-HA 3F10 antibody but not HA-cGnRH-R-I or HA-cGnRH-R-III 
(Fig. 5.13) indicated that the HA-epitope-tag of the chicken cDNA constructs was 
not being translated.  However, the detection of cGnRH-R-III compared to HA-
cGnRH-R-III in the cell membrane samples with anti-cGnRH-R-III antibody 
demonstrated that the HA-cGnRH-R-III protein was being translated but less protein 
was detectable when compared to the un-tagged construct.  This observation did not 
correlate with the radioligand binding data, which showed that equal amounts of 
“tagged” and un-tagged receptors were being expressed in the transfected COS-7 
cells (Fig 5.10), suggesting that the two proteins were being expressed (HA-cGnRH-
R-III and cGnRH-R-III).  This is possibly due to the design of the N-terminal HA-
cGnRH-R-I and HA-cGnRH-R-III constructs (Fig 5.9C-D), where a Kozak 
translation start consensus and HA-epitope-tagged are inserted upstream and in 
addition to the usual translational start site of the cDNA encoding cGnRH-R-I and 
cGnRH-R-III.  This would allow alternate translation from either the Kozak 
consensus or the physiological translational start site.  Therefore to further facilitate 
the detection of HA-cGnRH-R-III, the number of cells transfected was increased 
prior to immuno-precipitation with anti HA-3f10 antibody and immuno-blotting with 
anti-cGnRH-R-III antibody (Fig. 5.15).  Subsequently, several size forms of each 
HA-tagged receptor were detectable, allowing the composition of the cGnRH-R-III 
immuno-precipitate to be analysed in detail.  However, attempts at detecting the HA-
eptitope tag of both cGnRH-R-I and cGnRH-R-III with anti-HA 3F10 antibody were 
not possible.  Therefore, it was not possible to validate the immuno-precipitation of 
cGnRH-R-I as no anti-cGnRH-R-I antibody is available.  It would therefore be 
impossible to make a complete comparison of the cGnRH-R-I and cGnRH-R-III 
immuno-precipitated protein complexes.  It was concluded that it would be necessary 
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to redesign HA-epitope tagged cGnRH-R-I and cGnRH-R-III constructs, removing 
the physiological translational start site of cGnRH-R-I and cGnRH-R-III cDNAs 
prior to addition of the Kozak consensus and HA-epitope tag to ensure translation of 
only the cGnRH-R constructs encoding the HA-epitope tags.  However, it is also 
possible that there may be a conformational change in the HA epitope tagged 
cGnRH-R proteins once biosynthesised in COS-7 cells that may inhibit binding to 
the anti HA antibody and thereby compromise immuno-precipitation. 
 
In summary, the results of this chapter show that both chicken GnRH receptors 
induce phosphorylation of ERK in a similar manner in response to cGnRH-I and 
GnRH-II despite the three SH3 binding motifs in cGnRH-R-III.   Both cGnRH-Rs 
potentially activate ERK independently of PLC but dependent upon c-Src.  However, 
more research into the mechanism will be necessary, and possible effects of the 
inhibitor should be tested using Ca2+ assays which will enable verification of the 
inhibitor in the same time frame as the pERK experiments.  Mutagenesis of the 
individual SH3 binding motifs of cGnRH-R-III suggested that the SH3 binding 
motifs in cGnRH-R-III do not influence MAPK activation when compared to the 
native cGnRH-R-III in a transient transfection assay.  However, the SH3 binding 
motifs in cGnRH-R-III may recruit other protein-protein complex formations not 
tested in this thesis.  Therefore the SH3 binding motifs identified in cGnRH-R-III 
do not alter ERK activation when compared to cGnRH-R-I.  The signal 
transduction mechanisms leading to ERK activation via cGnRH-R-I and 
cGnRH-R-III are probably similar.  A method has been optimised to facilitate 
the immuno-precipitation of cGnRH-R-I and cGnRH-R-III in order to 
characterise the protein-protein complexes formed by these receptors.  
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5.6. Chapter Summaries   
5.6.1. Cloning, Characterisation and Tissue-Specific Expression of 
Chicken Type III GnRH Receptor 
The data presented in this chapter demonstrates that two GnRH receptor subtypes are 
expressed in the chicken (type I and type III).  This was shown by RT-PCR 
amplification and subsequent cloning and sequencing of the cGnRH-R-III cDNA 
from broiler chicken anterior pituitary glands.  Northern blot analysis indicated a 
single cGnRH-R-III transcript in the anterior pituitary gland, suggesting that the in-
vivo expression of cGnRH-R-III splice variants previously identified by RT-PCR 
(but undetectable by Northern blotting) is relatively low.  cGnRH-R-III was first 
designated as cGNRHR2 (Shimizu and Bedecarrats, 2006), whereas re-designation 
as cGnRH-R-III is more appropriate.  This was demonstrated by phylogenetic 
analysis performed in this chapter.  The type III GnRH receptor gene structure and 
amino acid sequence motifs were compared with cGnRH-R-I and the conservation of 
certain motifs suggests that the two cGnRH-R receptor homologs may have similar 
pharmacological profiles in relation to endogenous cGnRH ligands.  Attempts to 
confirm the cellular localisation of cGnRH-R-III expression within pituitary 
gonadotroph cells using in-situ hybridisation proved unsuccessful.  This may be 
because cGnRH-R-III mRNA is not expressed abundantly enough to be readily 
detected by in-situ hybridisation and it is possible that the cGnRH-R-III mRNA 
transcripts might not be concentrated in one particular subtype of pituitary cells, but 
may be spread over a number of different cell types.  Real-time RT-PCR analysis in 
juvenile and sexually mature male and female broiler chicken tissue samples showed 
that cGnRH-R-III is expressed predominantly in the anterior pituitary gland.  
cGnRH-R-III mRNA expression in the anterior pituitary gland was 92.5 times 
greater than in the testes or ovary.  A quantitative comparison of the expression of 
cGnRH-R-I and cGnRH-R-III demonstrated that the level of expression of cGnRH-
R-III mRNA was greater than cGnRH-R-I mRNA in the median eminence, gonads 
and small intestine, and particularly so in the anterior pituitary where cGnRH-R-III 
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mRAN expression was ~1400 times that of cGnRH-R-I mRNA.  No large 
differences in level of tissue-specific expression were detected for cGnRH-R-I 
mRNA, where expression in the testes and ovary was ~1.4 times greater than in the 
anterior pituitary.  Perhaps the most interesting finding was the detection of a 
pronounced sex and age difference in cGnRH-R-III mRNA expression, with 2.7 fold 
higher pituitary transcript levels in sexually mature females compared to juvenile 
females.  In contrast, 8.4 fold higher expression levels occurred in juvenile males 
compared to sexually mature males.  The higher abundance of expression of cGnRH-
R-III mRNA compared to cGnRH-R-I mRNA, and the correlation of cGnRH-R-III 
mRNA expression levels with reproductive status suggests that cGnRH-R-III is 
probably the major mediator of pituitary gonadotroph function, and that tissue-
specific recruitment of this cGnRH-R isoform has occurred during evolution.     
 
5.6.2. Pharmacological Characterisation of GnRH Agonist and 
Antagonist at Type I and Type III cGnRH Receptors and cGnRH-R-III 
Splice Variants 
The data presented in this chapter included analysis of the in-vitro pharmacological 
properties of cGnRH-R-I and cGnRH-R-III, inclusive of ligand-binding and inositol 
phosphate production in response to endogenous ligands (cGnRH-I and GnRH-II) 
and a panel of GnRH analogs (sGnRH-III, mammalian antagonist 27, 135-18 and 
135-25) in an attempt to identify a GnRH analog that may be applied to examine the 
differential effects of receptor subtypes on gonadotrophin synthesis and release.  The 
results indicated that cGnRH-R-III has a higher ligand-binding affinity for GnRH-II 
than cGnRH-I (IC50: 0.57 v 19.8 nM) and similar results were found for cGnRH-R-I, 
(IC50: 0.51 v 10.8 nM).  In accordance with the ligand-binding selectivity of cGnRH-
R-III, GnRH-II was more potent at stimulating inositol phosphate production at 
cGnRH-R-III than cGnRH-I (EC50: 0.8 v 4.38 nM).  Similar results were found for 
cGnRH-R-I, (EC50: 0.7 v 2.8 nM).  Therefore, cGnRH-R-III, like cGnRH-R-I is 
capable of coupling to the Gαq protein and subsequently activating PLC, which 
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results in the generation of inositol phosphate and diacyl-glycerol, leading to the 
elevation of intracellular Ca2+ and PKC signalling pathways, the predominant 
mediators of LH and FSH biosynthesis.  Mammalian antagonist 27 exhibited a large 
difference in antagonistic potency at cGnRH-R-I (IC50: 2.3 nM) compared to 
cGnRH-R-III (IC50: 351nM).  Therefore, application of this synthetic peptide may 
allow delineation of receptor subtype function in-vitro and in-vivo in order to study 
the physiological role of the chicken type III GnRH receptor.  The effect of the 
cGnRH-R-III splice variants on cGnRH-R-III receptor binding was also examined, 
and the results indicate that cGnRH-R-III_SV2 significantly affects cell surface 
expression of cGnRH-R-III when co-expressed with cGnRH-R-III, inferring that 
cGnRH-R-III splice variants may modulate cGnRH-R-III activity if over-expressed.  
Additionally, the ligand induced internalisation of both receptors was compared and 
results showed that the initial rate of receptor internalisation was faster for cGnRH-
R-III than cGnRH-R-I (26%.min-1 v 15.8%.min-1).  It is possible that the spatial 
arrangement of amino acid residues in the carboxyl-terminal region affected by 8 
additional residues in the carboxyl-terminal tail of cGnRH-R-III may contribute to 
the increased internalisation rate compared to cGnRH-R-I.  Interestingly, cGnRH-I is 
thought to be the hypothalamic peptide responsible for regulating the pituitary 
gonadotroph, however both cGnRH-Rs possess higher ligand selectivity for GnRH-II 
and have a higher potency in inositol phosphate production with GnRH-II than with 
GnRH-I.  These results suggest that evolutionary recruitment of ligand-receptor 
pairing for particular physiological processes does not necessarily correlate with 
ligand-binding affinity or potency of inositol phosphate production.   
 
5.6.3. MAPK Signalling Activated via Type I and Type III cGnRH 
Receptors 
The data presented in this chapter included investigations into whether three putative 
Src homology 3 (SH3) binding motifs present in the cytoplasmic C-terminal tail of 
cGnRH-R-III and not present in cGnRH-R-I may attribute a differential functional 
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capacity to cGnRH-R-III through interaction with SH3 domain-containing proteins.  
It was hypothesized that these motifs may enable differential activation of the MAPK 
signalling cascade.  The results of studies performed in transfected COS-7 cells 
showed a 4-6 fold increase in ERK1/2 phosphorylation following activation of type I 
or type III cGnRH receptors within 10 minutes of cGnRH-I or GnRH-II stimulation, 
indicating that both receptors signal through the MAPK pathway to ERK in a similar 
time-dependent and dose-dependent manner.  In an attempt to identify the protein 
complexes that couple to the two cGnRH receptors and result in MAPK activation, 
studies of the effects of pre-treatment with selected inhibitors were performed.  Pre-
treatment of these cells with phospholipase C (PLC) inhibitor or c-Src inhibitor 
showed that both cGnRH-Rs can activate ERK 1/2 independently of PLC but 
dependently upon c-Src at 10 minites of stimulation.  The influence of SH3 binding 
motifs was analysed by mutagenesis of the SH3 binding motifs in the cGnRH-R-III 
cDNA receptor construct.  Subsequent evaluation of the ERK activation by SH3 
binding motif mutants (P317A-cGnRH-R-III, P319A-cGnRH-R-III and P346A-
cGnRH-R-III) in comparison with the native cGnRH-R-III and cGnRH-R-I was 
performed in transfected COS-7 cells.  The data showed that ERK activation via 
P317A-cGnRH-R-III, P319A-cGnRH-R-III and P346A-cGnRH-R-III in response to 
cGnRH-I and GnRH-II was similar to both the native cGnRH-R-III and to cGnRH-
R-I.  Therefore, there is no evidence of an effect on ERK activation via direct 
coupling through the SH3 binding motifs in cGnRH-R-III.  Characterisation of 
receptor protein-protein complexes isolated by immuno-precipitation of either 
cGnRH-R subtypes was investigated, facilitated by HA epitope-tagging both 
cGnRH-R-I and cGnRH-R-III (HA-cGnRH-R-I and HA-cGnRH-R-III).  Several size 
forms of HA-cGnRH-R-III were detectable by western blotting and the composition 
of the immuno-precipitated protein complexes can be analysed in detail in future 
studies.  The results obtained thus far indicate that the SH3 binding motifs identified 
in cGnRH-R-III do not alter ERK activation and cGnRH-R-III possibly does not 
exert a differential role in the regulation of LH and FSH transcription through the 
differential activation of ERK when compared to cGnRH-R-I.  Other MAPK outputs 
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(p38 and JNK) were not investigated in this chapter and could be the focus of future 
investigations.   
 
5.7. Concluding Discussion 
During evolution GnRH isoforms have either been adopted for specialised 
physiological functions through gene duplication events and selection of certain 
motifs, or their roles have become redundant through residue mutations or deletions 
and subsequent silencing when their functions became redundant, in which case 
certain genes became psuedogenes or were completely lost during evolution (Millar 
et al., 2004; Okubo and Nagahama, 2008).  Vertebrate GnRH-I members vary 
diversely in peptide sequence, particularly in teleost species.  However, mammalian 
GnRH-I peptide is well conserved and is thought to be the ancestral form of GnRH-I 
(Kah et al., 2007; Okubo and Nagahama, 2008).  This is supported by the 
identification of this same peptide in a basal chordate (amphioxus) (Chambery et al., 
2009).  The conservation of mammalian GnRH-I peptide sequence coincides with the 
loss of GnRH-II in several mammalian species.  The pre-pro GnRH-II gene in some 
mammals is functionally compromised, although the retention of large sections of the 
GnRH-II gene in most mammals suggests that mammalian ancestors had a functional 
GnRH-II system (Stewart et al., 2009).  Conversely, the lack of conservation of 
GnRH-I peptide sequence in non-mammalian vertebrates coincides with the retention 
of GnRH-II peptide.  The GnRH-II decapeptide sequence is ubiquitously conserved 
in species from bony fish to humans, representing over 500 million years of 
evolution, suggesting it has an important physiological role (Millar, 2005).  The 
selective pressure to conserve GnRH-II structure in vertebrates has been proposed to 
result from a co-ordinated evolutionary selection of residues required for ligand 
conformation and high affinity binding to the GnRH receptor (Pfleger et al., 2002).  
It is also possible that the GnRH gene which retained its function during evolution 
assumed the functional role of the pseudogene or deleted gene (Kah et al., 2007; 
Okubo and Nagahama, 2008).  Alternatively, evolutionary loss of a GnRH isoform 
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may correlate with loss of functional requirement due to altered reproductive 
physiology.  Of the three distinct paralagous forms of vertebrate GnRH peptides, 
(GnRH-I, GnRH-II and GnRH-III), all three forms co-exist only in species of the 
teleost lineage (Kah et al., 2007).  The conservation of GnRH-III peptide sequence is 
also highly conserved, however, analysis of GnRH gene loci suggest that this gene 
may have been deleted during the early evolution of tetrapods prior to the divergence 
of amphibians, reptiles, aves and mammals (Okubo and Nagahama, 2008).  The 
retention of GnRH-II and GnRH-III may correlate with diverse endocrine functions 
for GnRH (e.g. influences on growth hormone, prolactin and somatolactin 
production) and intra-gonadal functions (Foran and Bass, 1999; Kakizawa et al., 
1997; Marchant et al., 1989; Weber et al., 1997).  This coincides with an 
undeveloped hypophyseal portal system, direct innervation of the different types of 
pituitary gland by GnRH neurons (Oka and Ichikawa, 1990; Peter et al., 1990) and 
the differentiation of pituitary gland gonadotroph cell lineages in these animals.   
 
There appears to be a functional refinement of GnRH peptide action during 
evolution which corresponds with refinement of reproductive strategy 
(development of pituitary, internal fertilisation, less eggs ovulated, investment of 
maternal care).  In this refinement, GnRH forms may have been adopted for 
specialised functions or their roles may have become redundant.  There is a 
correlation between the retention of GnRH peptide isoforms and the occurrence 
of GnRH receptor isoforms.   
 
In some fish up to five GnRH receptors genes are retained in the genome (e.g. masu 
salmon) (Jodo et al., 2005), although only two isoforms of the receptor (type I and 
type III) exist in teleost fish based on phylogenetic analysis.  Interestingly, unlike 
fish, amphibians and reptiles possess all three GnRH receptor isoforms (type I, type 
II and type III), as is seen in the bullfrog and the leopard gecko (Ikemoto and Park, 
2007; Wang et al., 2001a).  Only two receptor isoforms are functional in some 
mammals (type I and type II) (Stewart et al., 2009).  In this thesis, a second GnRH 
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receptor was identified and characterised in the chicken, confirming the existence of 
only two receptors in birds, type I and type III GnRH receptors (Joseph et al., 2009; 
Shimizu and Bedecarrats, 2006).  The organisation of the avian GnRH system is 
distinct in terms of retention of two GnRH ligands (GnRH-I and GnRH-II) and two 
GnRH receptors (GnRH-R-I and GnRH-R-III) (Morgan and Millar, 2004).  The 
GnRH receptors expressed in fish and birds are similar (types I and III only), with 
both lacking a type II GnRH receptor isoform.  Although, fish have three GnRH 
isoforms (GnRH-I, GnRH-II and GnRH-III), birds only have two (GnRH-I and 
GnRH-II).  However, unlike amphibians and reptiles where three GnRH receptors 
exist (type I, type II and type III), birds do not posses the type II GnRH receptor 
isoform.  Birds, amphibians and reptiles have two GnRH isoforms (GnRH-I and 
GnRH-II).  In contrast to mammals, where up to two GnRH ligands and receptor 
isoforms exist (type I and type II), again birds differ in not possessing the type II 
GnRH receptor isoform.  Type II and type III GnRH receptors are thought to have 
arisen by a gene duplication of a common ancestral gene (Ikemoto and Park, 2007; 
Millar, 2003; Millar, 2005), and it has been previously assumed that since only 
teleosts did not express type II receptors, the duplication event occurred after the 
divergence of the teleost and tetrapod lineages.  However, since both birds and fish 
do not possess type II receptors, it is probable that the duplication occurred before 
the split, and that the type II GnRH receptors were lost on separate occasions in both 
birds and fish genomes.  Therefore, studies into the GnRH systems in chickens will 
provide unique information to enable a better comprehension of the interplay 
between ligands and receptors in the control of avian reproduction and how GnRH 
systems evolved to assume their function in modern taxa.  It may also provide 
insights into the evident plasticity in utilisation of a particular GnRH receptor 
in particular tissues.  The approach used in this thesis to investigate this conundrum 
was to try to dissect the cellular and physiological functions of the two GnRH 
receptor subtypes isolated from the chicken (type I and type III). 
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In this thesis, plasticity in the spatiotemporal expression patterns of GnRH receptor 
subtypes was discovered in the chicken, with cGnRH-R-III being expressed 
predominantly in the anterior pituitary gland and with cGnRH-R-III expression being 
~1400 times more abundant than cGnRH-R-I.  Differential gene expression 
suggested that there is likely to have been evolutionary plasticity in pituitary 
utilisation of GnRH receptor subtypes for functional regulation of gonadotrophin 
production.  No developmental or sex-specific differences or changes in expression 
were detected for cGnRH-R-I mRNA; however a pronounced reciprocal sex 
difference in pituitary cGnRH-R-III mRNA expression was detected.  Higher 
cGnRH-R-III mRNA levels occur in adult females compared with adult males.  In 
contrast, in juvenile chickens, higher cGnRH-R-III mRNA levels occurred in males 
compared to females.  These observations lend further support for the existence of 
plasticity in evolutionary recruitment of GnRH receptor subtypes for regulation of 
pituitary gonadotrophin production.  As no differences in ligand selectivity or 
potency in inositol phosphate production were detected between the two receptors in 
response to endogenous ligands, the results of pharmacological profiling suggest that 
receptor ligand selectivity measured in-vitro does not necessarily correlate with the 
in-vivo role of GnRH receptor isoforms nor does it determine the designation of 
‘cognate’ receptors.  Perhaps evolutionary recruitment of ligand-receptor pairing for 
particular physiological processes is not determined by selection according to the 
highest affinity for ligand binding or potency in inositol phosphate production.  Thus 
delineation of ‘cognate’ ligand/receptor pairing requires the assessment of receptor 
protein expression in the target cell and assessment of ligand isoform delivery to that 
cell.  It is plausible that cGnRH-R-III splice variants may modulate cGnRH-R-III 
activity and may be physiological regulators if expressed at sufficient levels, which 
would in turn affect the physiological function of the cGnRH-R-III.  The increased 
internalisation rate of cGnRH-R-III compared to cGnRH-R-I may affect the 
longevity of the signalling cascades activated by cGnRH-R-III, in turn affecting LH 
and FSH gene transcription.   The signal transduction mechanisms leading to ERK 
activation via cGnRH-R-I and cGnRH-R-III are probably similar; therefore the SH3 
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binding motifs identified in cGnRH-R-III do not alter ERK activation when 
compared to cGnRH-R-I.   
 
In comparison with other species, some fish (e.g. catfish), amphibians (e.g. bullfrog 
and African clawed frog) and reptiles (e.g. leopard gecko), the chicken (bird), also 
shows species-specific recruitment of receptor subtypes and ligands within different 
tissues and there is also plasticity in the spatiotemporal expression patterns of GnRH 
receptor subtypes.  Interestingly, the predominant receptor expressed in the pituitary 
of the catfish (Bogerd et al., 2002) is a type I, the African clawed frog (Troskie et al., 
2000) is a type I (Troskie et al., 2000), the bullfrog (Wang et al., 2001a) is a type III 
and in the leopard gecko (Ikemoto and Park, 2007) is a type III.  Despite the three 
GnRH receptor isoforms expressed in the amphibian and reptilian lineages (type I, II 
and III), there is no evidence for specialised recruitment of the type II receptor in the 
regulation of pituitary gonadotroph function.  In contrast, fish and birds do not 
possess type II receptors.  This suggests that type II receptors may have been retained 
for specialised functions in amphibians and reptiles and were not retained in birds or 
fish.  Perhaps more detailed studies of GnRH-peptide hormone and GnRH-receptor 
isoform tissue-specific gene expression patterns can explain why different 
combinations of ligand and receptor have been retained in different vertebrate 
species.  Such studies will require more immunohistochemistry, promoter function 
studies and isolation of clonal immortalised cells from brain and pituitary for 
examination of gene expression patterns in-vitro.   
 
The reproductive physiologies of certain reptiles and birds are quite similar.  They 
both generate a hierarchical order of pre-ovulatory follicles (Ikemoto and Park, 2007; 
Johnson and Leone, 1985).  Interestingly, the leopard gecko (Ikemoto and Park, 
2007) GnRH-I peptide hormone is identical in amino acid sequence to the chicken.  
The striking difference between these two species is the retention of a type II GnRH 
receptor in the reptiles and a loss in the birds, again suggesting the plasticity in 
utilisation of a particular GnRH receptor in a particular tissue.  The type III receptor 
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is expressed exclusively in the anterior pituitary gland of the leopard gecko, and 
quantitative studies showed that the expression decreased by 88% after the egg-
laying season compared to during the egg-laying season (Ikemoto and Park, 2007).  
Similarly like the leopard gecko, in the chicken, the type III GnRH receptor is 
expressed in the anterior pituitary, however, the expression is predominant (~1400 
times more abundant) and coincides with the expression of the type I cGnRH 
receptor.  Although changes  of cGnRH-R-III mRNA were detected in the 
reproductive cycle of the birds, in a sex and age-dependent manner (Joseph et al., 
2009).   All three GnRH receptor forms were localised in the ovary of the leopard 
gecko, and type I GnRH receptor increased by 4 fold after the egg-laying season, 
whereas the other receptors did not show any changes in expression.  Similarly in the 
chicken, there is a ~10 fold higher expression of the type III GnRH receptor in the 
ovary, compared to the type I receptor, however no changes in ovarian expression 
were tested at different physiological stages of the birds.  There is also a distinct 
spatial expression pattern of the GnRH receptors in the ovary of the leopard gecko 
(Ikemoto and Park, 2007) and changes in expression among hierarchical follicles, 
although in this thesis it was not possible to detect cellular expression of cGnRH-R 
subtypes by in-situ hybridisation.  Identifying if there is a direct effect of GnRH on 
the ovary via gonadal GnRH receptors would prove interesting for future studies.  
Developments in the understanding of the GnRH system in the reptile (leopard 
gecko) is more advanced than studies in the chicken thus far, with comparisons 
between ovarian and pituitary GnRH systems established (Ikemoto and Park, 2007).  
Further comparison of the avian and the reptilian GnRH system will provide a key 
understanding of the function of the type I, II and III GnRH receptors.  However, 
more research would be necessary in the chicken in order to compare it with reptilian 
species.  Research would facilitate understanding of the underlying question of the 
GnRH systems in terms of the plasticity in evolutionary recruitment of GnRH 
receptor subtypes for regulation of pituitary gonadotroph function and ovarian 
function and the correlation with reproductive physiologies.  There is also 
promiscuity of receptor subtype activation in-vitro by different endogenous ligands 
and complex in-vivo interplay between ligands and receptors, which needs to be 
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considered, keeping in mind the potency of the ligands on the receptor subtypes and 
delivery of appropriate forms of GnRH isoforms to the target cells.   
 
5.8. Future Work 
5.8.1. Dissecting the cellular and physiological functions of cGnRH-R-I 
and cGnRH-R-III 
Key to the understanding of the differential functional capacity of the two GnRH 
receptor isoforms is the characterisation of the receptor isoforms in different cell 
types, both in the pituitary and in the ovary.  This will provide evidence for the effect 
of GnRH on specific cell types by delivery through the hypophyseal portal system 
and possibly through direct autocrine/paracrine effects in the gonads.  Although in-
situ hybridisation methods used in this thesis (Chapter 3) proved impossible to 
identifying pituitary cellular expression of GnRH receptor subtypes, it may be 
possible to employ the use of the cGnRH-R-III antibody as it was shown in this 
thesis (Chapter 5) to be quite specific for cGnRH-R-III.  Employing double 
immunohistochemistry to detect the co-localisation of the cGnRH-R-III receptor 
subtypes in the gonadotrophs (LH and FSH) will provide understanding of the 
possible role of cGnRH-R-III in the control of LH or FSH gene transcription.  In the 
ovary, characterisation of the cGnRH-R subtypes in hierarchical follicles and ovarian 
cell types will allow inference of functions of possible intra-gonadal effects of 
GnRH.  Another possible method to identify the expression of the receptor subtypes 
in segregating populations of LH and FSH gonadotrophs using the laser capture 
technique that was attempted (Chapter 3).  Although it was possible to detect LH 
stained gonadotrophs (Chapter 3), laser capture of pure gonadotrophs was 
impossible because the size limit for the micro-dissected area was greater than that of 
a single gonadotroph cell.  It is plausible that this method could be applied in-vitro 
on dispersed pituitary cells.     
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As mentioned (in Chapter 4) mammalian antagonist 27 showed a 153-fold more 
potent antagonistic effect at cGnRH-R-I than cGnRH-R-III and it may be possible to 
utilise this antagonist to preferentially block chicken type I GnRH receptor function 
in-vivo in order to study the physiological role of the chicken type III GnRH 
receptor.  However, as the peptide stock used to perform these experiments were 
depleted, additional stocks of the antagonist were sourced from Dr. Arieh Katz 
laboratory at the University of Cape Town in South Africa.  Unfortunately, once this 
new batch was tested, there were different pharmacological responses to those 
determined using the initial stock used for my experiments.  Mass spectrometry 
analysis was performed, which showed that there were different degradation patterns 
between the two stocks of peptides, which may have attributed to their different 
pharmacological profiles at the two cGnRH receptor subtypes.  Therefore, it was not 
possible to investigate the in-vivo effects of mammalian antagonist 27 in order to 
study physiological role of the chicken type III GnRH receptor.  Identifying a 
different source of synthetic peptide 27, or an identical batch of peptide to the one 
was used in this thesis, would allow these studies to be performed, and should be a 
focus of future investigations.   
 
The effects of oestrogen on cGnRH-R-I expression has been studied previously and 
shown to reduce mRNA levels in castrated juvenile cockrels (Sun et al., 2001a).  In 
general, our observations (Chapter 3) suggest that the level of GnRH-R-III mRNA 
may be inversely related to the capacity of gonadotrophs to release LH in adult 
females (Joseph et al., 2009).  It can be hypothesised that elevated levels of cGnRH-
R-III mRNA in the adult female may be reflective of expression of membrane 
cGnRH-R-III receptor number and that increased levels of ovarian steroid or peptide 
hormones may act to diminish the LH response to GnRH at the gonadotroph, through 
down-regulation of intracellular signalling pathways.  Therefore, understanding the 
effects of steroids (oestrogen and progesterone) on control of expression of cGnRH-
R-I and cGnRH-R-III will provide an indication of the possible roles of GnRH 
receptors in the reproductive cycles of the birds. Additionally,  immunoneutralisation 
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of inhibin in cockrels showed that there was accelerated puberty and hindered age-
related sexual senescence in these birds (Satterlee et al., 2006).  It is feasible that 
inhibin has an inhibitory effect on gonadotrophin biosynthesis (Dunn I. C. et al., 
2009).  Activin which is expressed in folliculo stelate cells may have a role in 
modulating GnRH-R expression (Kaiser et al., 1992; Rispoli and Nett, 2005).  
Therefore, identifying the effects of inhibin and or activin on the expression of 
receptor subtypes would provide a further understanding of the exact molecular 
mechanisms in which they affect gonadotrophin biosynthesis.   
 
Although it was not possible to differentiate between the receptors in terms of their 
pharmacological response to endogenous ligands (Chapter 4), a statistically 
significant difference in terms of ligand-induced internalisation rates was identified 
with cGnRH-R-III internalising at a faster initial rate than cGnRH-R-I (Chapter 4).  
It would be interesting to identify if these differences in internalisation rates affected 
the longevity of the signalling cascades activated by the two cGnRH receptor 
isoforms, with potential effects on LH and FSH gene transcription.  cGnRH-R-
III_SV2 significantly affected the cell surface expression of full-length cGnRH-R-III 
when co-expressed in COS-7 cells, inferring that cGnRH-R-III splice variants may 
modulate cGnRH-R-III activity if over-expressed (Chapter 4), however, the effects 
of co-expression of type I and type III GnRH receptor isoforms was not investigated.  
Interestingly, co-transfection of leopard gecko cDNA receptor isoform constructs 
was shown to elicit a distinct pharmacology compared to single isoform transfection 
(Ikemoto and Park, 2007).  As cGnRH-R-I and cGnRH-R-III are both expressed in 
the pituitary gland and may be expressed in identical cell types, it would be 
interesting to determine the effects of co-expression of cGnRH-R isoforms in relative 
quantities similar to those expressed in the pituitary gland to determine the effects on 
pharmacological properties and cellular responses.   
 
The hypothesis that three putative Src homology 3 (SH3) binding motifs present in 
the cytoplasmic C-terminal tail of cGnRH-R-III and not present in cGnRH-R-I may 
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attribute a differential functional capacity to cGnRH-R-III through interaction with 
SH3 domain-containing proteins may be further investigated as the method for 
immuno-precipitation has been optimized (Chapter 5).  Several size forms of HA-
cGnRH-R-III were detectable by western blotting and the composition of the 
immuno-precipitated protein complexes can be analysed in detail in future studies 
(Chapter 5).  The results obtained thus far indicate that the SH3 binding motifs do 
not alter ERK activation of cGnRH-R-III when compared to cGnRH-R-I (Chapter 
5), however, they may affect other MAPK outputs (p38 and JNK), and should be the 
focus of future investigations.   
 
In-vitro GnIH stimulation of cockerel pituitary fragments reduced the common 
gondotrophin alpha and the FSH beta subunit mRNA levels, although it failed to 
impact upon LH beta mRNA levels (Ciccone et al., 2004).  Additionally, there is a 
reciprocal relationship in the expression of cGnRH-R-III and cGnIH-R during the 
reproductive cycles in chickens (Bedecarrats et al., 2009).  Characterising possible 
cross-talk between GnIH and GnRH receptor signalling may prove beneficial in 
understanding the molecular mechanisms of the control of reproduction by GnIH.  
Use of a cAMP responsive element (CRE) luciferase reporter construct showed that 
in cGnRH-R-I and cGnRH-R-III transfected cells there is an increase in CRE-luc 
activity on GnRH stimulation (Shimizu M et al., 2008).  In contrast, activation of the 
cGnIH-R reduced the cGnRH-I induced activation of CRE-luc in a dose-dependent 
manner, and this effect is also dependent on receptor expression ratio (Shimizu M et 
al., 2008).  It has also been reported that in sheep pituitary cells, GnIH can abrogate 
GnRH-induced ERK phosphorylation (Sari et al., 2009).  cGnRH-I induced 
activation of the cGnRH-R-III and cGnRH-R-I and leads to ERK phosphorylation 
(Chapter 5), and determining if the effect of GnIH on GnRH-induced CRE 
activation and ERK phosphorylation are interrelated may be the focus of future 
investigations. 
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Both GnRH and GnIH have been shown to impact upon gonadotrophin gene 
expression. However, it is not clear whether cGnRH-R isoforms are involved 
independently or differentially, and if GnIH-R signalling directly acts on target gene 
promoters or merely interacts with GnRH-Rs signalling.  Thus to go beyond 
signalling, it would be of great interest to characterize gonadotrophin subunit gene 
promoters.  This could be achieved by generating reporter constructs encoding 
chicken LH-beta and FSH-beta as well as the common alpha subunit promoters fused 
to luciferase.  This construct could then be transfected alongside cGnRH-R isoforms 
and GnIH-R and any effect on gene expression could be monitored following GnRH 
and GnIH stimulation. 
One ambitious way to examine GnRH receptor subtype function in pituitary 
gonadotrophs would be to isolate clonal gonadotroph cell lines.  This could be 
achieved by immortalisation of embryonic pituitary cell cultures with FDH/LH-beta 
promoter-SV40-TAG or FSH/LH beta-hTERT promoter constructs) with subsequent 
examination of which receptors are endogenously expressed in clonal cell lines.  
Alternatively, employing the application of lentiviral SI-RNA constructs to knock 
down GnRH receptor isoform expression in chickens would provide information on 
the role of the GnRH-R isoforms in the control of reproduction.   
 
5.8.2. Understanding evolutionary recruitment of GnRH receptor 
isoforms 
With the near completion of a number of genome sequencing projects it will become 
increasingly possible to compare the syntenic gene loci of GnRH peptide precursor 
genes and receptor isoform genes.  This will provide greater understanding of 
possible evolutionary mechanisms in which GnRH systems were recruited and their 
correlation with reproductive strategies.  Of particular interest will be a comparison 
of the Chicken, Zebra Finch, and Anole Lizard genomes.  Both the Zebra Finch and 
Anole Lizard preliminary genome assemblies have been released (Ensembl) 
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Appendix A: Ballesteros and Weinstein ‘Numbering Convention’ 
Common numbering scheme according to Ballesteros, J.A and Weinstein, H 
(Ballesteros and Weinstein, 1995).  This has been adopted as a common numbering 
scheme that allows comparison between a particular GPCR e.g. GnRH receptors.  
The most conserved amino acid (AA) throughout the rhodopsin-like family of 
GPCRs in each transmembrane helix is arbitrarily designated the number 50, and AA 
upstream and downstream within the helix are number according to the anchored 50 
position.  The residues at the anchored 50 position are illustrated in Figure 
Appendix 1.1. 
Figure Appendix 1. 1 
 
Fig. Appendix.1 Alignment of human and chicken GnRH receptor sequences.  The box 
regions correspond the conserved amino acid (AA) in each transmembrane helix arbitrarily 




The actual residues and the conversion to the ‘Ballesteros numbering convention’ for 
the residues attributed the number 50. This will enable derivation of any desired 
Ballersteros number from the alignment above.  The number in the brackets indicates 
the actual residue number in the respective sequence.  See Table Appendix 1.1 for 
‘Ballesteros numbering’ of transmembrane helices AA’s.   











1 1.50 Asn1.50(53) Asn1.50(60) Asn1.50(83) 
2 2.50 Asn2.50(87) Asp2.50(87) Asp2.50(112) 
3 3.50 Arg3.50(139) Arg3.50(139) Arg3.50(164) 
4 4.50 Trp4.50(164) Trp4.50(162) Trp4.50(190) 
5 5.50 Pro5.50(223) Pro5.50(216) Pro5.50(245) 
6 6.50 Pro6.50(282) Pro6.50(273) Pro6.50(307) 














Table Appendix 1. 2 
Ballesteros and Weinstein ‘Numbering Conversion’ for cGnRH-R-I, cGnRH-R-III 
and hGnRH-R-I.  In each column the residues are ordered according to the multiple 
sequence alignment in Fig. Apen.1. The NH2 terminal of each receptor is shaded in 
yellow, the transmembrane domains are shaded in blue, the extracellular loops in 
grey and the intracellular loops in pink.  The C-terminal cytoplamsic tail domains of 
the cGnRH-R isoforms are shaded in green.  The ‘Ballesteros and Weinstein 
Number’ for each transmembrane domain is shown, and can be completed by 
inserting the actual residue number from the respective receptor in brackets after the 
‘Ballesteros and Weinsteain Number’ as shown in Table Appen. 1.  The AA in the 
loops, are numbered according to the proximity of the transmembrane boundary, 
which determines which identifier is used (Ballesteros and Weinstein, 1995).   
 
Chicken  Chicken  Human Ballesteros  
GnRH-R-I GnRH-R-III GnRH-R-I Number 
             1 M     
             2 A     
             3 R     
             4 L     
             5 G     
             6 G     
             7 G     
             8 T     
             9 G     
            10 Q     
            11 D     
            12 A     
           1 M           13 A     
           2 C           14 A     
           3 V           15 A     




           5 A           17 G     
           6 A           18 G     
           7 L           19 W            1 M   
           8 I           20 L            2 A   
           9 E           21 D            3 N   
          10 A           22 P            4 S   
          11 E           23 G            5 A   
          12 P           24 P            6 S   
          13 P           25 T            7 P   
          14 H           26 V            8 E   
          15 H           27 G            9 Q   
          16 P           28 N           10 N   
          17 T           29 V           11 Q   
          18 T           30 S           12 N   
          19 E           31 T           13 H   
          20 G           32 E           14 C   
          21 D           33 P           15 S   
          22 T           34 S           16 A   
          23 N           35 S           17 I   
          24 T           36 S           18 N   
          25 S           37 T           19 N   
          26 A           38 S           20 S   
          27 T           39 H           21 I   
            40 P           22 P   
            41 K     
            42 R     
            43 G     
            44 C     
            45 A     
            46 W     
            47 S     
            48 P     
            49 R     
            50 L     




          28 H           52 S     
          29 C           53 A     
          30 L           54 E           23 L   
          31 E           55 E           24 M   
          32 H           56 P           25 Q   
          33 W           57 L           26 G   
          34 V           58 L           27 N   
          35 E           59 L           28 L   
          36 P           60 P           29 P   
          37 R           61 T           30 T   
          38 F           62 F           31 L   
          39 T           63 S           32 T   
          40 K           64 P           33 L   
          41 A           65 A           34 S   
          42 A           66 A           35 G   
          43 K           67 Q           36 K 1.33 
          44 V           68 A           37 I 1.34 
          45 R           69 R           38 R 1.35 
          46 V           70 V           39 V 1.36 
          47 A           71 A           40 T 1.37 
          48 I           72 A           41 V 1.38 
          49 T           73 T           42 T 1.39 
          50 A           74 F           43 F 1.40 
          51 V           75 V           44 F 1.41 
          52 F           76 L           45 L 1.42 
          53 F           77 F           46 F 1.43 
          54 L           78 V           47 L 1.44 
          55 L           79 L           48 L 1.45 
          56 A           80 S           49 S 1.46 
          57 A           81 A           50 A 1.47 
          58 C           82 G           51 T 1.48 
          59 S           83 C           52 F 1.49 
          60 N           84 N           53 N 1.50 
          61 T           85 V           54 A 1.51 




          63 V           87 V           56 F 1.53 
          64 L           88 L           57 L 1.54 
          65 G           89 R           58 L 1.55 
          66 S           90 A           59 K 1.56 
          67 L           91 A           60 L 1.57 
          68 L           92 G           61 Q   
              62 K   
              63 W   
              64 T   
              65 Q   
              66 K   
          69 R           93 G           67 K   
          70 K           94 R           68 E   
          71 R           95 R           69 K   
            96 G           70 G   
            97 G           71 K   
          72 R           98 G           72 K   
          73 K           99 R           73 L   
          74 C          100 S           74 S   
          75 H          101 H           75 R   
          76 V          102 I           76 M   
          77 R          103 R           77 K   
          78 P          104 V           78 L   
          79 L          105 L           79 L 2.42 
          80 I          106 L           80 L 1.23 
          81 L          107 R           81 K 2.44 
          82 S          108 H           82 H 2.45 
          83 L          109 L           83 L 2.46 
          84 A          110 A           84 T 2.47 
          85 L          111 A           85 L 2.48 
          86 A          112 A           86 A 2.49 
          87 D          113 D           87 N 2.50 
          88 L          114 L           88 L 2.51 
          89 L          115 L           89 L 2.52 




          91 T          117 T           91 T 2.54 
          92 V          118 V           92 L 2.55 
          93 A          119 V           93 I 2.56 
          94 V          120 V           94 V 2.57 
          95 M          121 M           95 M 2.58 
          96 P          122 P           96 P 2.59 
          97 L          123 L           97 L 2.60 
          98 D          124 D           98 D 2.61 
          99 A          125 A           99 G 2.62 
         100 A          126 I          100 M 2.63 
         101 W          127 W          101 W 2.64 
         102 N          128 N          102 N 2.65 
         103 V          129 I          103 I 2.66 
         104 T          130 T          104 T   
         105 V          131 L          105 V   
         106 Q          132 Q          106 Q   
         107 W          133 W          107 W   
         108 Y          134 R          108 Y   
         109 G          135 A          109 A   
         110 G          136 G          110 G   
         111 D          137 D          111 E   
         112 L          138 L          112 L   
         113 S          139 A          113 L   
         114 C          140 C          114 C   
         115 K          141 R          115 K   
         116 L          142 L          116 V 3.27 
         117 L          143 L          117 L 2.28 
         118 N          144 M          118 S 2.29 
         119 F          145 Y          119 Y 3.30 
         120 L          146 L          120 L 3.31 
         121 K          147 R          121 K 3.32 
         122 L          148 L          122 L 3.33 
         123 F          149 L          123 F 3.34 
         124 A          150 A          124 S 3.35 




         126 Y          152 Y          126 Y 3.37 
         127 A          153 A          127 A 3.38 
         128 A          154 S          128 P 3.39 
         129 A          155 A          129 A 3.40 
         130 L          156 F          130 F 3.41 
         131 V          157 V          131 M 3.42 
         132 L          158 T          132 M 3.43 
         133 V          159 V          133 V 3.44 
         134 V          160 V          134 V 3.45 
         135 I          161 I          135 I 2.46 
         136 S          162 S          136 S 2.47 
         137 L          163 L          137 L 3.48 
         138 D          164 D          138 D 3.49 
         139 R          165 R          139 R 3.50 
         140 H          166 Q          140 S 3.51 
         141 A          167 A          141 L   
         142 A          168 A          142 A   
         143 V          169 I          143 I   
         144 L          170 L          144 T   
         145 Q          171 R          145 R   
         146 P          172 P          146 P   
           173 L          147 L   
           174 A          148 A   
         147 F          175 I          149 L   
         148 A          176 A          150 K   
         149 R          177 R          151 S   
         150 A          178 A          152 N   
         151 R          179 R          153 S 4.39 
         152 R          180 C          154 K 4.40 
         153 R          181 R          155 V 4.41 
         154 N          182 N          156 G 4.42 
         155 G          183 R          157 Q 4.43 
         156 L          184 A          158 S 4.44 
         157 L          185 M          159 M 4.45 




         159 R          187 R          161 G 4.47 
         160 A          188 A          162 L 4.48 
         161 A          189 A          163 A 4.49 
         162 W          190 W          164 W 4.50 
         163 L          191 M          165 I 4.51 
         164 G          192 L          166 L 4.52 
         165 S          193 S          167 S 4.53 
         166 V          194 A          168 S 4.54 
         167 L          195 A          169 V 4.55 
         168 L          196 L          170 F 4.56 
         169 A          197 A          171 A 4.57 
         170 S          198 V          172 G 4.58 
         171 P          199 P          173 P 4.59 
         172 Q          200 Q          174 Q 4.60 
         173 L          201 L          175 L 4.61 
         174 F          202 F          176 Y 4.62 
         175 L          203 L          177 I 4.63 
         176 F          204 F          178 F 4.64 
         177 H          205 H          179 R 4.65 
         178 V          206 T          180 M 4.66 
         179 H          207 V          181 I   
         180 T          208 T          182 H   
         181 V          209 L          183 L   
         182 P          210 H          184 A   
         183 G          211 A          185 D   
           212 P          186 S   
             187 S   
             188 G   
             189 Q   
             190 T   
         184 G          213 H          191 K   
         185 N          214 N          192 V   
         186 F          215 F          193 F   
         187 T          216 T          194 S   




         189 C          218 C          196 C   
         190 V          219 T          197 V   
         191 T          220 T          198 T   
         192 H          221 H          199 H   
         193 G          222 G          200 C   
         194 S          223 S          201 S   
         195 F          224 F          202 F   
         196 R          225 P          203 S   
         197 A          226 Q          204 Q   
         198 H          227 P          205 W   
         199 W          228 W          206 W   
         200 E          229 H          207 H   
         201 E          230 E          208 Q 5.35 
         202 T          231 T          209 A 5.36 
         203 V          232 L          210 F 5.37 
         204 Y          233 Y          211 Y 5.38 
         205 N          234 N          212 N 5.39 
         206 M          235 M          213 F 5.40 
         207 F          236 L          214 F 5.41 
         208 T          237 S          215 T 5.42 
         209 F          238 F          216 F 5.43 
         210 T          239 S          217 S 5.44 
         211 T          240 C          218 C 5.45 
         212 L          241 L          219 L 5.46 
         213 Y          242 F          220 F 5.47 
         214 I          243 L          221 I 5.48 
         215 T          244 L          222 I 5.49 
         216 P          245 P          223 P 5.50 
         217 L          246 L          224 L 5.51 
         218 S          247 L          225 F 5.52 
         219 I          248 I          226 I 5.53 
         220 M          249 M          227 M 5.54 
         221 I          250 V          228 L 5.55 
         222 V          251 C          229 I 5.56 




         224 Y          253 Y          231 N 5.58 
         225 V          254 T          232 A 5.59 
         226 R          255 R          233 K   
         227 I          256 I          234 I   
         228 I          257 L          235 I   
         229 W          258 L          236 F   
         230 E          259 E          237 T   
         231 I          260 I          238 L   
         232 S          261 S          239 T   
         233 K          262 R          240 R   
         234 Q          263 R          241 V   
         235 L          264 M          242 L   
           265 G          243 H   
           266 S          244 Q   
           267 S     
           268 L     
           269 F     
         236 K          270 S          245 D   
         237 I          271 S          246 P   
         238 N          272 R          247 H   
         239 K          273 D          248 E   
         240 S          274 V          249 L   
         241 L          275 P          250 Q   
         242 V          276 L          251 L   
         243 R          277 R          252 N   
         244 S          278 C          253 Q   
         245 Q          279 S          254 S   
         246 N          280 G          255 K   
         247 D          281 S          256 N   
         248 H          282 N          257 N   
         249 I          283 I          258 I   
         250 S          284 P          259 P   
         251 K          285 R          260 R   
         252 A          286 A          261 A   




         254 M          288 L          263 L   
         255 K          289 R          264 K   
         256 T          290 T          265 T   
         257 L          291 L          266 L   
         258 K          292 K          267 K 6.35 
         259 M          293 M          268 M 6.36 
         260 T          294 S          269 T 6.37 
         261 I          295 L          270 V 6.38 
         262 V          296 V          271 A 6.39 
         263 I          297 I          272 F 6.40 
         264 V          298 V          273 A 6.41 
         265 A          299 S          274 T 6.42 
         266 S          300 S          275 S 6.43 
         267 F          301 F          276 F 6.44 
         268 I          302 I          277 T 6.45 
         269 I          303 L          278 V 6.46 
         270 C          304 C          279 C 6.47 
         271 W          305 W          280 W 6.48 
         272 T          306 T          281 T 6.49 
         273 P          307 P          282 P 6.50 
         274 Y          308 Y          283 Y 6.51 
         275 Y          309 Y          284 Y 6.52 
         276 L          310 L          285 V 6.53 
         277 L          311 L          286 L 6.54 
         278 G          312 G          287 G 6.55 
         279 L          313 L          288 I 6.56 
         280 W          314 W          289 W 6.57 
         281 Y          315 Y          290 Y 6.58 
         282 W          316 W          291 W 6.59 
         283 F          317 F          292 F   
         284 H          318 C          293 D   
         285 P          319 P          294 P   
           320 R     
         286 A          321 A          295 E   




         288 I          323 Q          297 L   
         289 Q          324 Q          298 N   
         290 R          325 K          299 R   
         291 M          326 V          300 L   
         292 P          327 P          301 S   
         293 E          328 P          302 D   
         294 Y          329 S          303 P   
         295 I          330 L          304 V 7.34 
         296 N          331 S          305 N 7.35 
         297 H          332 H          306 H 7.36 
         298 S          333 I          307 F 7.37 
         299 F          334 L          308 F 7.38 
         300 F          335 F          309 F 7.39 
         301 L          336 I          310 L 7.40 
         302 F          337 F          311 F 7.41 
         303 G          338 G          312 A 7.42 
         304 L          339 L          313 F 7.43 
         305 L          340 F          314 L 7.44 
         306 H          341 N          315 N 7.45 
         307 T          342 A          316 P 7.46 
          308 C          343 C          317 C 7.47 
         309 T          344 L          318 F 7.48 
         310 D          345 D          319 D 7.49 
         311 P          346 P          320 P 7.50 
         312 I          347 I          321 L 7.51 
         313 I          348 T          322 I 7.52 
         314 Y          349 Y          323 Y 7.53 
         315 G          350 G          324 G 7.54 
         316 L          351 L          325 Y 7.55 
         317 Y          352 F          326 F 7.56 
         318 T          353 T          327 S 7.57 
         319 P          354 I          328 L 7.58 
         320 S          355 P     
         321 F          356 F     




         323 E          358 R     
         324 D          359 R     
         325 V          360 C     
         326 Q          361 G     
         327 L          362 C     
         328 C          363 P     
         329 L          364 C     
         330 R          365 G     
         331 G          366 H     
         332 I          367 S     
         333 E          368 S     
         334 A          369 E     
         335 A          370 P     
         336 I          371 E     
         337 S          372 P     
         338 Q          373 P     
         339 H          374 S     
         340 V          375 P     
         341 R          376 A     
         342 H          377 T     
         343 K          378 G     
         344 P          379 S     
         345 I          380 F     
         346 S          381 H     
         347 V          382 C     
         348 S          383 S     
         349 E          384 A     
         350 K          385 S     
         351 T          386 S     
         352 T          387 L     
         353 K          388 R     
         354 D          389 G     
           390 R     
           391 Q     




           393 M     
         355 G          394 G     
         356 D          395 G     
         357 V          396 T     
         358 N          397 E     
         359 G          398 G     
           399 P     
           400 H     
           401 P     
         360 Q          402 P     
         361 V          403 I     
         362 T          404 E     
         363 S          405 L     
         364 G          406 G     
         365 G          407 L     
         366 S          408 P     
         367 N          409 T     
         368 G          410 G     
         369 T          411 A     
           412 G     
         370 T          413 S     
         371 V          414 C     
         372 N          415 Q     
         373 T          416 S     
         374 V          417 S     
         375 C          418 A     









Appendix B: Supporting data for cGnRH-R-III protein expression 
Since submission of this thesis, there has been some unpublished data that has 
become available on cGnRH-R-III protein expression (Mcfarlane et al., in 
preparation).  The finding in this thesis that cGnRH-R-III cDNA showed that it is 
predominantly expressed in the anterior pituitary, ~1400 times more abundant than 
cGnRH-R-I cDNA and the pronounced sex and age difference existed, with higher 
pituitary transcript levels in sexually mature females versus juvenile females in 
contrast to, higher expression levels occurring in juvenile males compared to 
sexually mature males is based on the assumption that mRNA is translated into 
protein in proportional quantities.  However, cGnRH-R-III protein expression 
appears to correlate with reproductive stages and showed that levels remain low until 
peak sexual activity is reached (Mcfarlane et al., in preparation).  (Fig. Appendix 
1.2 and 1.3).  No research has been performed to compare the protein expression 
levels of cGnRH-R-I and cGnRH-R-III.  The translation of mRNA into protein is 
dependent on a number of variables which may explain why the assumption that 
mRNA is translated into protein in proportional quantities may be presumptive.  
These include: RNA transport (Nakielny et al., 1997) and mRNA degradation (Ross, 
1995). 
 
H. McFarlane, N. T. Joseph, S.R. Maddineni, R.Ramachandran and G. Bedecarrats.  
Development, validation and utilisation of a novel antibody specific to the type III 
chicken gonadotrophin-releasing hormone receptor.  (In preparation) 
 
Permission has been granted by the authors (listed above) for inclusion of this data 






Figure Appendix 1. 2 
 
Fig. Appendix 1.2. Representative immunoblots of individual pituitary gland samples 
with cGnRH-R-III antibody. The positive control (+) corresponds to a pooled pituitary 
sample which was used as inter-blot calibrator, whereas a skeletal muscle sample was used 
as negative control (-). The cGnRH-R-III protein immunoreactive band at 50kDa in all 
samples except the negative tissue was used for quantification (A). A representative (21 wk 





Figure Appendix 1. 3 
 
Fig. Appendix 1.3. Changes in cGnRH-R-III protein levels in chicken pituitary glands 
at varying reproductive stages. Values for individual samples were normalized for 
GAPDH protein and corrected with the inter-blot calibrator (pooled sample). Arrow 
indicates time of photostimulation (17 wk: males, 18 wk: females). Asterisk represents 


















Appendix C: Publication 
 
The majority of the data presented in Chapter 3 and 4 of this thesis has been 
published in a paper in Journal of Endocrinology: 
 
N. T. Joseph, K. Morgan, R. Sellar, D. McBride, R. P. Millar and I. C. Dunn. 
(2009).  The chicken type III GnRH receptor homologue is predominantly expressed 
in the pituitary, and exhibits similar ligand selectivity to the type I receptor.  Journal 
of Endocrinology 202:179-190 
Permission has been granted by the authors (listed above) for inclusion in this thesis. 
 
 
